


































Silver-impregnated, antibiotic-impregnated or non-impregnated
ventriculoperitoneal shunts to prevent shunt infection: the BASICS three-
arm RCT
Mallucci, C.L.; Jenkinson, Michael; Conroy, Elizabeth J.; Hartley, John C.;
Brown, Michaela; Moitt, Tracey; Dalton, Joanne; Kearns, Tom; Griffiths, Michael





Publisher's PDF, also known as Version of record
Cyswllt i'r cyhoeddiad / Link to publication
Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Mallucci, C. L., Jenkinson, M., Conroy, E. J., Hartley, J. C., Brown, M., Moitt, T., Dalton, J.,
Kearns, T., Griffiths, M. J., Culeddu, G., Solomon, T., Hughes, D., & Gamble, C. (2020). Silver-
impregnated, antibiotic-impregnated or non-impregnated ventriculoperitoneal shunts to prevent
shunt infection: the BASICS three-arm RCT. Health Technology Assessment, 24(17).
https://doi.org/10.3310/hta24170
Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or
other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal
requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private
study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to
the work immediately and investigate your claim.




or non-impregnated ventriculoperitoneal 
shunts to prevent shunt infection:  
the BASICS three-arm RCT 
Conor L Mallucci, Michael D Jenkinson, Elizabeth J Conroy, John C Hartley,  
Michaela Brown, Tracy Moitt, Joanne Dalton, Tom Kearns, Michael J Griffiths,  
Giovanna Culeddu, Tom Solomon, Dyfrig Hughes, Carrol Gamble and  
the BASICS study collaborators
Health Technology Assessment





shunts to prevent shunt infection: the BASICS
three-arm RCT
Conor L Malluccio ,1* Michael D Jenkinsono ,2,3
Elizabeth J Conroyo ,4 John C Hartleyo ,5
Michaela Browno ,4 Tracy Moitto ,4 Joanne Daltono ,4
Tom Kearnso ,4 Michael J Griffithso ,6,7
Giovanna Culedduo ,8 Tom Solomono ,6,9
Dyfrig Hugheso ,8 Carrol Gambleo 4 and the BASICS
study collaborators†
1Department of Paediatric Neurosurgery, Alder Hey Children’s NHS Foundation Trust,
Liverpool, UK
2Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
3Institute of Translational Medicine, University of Liverpool, Liverpool, UK
4Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK
5Department of Microbiology, Great Ormond Street Hospital for Children,
London, UK
6Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
7Department of Paediatric Neurology, Alder Hey Children’s NHS Foundation Trust,
Liverpool, UK
8Centre for Health Economics and Medicines Evaluation, Bangor University,
Bangor, UK
9Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
*Corresponding author
†The BASICS study collaborators can be found in Appendix 1.
Declared competing interests of authors: Michael J Griffiths has a patent 068347A1 pending for a
novel method of detection of bacterial infection.Tom Solomon reports grants from the National Institute for
Health Research (NIHR) outside the submitted work and other support from the Data Safety andMonitoring
Committee of the GlaxoSmithKline plc (London, UK) study to evaluate the safety and immunogenicity of a
candidate ebola vaccine in children (GSK3390107A) (ChAd3 EBO-Z), outside the submitted work. He also
chairs the Siemens Healthineers (Munich, Germany) Clinical Advisory Board. Dyfrig Hughes was member
of the Health TechnologyAssessment (HTA) programme Pharmaceuticals Panel (2008–12) and the HTA
programme Clinical Evaluation and Trials board (2010–16). Carrol Gamble reports grants from NIHR outside





This report should be referenced as follows:
Mallucci CL, Jenkinson MD, Conroy EJ, Hartley JC, Brown M, Moitt T, et al. Silver-impregnated,
antibiotic-impregnated or non-impregnated ventriculoperitoneal shunts to prevent shunt
infection: the BASICS three-arm RCT. Health Technol Assess 2020;24(17).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.





Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics
Science Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE)
(www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be
purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme,
and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis
methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can
be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate
any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that
have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote
health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include
any intervention used in the treatment, prevention or diagnosis of disease.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform
National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for
National Screening Committee (NSC) policy decisions.
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 10/104/30. The
contractual start date was in December 2012. The draft report began editorial review in April 2019 and was accepted for
publication in November 2019. The authors have been wholly responsible for all data collection, analysis and interpretation,
and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would
like to thank the reviewers for their constructive comments on the draft report document. However, they do not accept liability
for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions
expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR,
NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this
publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect
those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Mallucci et al. under the terms of a
commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for
the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.
Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health
Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library
Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK
NIHR Journals Library Editors
Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. 
 Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Senior Clinical 
Professor Andrée Le May
Professor Matthias Beck
Dr Tessa Crilly





Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK





Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK
Professor Jim Thornton
Professor Martin Underwood
Please visit the website for a list of editors: 
Editorial contact:  
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Silver-impregnated, antibiotic-impregnated or non-impregnated
ventriculoperitoneal shunts to prevent shunt infection: the
BASICS three-arm RCT
Conor L Malluccio ,1* Michael D Jenkinsono ,2,3 Elizabeth J Conroyo ,4
John C Hartleyo ,5 Michaela Browno ,4 Tracy Moitto ,4 Joanne Daltono ,4
Tom Kearnso ,4 Michael J Griffithso ,6,7 Giovanna Culedduo ,8
Tom Solomono ,6,9 Dyfrig Hugheso ,8 Carrol Gambleo 4 and the BASICS
study collaborators†
1Department of Paediatric Neurosurgery, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
2Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
3Institute of Translational Medicine, University of Liverpool, Liverpool, UK
4Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK
5Department of Microbiology, Great Ormond Street Hospital for Children, London, UK
6Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
7Department of Paediatric Neurology, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
8Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK
9Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
*Corresponding author cmallucci@me.com
†The BASICS study collaborators can be found in Appendix 1.
Background: Insertion of a ventriculoperitoneal shunt to treat hydrocephalus is one of the most
common neurosurgical procedures worldwide. Shunt infection affects up to 15% of patients, resulting
in long hospital stays, multiple surgeries and reduced cognition and quality of life.
Objectives: The aim of this trial was to determine whether or not antibiotic-impregnated
ventriculoperitoneal shunts (hereafter referred to as antibiotic shunts) (e.g. impregnated with
rifampicin and clindamycin) or silver-impregnated ventriculoperitoneal shunts (hereafter referred to as
silver shunts) reduce infection compared with standard ventriculoperitoneal shunts (hereafter referred
to as standard shunts).
Design: This was a three-arm, superiority, multicentre, parallel-group randomised controlled trial.
Patients and a central primary outcome review panel, but not surgeons or operating staff, were blinded
to the type of ventriculoperitoneal shunt inserted.
Setting: The trial was set in 21 neurosurgical wards across the UK and the Republic of Ireland.
Participants: Participants were patients with hydrocephalus of any aetiology who were undergoing
insertion of their first ventriculoperitoneal shunt.
Interventions: Participants were allocated 1 : 1 : 1 by pressure-sealed envelope to receive a standard
non-impregnated, silver-impregnated or antibiotic-impregnated ventriculoperitoneal shunt at the time
of insertion. Ventriculoperitoneal shunts are medical devices, and were used in accordance with the
manufacturer’s instructions for their intended purpose.
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Main outcome measures: The primary outcome was time to ventriculoperitoneal shunt failure due
to infection. Secondary outcomes were time to failure for any cause, reason for failure (infection,
mechanical), types of ventriculoperitoneal shunt infection, rate of infection after first clean
(non-infected) revision and health economics. Outcomes were analysed by intention to treat.
Results: Between 26 June 2013 and 9 October 2017, 1605 patients from neonate to 91 years of
age were randomised to the trial: n = 36 to the standard shunt, n = 538 to the antibiotic shunt and
n = 531 to the silver shunt. Patients who did not receive a ventriculoperitoneal shunt (n = 4) or who
had an infection at the time of insertion (n = 7) were not assessed for the primary outcome. Infection
occurred in 6.0% (n = 32/533) of those who received the standard shunt, in 2.2% (n = 12/535) of those
who received the antibiotic shunt and in 5.9% (n = 31/526) of those who received the silver shunt.
Compared with the standard shunt, antibiotic shunts were associated with a lower rate of infection
(cause-specific hazard ratio 0.38, 97.5% confidence interval 0.18 to 0.80) and a decreased probability
of infection (subdistribution hazard ratio 0.38, 97.5% confidence interval 0.18 to 0.80). Silver shunts
were not associated with a lower rate of infection than standard shunts (cause-specific hazard ratio
0.99, 97.5% confidence interval 0.56 to 1.74). The ventriculoperitoneal shunt failure rate attributable
to any cause was 25.0% overall and did not differ between arms. Antibiotic shunts save £135,753 per
infection avoided. There were no serious adverse events.
Limitations: It was not possible to blind treating neurosurgeons to the ventriculoperitoneal shunt type.
The return rate for patient-reported outcomes was low. Limitations to the economic evaluation
included failure to obtain Hospital Episode Statistics data from NHS Digital, as per protocol. Reliance
on patient-level information and costing systems data mitigated these limitations.
Conclusions: Antibiotic shunts have a reduced infection rate compared with standard shunts, whereas
silver shunts do not. Antibiotic shunts are cost-saving.
Future work: A sample collection has been established that will enable the study of surrogate markers
of ventriculoperitoneal shunt infection in cerebrospinal fluid or blood using molecular techniques.
A post hoc analysis to study factors related to shunt failure will be performed as part of a future study.
An impact analysis to assess change in practice is planned.
Trial registration: Current Controlled Trials ISRCTN49474281.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 17. See the NIHR Journals Library website for further project information.
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Hydrocephalus (commonly known as ‘water on the brain’) is a condition that can affect all agegroups, from babies to the elderly. In hydrocephalus, there is an accumulation of the normal brain
fluid in the fluid cavities (ventricles) of the brain. Untreated, hydrocephalus can be life-threatening. The
most common treatment involves an operation to insert a tube into the swollen ventricles to drain off
the excess fluid. This is called a ventriculoperitoneal shunt.
In the UK, 3000–3500 shunt operations are performed each year. The main risks of a shunt operation
are infection (surgical meningitis) and blockage without infection. Infection results in the need for at
least two further surgeries, antibiotic treatment and a prolonged hospital stay (minimum of 2 weeks).
Shunt infections can affect mental abilities and can be life-threatening. People who have blockages
without infection, on the other hand, usually need only a single operation to replace the blocked part
and only a few days in hospital.
Two new types of shunt catheter have been introduced to try to reduce shunt infection: antibiotic-
impregnated shunts and silver-impregnated shunts. This study was designed to assess whether or not
either of these new shunts reduce infection compared with standard shunts. This study also included
an analysis of the cost and health benefits of the different shunts used.
A total of 1605 children and adults, who were treated in neurosurgical units across the UK and the
Republic of Ireland, participated in this study. Consent was provided by all participants in the trial.
Each participant had an equal chance of receiving one of the three shunt types.
Shunt infection occurred in 6% of participants receiving standard shunts, 5.9% of participants receiving
silver-impregnated shunts and 2.2% of participants receiving antibiotic-impregnated shunts.
This study has demonstrated a major reduction in shunt infections in new shunts when using
antibiotic-impregnated shunts compared with standard or silver-impregnated shunts. A health
economic analysis has indicated that antibiotic-impregnated shunts are cost-saving.
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Hydrocephalus affects one in every 500 births; thus, it is one of the most common developmental
disabilities in children. The condition also affects older children and adults of all ages, and can be
secondary to a variety of causes, including intracranial tumours, haemorrhage and infection.
Standard treatment for hydrocephalus remains the ventriculoperitoneal shunt. Insertion of a
ventriculoperitoneal shunt to treat hydrocephalus is now one of the most common procedures
performed in neurosurgical units, and between 3000 and 3500 shunt operations are carried out per
year in the UK in adults and children. Currently, three types of shunt catheter are available: standard
silicone shunts (hereafter referred to as standard shunts), antibiotic-impregnated shunts (hereafter
referred to as antibiotic shunts) and silver-impregnated shunts (hereafter referred to as silver shunts).
There is no standard practice or guidance in the UK as to which shunt catheter is the most effective at
reducing infection.
The incidence of shunt infection varies markedly in the literature from 3% to 27%, and is higher in certain
groups, such as neonates and children aged < 1 year. Episodes of shunt infection have a significant impact
on patients and the NHS and require prolonged inpatient hospitalisation, additional surgery to remove
the infected hardware, intravenous and intrathecal antibiotics, and further surgery to place a new shunt
once the infection has been treated. This trial, therefore, addresses the primary question of which shunt
catheter is the most effective in reducing shunt infection and has secondary questions addressing the
consequences of infection in a clinical and financial context.
Objectives
The trial addressed the following objectives.
Primary outcome
The primary outcome was the time to failure of a first ventriculoperitoneal shunt due to infection, as
assessed by a blinded central review panel. The central review panel comprised the chief investigator
(or delegate, for participants treated by the chief investigator) and a microbiologist, both of whom
were masked to participant allocations.
Secondary outcomes
The secondary outcomes were to compare the following outcomes in the standard shunt arm with the
antibiotic and silver shunt arms, respectively:
l time to removal of a first ventriculoperitoneal shunt due to suspected infection, as assessed by the
treating surgeon
l time to ventriculoperitoneal shunt failure for any cause
l reason for failure (infection, mechanical, patient, functional)
l types of bacterial ventriculoperitoneal shunt infection (organism, antibiotic resistance)
l time to ventriculoperitoneal shunt infection following first clean (non-infected) revision
l quality of life, assessed using the Hydrocephalus Outcome Questionnaire
l incremental cost per ventriculoperitoneal shunt failure (any cause) averted
l incremental cost per quality-adjusted life-year gained.
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Participants were screened for eligibility in 21 neurosurgical units across the UK and the Republic of
Ireland. All participating centres met the British Antibiotic and Silver Impregnated Catheters for
ventriculoperitoneal Shunts (BASICS) centre inclusion criteria.
Patients were eligible to participate in the trial if they had hydrocephalus of any aetiology (including
idiopathic intracranial hypertension) requiring a first ventriculoperitoneal shunt. Note that failed
primary endoscopic third ventriculostomy, indwelling ventricular access device (e.g. Ommaya or
Rickham reservoir or ventriculosubgaleal shunt or similar) and indwelling external ventricular drains
were allowed.
Patients with the following characteristics were excluded from the trial:
l previous indwelling ventricular or lumbar peritoneal or atrial shunt
l active and ongoing cerebrospinal fluid or peritoneal infection (previous infected cases were allowed
once cleared of infection)
l multiloculated hydrocephalus requiring multiple ventriculoperitoneal shunts or neuroendoscopy
l ventriculoatrial or ventriculopleural shunt planned
l allergy to antibiotics associated with the antibiotic shunt
l allergy to silver.
Trial procedures
Patients were eligible to be randomised to the trial if written consent was provided by the patient,
parent, legal representative or consultee, as appropriate. Patients were randomised, by envelope, in a
ratio of 1 : 1 : 1 in the operating theatre at the time when the ventriculoperitoneal shunt was required. The
randomisation sequence was generated by an independent statistician and stratified by neurosurgical unit,
age group (adult or paediatrics were defined according to unit practice) and envelope storage room within
the neurosurgical unit. Patients and a central review panel, but not surgeons or operating staff, were
blinded to the type of ventriculoperitoneal shunt inserted. All ventriculoperitoneal shunt types were
medical devices used in accordance with the manufacturers’ instructions for their intended purpose.
All patients having a first ventriculoperitoneal shunt for hydrocephalus of any aetiology (including
idiopathic intracranial hypertension) were screened for eligibility and recorded on a centre-held
screening log. Reasons for non-recruitment were documented (e.g. not eligible, declined consent) and
the information was used for monitoring purposes.
Data were collected at baseline (pre-operative assessment), randomisation (first surgery), early
post-operative assessment, first routine post-operative assessment, 12-weekly follow-up assessments,
subsequent routine post-operative assessments and, when applicable, unscheduled visits/admissions
and at shunt revision/removals. Patients were followed for a minimum of 6 months and a maximum
of 2 years.
An economic evaluation was conducted to estimate the incremental cost-effectiveness of impregnated
ventriculoperitoneal shunt catheters, expressed as all-cause ventriculoperitoneal shunt failures averted.
Sample size
The sample size for the primary outcome was calculated using the Pintilie method (Pintilie M. Dealing
with competing risks: testing covariates and calculating sample size. Stat Med 2002;21:3317–24), and
assumed the following: (1) failure due to infection was the event of interest, with all other reasons for
failure a competing risk; (2) the rate of infection was 8% in the standard silicone arm and 4% in the
impregnated shunt catheter arms; (3) the competing risk event rate was 30%; and (4) a 5% loss to
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follow-up. An initial total sample size of 1200 with 119 events demonstrated good statistical power
(88%), with leverage for a lower event rate if required.
Ongoing monitoring of the infection rate identified a deviation from the assumptions and,
subsequently, a need to revise the original sample size. In January 2016, the target sample size was
increased to 1606 participants with 101 events and 80% power. The Independent Data and Safety
Monitoring Committee oversaw this revision and the Trial Steering Committee agreed and approved
this change.
Statistical analysis
Efficacy outcomes were analysed according to the intention-to-treat principle, as far as practically
possible, and safety analyses were analysed according to the type of ventriculoperitoneal shunt in situ.
A Bonferroni adjustment was made to allow for multiple comparisons and a 2.5% statistical significance
level, and 97.5% confidence intervals were used throughout. The statistical analysis plan was developed
prior to analysis.
Outcomes with infection as the event of interest used Fine and Gray (Fine PF, Gray RJ. A proportional
hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509) survival
regression models with cause-specific hazard ratios and subdistribution hazard ratios presented. Cox
regression models were used to analyse time to ventriculoperitoneal shunt failure as a result of any
cause. Reason for ventriculoperitoneal shunt failure is presented descriptively and with a chi-squared
test. Types of organisms, and their resistances and sensitives, are presented descriptively. Quality-of-life
outcomes were analysed using mixed models.
Economic evaluation
The health economic analysis adopted the perspective of the NHS and Personal Social Services. Costs
(2016/17) were estimated from questionnaires, entries made in case report forms and from patient-level
information and costing systems. The primary economic effectiveness outcome was ventriculoperitoneal
shunt failure as a result of any cause, with failure due to infection and quality-adjusted-life years – based
on responses to the EuroQol-5 Dimensions, three-level version – as important secondary outcomes. Costs
and benefits occurring after the first year were discounted at 3.5% per annum. The joint uncertainty
in costs and benefits were considered in regression analyses and in non-parametric bootstrapping.
Stratified cost-effectiveness analyses considered important subgroups [paediatrics (aged up to 16 years),
adults aged 16–65 years and adults aged > 65 years].
Results
Participants
A total of 3505 patients were screened for eligibility from 21 centres, 1605 of whom were
subsequently randomised. The overall consent rate in patients who were approached for consent was
82% (n = 1672/2041). The three arms were similar in their baseline characteristics and their baseline risk
assessments. Approximately 40% of all participants were admitted as paediatric patients (n = 599/1605)
and one-quarter of all participants were aged < 1 year.
The randomised groups were approximately equal in size (standard shunt: n = 536; antibiotic shunt: n= 538;
silver shunt: n= 531). Of those randomised, 1585 (98.8%, n= 1605) received the ventriculoperitoneal shunt
as randomised; 16 (1.0%) received an alternative trial ventriculoperitoneal shunt; and four (0.2%) received no
ventriculoperitoneal shunt.
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Primary outcome: time to failure of first ventriculoperitoneal shunt due to infection,
as assessed by a blinded central review panel
Seven patients had an infection at insertion and were not included in the primary outcome set. Of those
remaining (n = 1594), 398 patients had revision operations (25.0%), with 75 being centrally classified as
having ventriculoperitoneal shunt infections (4.7%). The rate of infection was approximately equal in the
standard and silver shunt arms [6.0% (n = 32/533) and 5.9% (n = 31/526), respectively] and lower in the
antibiotic shunt arm (2.2%, n = 12/535).
When compared with the standard shunt, antibiotic shunts decreased the risk of infection (cause-specific
hazard ratio 0.38, 97.5% confidence interval 0.18 to 0.80). Silver shunts were comparable to standard
shunts (cause-specific hazard ratio 0.99, 97.5% confidence interval 0.56 to 1.74). The majority of
centrally assessed infections were classified as definite – culture positive (n = 53/75, 70.7%).
Secondary outcome 1: time to removal of first ventriculoperitoneal shunt due to suspected
infection, as assessed by the treating surgeon
Of the 398 revisions, 78 (4.9%) were defined by the treating surgeon as being due to suspected
infection. As with the primary outcome, when compared with the standard shunt, the antibiotic shunt,
but not the silver shunt, was associated with a significant decrease of infection [antibiotic shunt:
cause-specific hazard ratio 0.45 (97.5% confidence interval 0.23 to 0.91), silver shunt: cause-specific
hazard ratio 0.93 (97.5% confidence interval 0.53 to 1.64)].
Secondary outcome 2: time to ventriculoperitoneal shunt failure due to any cause
The revision rate was approximately equal across the three arms, and varied from 24.4% in the standard
shunt arm (n = 103/533) to 25.9% in the silver shunt arm (n = 136/526). No significant difference was
observed for time to failure between the antibiotic and silver shunt arms when compared with the
standard shunt [antibiotic shunt: hazard ratio 1.01 (97.5% confidence interval 0.77 to 1.33), silver shunt:
hazard ratio 1.08 (97.5% confidence interval 0.82 to 1.42)].
Secondary outcome 3: reason for shunt failure
Although the number of ventriculoperitoneal shunt failures was similar between the three arms, the
underlying reason, as classified by the treating surgeon, differed when comparing the standard shunt
with the antibiotic shunt (p = 0.02); there were fewer infections with antibiotic shunts, but a higher
frequency of failure due to other causes. The underlying reason did not differ significantly when
comparing the standard shunt with the silver shunt (p = 0.71).
Secondary outcome 4: type of bacterial infection
The central review panel classified all shunt infections that were ‘definite – culture positive’ and
‘probable – culture uncertain’ (n = 56/75) by one organism that was cultured. Staphylococcus aureus
accounted for 30% of cultured organisms in ventriculoperitoneal shunt infection (n = 17/56).
Secondary outcome 5: time to ventriculoperitoneal shunt infection following first
clean revision
Among participants with a first clean (non-infected) revision (n = 323), the proportion with a subsequent
revision for any reason was 39.6% (n= 128/323). This rate was 25% (n= 398/1594) in participants with
de novo ventriculoperitoneal shunts. The infection rate was 6.2% (n= 20/323) for participants who had
their de novo shunt revised for reasons other than infection (n = 323) and subsequently went on to have
this replacement shunt revised due to infection (n = 20). This infection rate was higher than that for de
novo ventriculoperitoneal shunts [4.7% (n= 75/1594)]. However, there was no significant between-group
difference in time to infection following first clean revision when comparing either antibiotic or silver
shunts with the standard shunt [antibiotic shunt: cause-specific hazard ratio 0.55 (97.5% confidence
interval 0.17 to 1.75); silver shunt: cause-specific hazard ratio 0.48 (97.5% confidence interval 0.14 to 1.67)].
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Secondary outcome 6: quality of life, assessed using Hydrocephalus Outcome Questionnaire
Insufficient data were returned to formally analyse the Hydrocephalus Outcome Questionnaire results.
Cost-effectiveness analysis
Secondary outcome 7: incremental cost per ventriculoperitoneal shunt failure averted
In the base-case analysis, both antibiotic and silver shunts were located in the south-west quadrant of
the cost-effectiveness plane, in relation to the standard shunt. Incrementally, silver shunts save £62,358
for each additional failure compared with standard shunts, and antibiotic shunt catheters save £638,600
per additional failure compared with silver shunts.
Secondary outcome 8: incremental cost per quality-adjusted life-year gained
Based on the incremental cost per confirmed ventriculoperitoneal shunt infection averted, antibiotic
shunt catheters were dominant, saving £4059 (97.5% confidence interval –£1422 to £12,567) per 0.030
(97.5% confidence interval 0.002 to 0.058) fewer infection-related ventriculoperitoneal shunt failures;
compared with the standard shunt, antibiotic shunt catheters save £135,753 per ventriculoperitoneal
shunt infection avoided. Silver shunt catheters were dominated by the standard shunt.
In the cost–utility analysis of trial participants aged ≥ 5 years, antibiotic shunt catheters were
dominated by silver shunts. Compared with standard shunts, the incremental cost-effectiveness of
silver shunts was £1904 per quality-adjusted life-year gained. The probabilities of cost-effectiveness at
£20,000 per quality-adjusted life-year are 0.206 (standard shunt), 0.274 (antibiotic shunt) and 0.52
(silver shunt); at £30,000 per quality-adjusted life-year, the cost-effectiveness probabilities are 0.147
(standard shunt), 0.267 (antibiotic shunt) and 0.586 (silver shunt).
Adverse events
There were no serious adverse events. A total of 654 adverse events were reported in 413 patients
(constituting 25.8% of n = 1601 participants who received a de novo shunt). The proportion of patients
experiencing an event was similar across the arms (standard shunt: n = 135/531, 25.4%; antibiotic
shunt: n = 136/545, 25.0%; silver shunt: n = 140/525, 26.7%). Common adverse events were ventricular
shunt catheter obstruction (96 events in 79/1601 patients, 4.9%), shunt valve obstruction (65 events in
52/1601 patients, 3.2%) and valve change for symptomatic over-/underdrainage (54 events in 50/1601
patients, 3.1%).
Conclusions
Implications for health care
Antibiotic ventriculoperitoneal shunt reduces the infection rate compared with standard shunts, and,
in doing so, is cost-saving. Silver ventriculoperitoneal shunts are not associated with a lower rate of
infection. The significant effective benefit for the patient of the antibiotic shunt in reducing shunt
infection, combined with the economic benefit in terms of costs saved per ventriculoperitoneal shunt
infection averted, would support all patients receiving an antibiotic-impregnated ventriculoperitoneal
shunt at first shunt insertion.
Implications for research
The BASICS trial is the largest prospective randomised trial on ventriculoperitoneal shunts for
hydrocephalus ever performed, to our knowledge. The information collected will fuel many future
studies on both the molecular biology of infection and the reasons behind both infective and
mechanical shunt failure.
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Trial registration
This trial is registered as ISRCTN49474281.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 17.
See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Parts of this chapter have been reproduced from Jenkinson et al.1 This is an Open Access articledistributed under the terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. The text below includes minor additions and formatting
changes to the original text.
Parts of this chapter have been reproduced from Mallucci et al.2 This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/
by-nd/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The text below includes minor additions and formatting changes to the
original text.
Current practice
Hydrocephalus affects one in every 500 births,3 and is thus one of the most common developmental
disabilities in children. The condition also affects older children and adults of all ages, and can be
secondary to a variety of causes, including intracranial tumours, haemorrhage and infection. In the
late 1950s, the development of a treatment with cerebral shunts revolutionised the management of
these patients.
Standard treatment for hydrocephalus remains the ventriculoperitoneal shunt (VPS) catheter. A VPS
comprises silicone tubing with the addition of an in-line valve that is designed to control the rate of
cerebrospinal fluid (CSF) flow. The tubing passes from the brain fluid cavities (ventricles) under the skin
to the peritoneum (abdominal cavity). The shunt drains CSF from the ventricles to the peritoneal cavity.
Insertion of a VPS to treat hydrocephalus is now one of the most common procedures performed in
neurosurgical units, and between 3000 and 3500 shunt operations are carried out per year in the UK in
adults and children.4 Once inserted, a shunt is generally required for life; it will inevitably be susceptible
to failure, in terms of both infection (as it remains an implanted foreign body) and mechanical failure,
usually due to blockage of tubing or valve failure. Thus, patients with shunts will need lifelong follow up
and usually require multiple surgeries. Therefore, VPS treatment for hydrocephalus is a major health
burden to the NHS.
Industry produces a number of different VPS types, and costs associated with these can vary.
The market comprises a wide variety of different valves and, more recently, different types of shunt
catheter. The treating surgeon and hospital often chooses the type of valve and shunt tubing based on
personal preference and/or associated costs.
There are three types of VPS catheter available (standard, antibiotic impregnated and silver impregnated).
There is no standard practice or guidance in the UK as to which shunt catheter is the most effective at
reducing infection. Practice is variable across the UK and the world. There are no current National Institute
for Health and Care Excellence (NICE) guidelines, nor is there a position statement from the Society of
British Neurological Surgeons regarding the use of any type of VPS.
As an infection in a newly implanted shunt can have such devastating consequences for the patient,
with far-reaching health economic sequelae,5 the industry has led the way in trying to develop types
of shunt catheters that will reduce infection. It is incumbent on clinical researchers to assess the
effectiveness of these developments; this study attempts to answer this question.
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Rationale
Shunt failure due to infection has plagued this neurosurgical advance ever since it was developed.
The reported incidence of shunt infection varies markedly in the literature from 3% to 27%6–10 and
is higher in certain groups, for example neonates and children aged < 1 year, and patients treated
with a previous temporary external ventricular drain (EVD). Episodes of shunt infection have a major
impact on both patients and the NHS and require prolonged inpatient hospitalisation, additional
surgery to remove the infected hardware, placement of a temporary EVD, intravenous and intrathecal
antibiotics and further surgery to place a new shunt once the infection has been treated. Other clinical
consequences of infection, including epilepsy, reduced intelligence quotient (IQ) and loculation, have
often been reported8 but never formally studied in the context of a prospective clinical trial. The
number of shunt infections is an independent predictor of death in patients requiring CSF shunts
[hazard ratio (HR) 1.66, 95% confidence interval (CI) 1.02 to 2.72].11
The most common pathogens detected were staphylococcus species, but, in a proportion of patients
with suspected infection, the organism is never determined, especially if the patient has already
received antimicrobial treatment or if there was a delay in culturing the organism, both of which
hamper microbiological treatment.5 However, newer molecular approaches are being developed,12
including the substudy within this trial.
Data from the UK shunt registry (to which most neurosurgical units contribute) report that 15% of
shunt revisions are for infection.13 In the largest randomised controlled shunt trial worldwide, the
infection rate was 8.4% for primary VPSs.14
Impregnated VPS catheters have been introduced as a means to reduce VPS infection, in addition to
the usual surgical site infection prevention care bundles that are not standardised across neurosurgery
clinical practice.
There are three types of VPS catheters available, and there are cost implications associated
with impregnated shunt catheters that, typically, are more than double the cost of the standard
non-impregnated VPS catheters:
1. standard VPSs are made of silicone and are available and supplied by a number of different companies
2. antibiotic-impregnated VPSs are made of silicone and are impregnated with antibiotics (0.15%
clindamycin and 0.054% rifampicin) [available as Bactiseal® (Codman®; Integra LifeSciences Holdings
Corporation, Plainsboro, NJ, USA) and Ares™ (Medtronic plc, Dublin, Ireland)]
3. silver-impregnated VPSs are made of silicone and impregnated with silver [available as Silverline®
(Spiegelberg GmbH & Co. KG, Hamburg, Germany)].
Despite a large number of publications15–22 prior to our study, there has been limited evidence to date
indicating the clinical effectiveness of these impregnated shunt catheters. Prior to our study, a systematic
review and meta-analysis23 of the Bactiseal VPS identified one randomised controlled trial (RCT)15 and
11 observational studies. The RCT,15 conducted in a single centre in South Africa, demonstrated a trend
favouring impregnated VPSs, but did not show a statistically significant difference between the two
trial groups [relative risk (RR) 0.38, 95% CI 0.11 to 1.30; p = 0.12]; however, meta-analysis of the 11
observational studies showed a statistically significant difference favouring the Bactiseal VPS (RR 0.37,
95% CI 0.23 to 0.60; p< 0.01).23 Research on the Bactiseal VPS conducted in Liverpool, UK, has shown that,
over a 2-year period, the infection rate reduced among paediatric patients who were given the Bactiseal
VPS compared with historical controls.16 However, continued data collection over 3.5 years, published as
part of a Liverpool-led multicentre observational study in collaboration with two other UK paediatric
neurosurgical units, showed no significant reduction in infection.17 Indeed, the reduction in infection
achieved by the Bactiseal VPS in the multicentre observational study17 was seen only in neonates and was
heavily weighted by the results from one unit. This study17 was not part of the published systematic review.23
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Silver-impregnated shunts were launched in the UK in March 2011. There is little doubt that silver
ions have antimicrobial effects and they elute from Silverline shunt catheters. However, the efficacy
of Silverline shunt catheters at preventing VPS infections is not proven. In vitro models have shown
varying results and clinical studies are limited.18,19 There is one observational study of the Silverline
VPS,20 in which the Silverline VPS was used to successfully treat seven patients with active CSF
infection. There are no observational studies comparing Silverline VPS infection rates with those of
either standard or Bactiseal VPSs. However, in a RCT of EVDs (an EVD is a temporary tube placed in
the ventricles that is prone to infection) in children and adults, Silverline EVDs have been shown to
reduce infection from 21.4% (30/140) with standard shunt catheters to 12.3% (17/138) (p = 0.043) for
silver shunt catheters.22 Two further observational studies comparing standard with Silverline EVDs
also show a reduction in infection rates.21,24
Risks and benefits
The potential beneficial effect on health status of these impregnated shunt catheters is reduced shunt
infection and its negative sequelae. Prior to this study, approximately 70%4,13 of shunt operations in
the UK were with Bactiseal shunts (verified by feasibility screening logs) and it was felt that, just like
Bactiseal, there was likely to be a significant uptake of Silverline shunts by neurosurgeons, despite the
lack of evidence of clinical or cost benefit.
The potential adverse effects of impregnated shunt catheters has never been studied prospectively,
to our knowledge. One of the potential concerns of antibiotic-impregnated shunt catheters is the
potential for selecting out resistant organisms or missing potential infections owing to an inability to
culture them.
Thus, before the wide adoption of these impregnated shunt catheters, an adequately powered RCT
is needed to assess their effectiveness at reducing infection and to determine their safety (including
the type of organisms cultured), antibiotic sensitivities and antibiotic resistances.
Aims and objectives
Primary objective
The primary objective was to determine whether or not antibiotic- or silver-impregnated VPSs reduce
infection compared with standard VPSs in patients with hydrocephalus, following insertion of a de
novo VPS.
Secondary objectives
l To determine the proportion of first VPS infections occurring > 6 months after insertion of a
de novo VPS.
l To determine whether or not antibiotic- or silver-impregnated VPSs reduce shunt failure due to any
cause compared with standard VPSs in patients with hydrocephalus following insertion of a de novo VPS.
l To assess whether or not the reason for shunt failure is different across the three different types of VPS.
l To determine which organisms and their resistances/sensitivities subsequently infect three
alternative VPSs.
l To determine whether or not antibiotic- or silver-impregnated VPSs reduce infection following first
(non-infected) clean VPS revision for mechanical failure, compared with standard VPSs in patients
with hydrocephalus, following insertion of a de novo VPS.
l To assess the impact of VPS infection on patients in terms of quality of life.
l To assess the cost-effectiveness of antibiotic- and silver-impregnated VPSs compared with
standard VPSs.
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Chapter 2 Trial design and methods
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changes to the original text.
Parts of this chapter have been reproduced from Mallucci et al.2 This is an Open Access article distributed
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original work is properly cited. The text below includes minor additions and formatting changes to the
original text.
Trial design
A schematic representation of the trial design is given in Figure 1.
Ethics approval and research governance
The protocol was approved by the Greater Manchester South Research Ethics Committee (reference
number 12/NW/0790). The trial was funded by the National Institute for Health Research Health
Technology Assessment programme (number 10/104/30) and included on the International Standard
Randomised Controlled Trial Number registry (ISRCTN49474281). Centre-specific approval was
obtained at all of the recruiting centres.
The protocol has been published previously.1 The trial opened on protocol version 3.0, and the final
approved version of the protocol was version 13.0, which contains a complete list of protocol changes
[see www.fundingawards.nihr.ac.uk/award/10/104/30 (accessed 22 January 2020)]. A summary of
substantial protocol amendments are provided in Table 1.
Selection of trial centres
Participants were recruited from 21 regional adult and paediatric neurosurgery centres in the UK
and the Republic of Ireland. To be eligible to participate in the trial, centres had to meet the British
Antibiotic and Silver Impregnated Catheters for ventriculoperitoneal Shunts (BASICS) trial centre
suitability assessment criteria:
l minimum of three patients per month
l neurosurgical unit treating adults or paediatrics
l evidence of a team to undertake trial activities
l principal investigator (PI) had previous experience of RCTs or a significant role
l no local issues to prevent trial set-up
l completion of prospective screening log.
Participants
The trial was open to all patients (children and adults) who had hydrocephalus requiring treatment
with a first permanent VPS who met the eligibility criteria.
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Inclusion criterion
Patients were considered for inclusion in the trial if they met the following criterion:
l Hydrocephalus of any aetiology [including idiopathic intracranial hypertension (IIH)] requiring a
first VPS.
Note that failed primary endoscopic third ventriculostomy was allowed, indwelling ventricular access
devices (e.g. Ommaya or Rickham reservoir or ventriculosubgaleal shunt or similar) were allowed and













Day 8 to month 30 post operation
3-monthly follow-up
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• Post-operative CT/MRI according to local unit practice
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• CSF/blood sample for
    substudy Infection
Continue follow-up
for safety analysis
FIGURE 1 Trial design. CT, computerised tomography; MRI, magnetic resonance imaging. Reproduced from Jenkinson
et al.1 This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. The figure includes minor additions and formatting changes to the original.
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TABLE 1 Key protocol amendments
Protocol version and date Key amendments
2.0 (21 November 2012) l Protocol: ‘Allergy to antibiotics associated with the antibiotic shunt’ added to the
exclusion criteria
3.0 (22 March 2013) l Section 1: protocol summary – primary objective wording changed to:
To determine whether antibiotic or silver impregnated VPS reduce infection compared to
standard VPS in hydrocephalus following insertion of de novo VPS
l Section 4: trial design – secondary end point added: ‘e. Quality of Life’
l Section 5: inclusion criteria changed to ‘Hydrocephalus of any aetiology (including IIH)
requiring first VPS’
l Section 7: trial interventions –
¢ 7.4.1.1 changed to ‘Initial insertion of new randomised VPS’
¢ 7.4.1.2 changed to ‘First Shunt Revision (includes first infection or
mechanical revision)’
4.0 (25 July 2013) l Section 5.1: inclusion criteria and exclusion criteria updated to –
¢ indwelling ventricular access devices (e.g. Ommaya or Rickham reservoir or
ventriculosubgaleal shunt or similar) are allowed
¢ indwelling EVD allowed
5.0 (20 December 2013) l Section 4: trial design
l Primary end point changed to read ‘Time to failure of the first VPS due to infection’
l Section 5.2: exclusion criteria changed to –
¢ previous indwelling ventricular or lumbar peritoneal or atrial shunt
¢ allergy to silver
6.0 (1 April 2014) l Section 11.3.5: nominated consent added
8.0 (10 August 2015) l Protocol summary section, study duration: maximum follow-up changed from
2.5 years to 2 years
9.0 (10 August 2016) l Change of trial end date to 31 August 2017
l Section 1: protocol summary
¢ Population: trial population changed to up to 1650 patients
¢ Study Centres and Distribution: amended to 19 neurosurgical wards across the UK
and the Republic of Ireland
Trial duration: amended the duration to ‘utilising a recruitment period of 4 years, 2 months’
10.0 (11 August 2017) l Section 4.1 changed to:
Time to failure of the first VPS due to infection. Infection will be classified as in section 8.2.
Where there is insufficient information to classify in this way, the information captured on
whether the VPS was removed for suspected infection or revised for mechanical failure will
be used to make the classification
A sensitivity analysis will be undertaken where infection is defined only by the classification
in section 8.2, where patients who are unable to be classified will be removed from the
analysis altogether
l Section 4.2: addition of ‘Time to removal of the first VPS due to suspected infection’
11.0 (5 April 2018) Section added to the protocol to access HES data for patients with a Welsh postcode
13.0 (25 September 2018) l Trial end date changed to 31 January 2019
HES, Hospital Episode Statistics; IIH, idiopathic intracranial hypertension.
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Exclusion criteria
Patients with the following characteristics were excluded from the trial:
l previous indwelling ventricular or lumbar peritoneal or atrial shunt
l active and ongoing CSF or peritoneal infection (previously infected cases were allowed once they
were clear of infection)
l multiloculated hydrocephalus requiring multiple VPS or neuroendoscopy
l ventriculoatrial or ventriculopleural shunt planned
l allergy to antibiotics associated with the antibiotic shunt
l allergy to silver.
Recruitment procedure
Screening
Screening was performed daily by clinical staff or the designated research nurse (throughout this
report, ‘research nurse’ means either the research nurse or someone who has been delegated that
duty) to identify potentially eligible patients. This was carried out on the daily ward rounds or at an
appropriate time point, depending on the clinical setting.
All patients having a first VPS for hydrocephalus of any aetiology (including IIH) were screened for
eligibility and recorded on the screening log. Reasons for non-recruitment were documented (e.g. not
eligible, declined consent) and the information was used for monitoring purposes.
Informed consent
Eligible patients were provided with patient information sheets. In the case of children or adults who
lacked mental capacity to consent, the parents, consultee or legal representative were approached to
discuss participation. When feasible, this was at a clinic visit prior to admission. The research nurse gave
the family sufficient time to discuss the trial and to decide whether or not to consent to trial entry.
Patients were eligible to be randomised to the trial if written consent was provided by the patient,
parent, legal representative or consultee.
Randomisation, concealment and blinding
Patients were randomised to standard silicone or antibiotic- or silver-impregnated VPS catheters in a
ratio of 1 : 1 : 1 in random permuted blocks of three and six. The randomisation sequence was generated
by an independent statistician and was stratified by neurosurgical unit, age group (adult or paediatrics
was defined according to unit practice) and envelope storage room within the neurosurgical unit.
Randomisation was undertaken in the operating theatre at the time when the VPS was required.
Pressure-sealed envelopes were opaque and tamper-proof: they were opened by tearing perforated
edges. Patients and a central review panel, but not surgeons or operating staff, were blinded to the type
of VPS inserted. VPS type was not recorded in the operating record and was not disclosed outside the
operating room. Training on non-disclosure of VPS type was provided to all investigators. All VPS types
were medical devices used in accordance with the manufacturer’s instructions for their intended purpose.
Trial assessments
Table 2 provides the schedule of trial assessments. Participants were followed up for a minimum of
6 months and a maximum of 2 years, dependent on their randomisation date.
Data collection
Data were collected on paper-based case report forms (CRFs) completed by centre staff who were
authorised to do so and returned to the Liverpool Clinical Trials Centre (LCTC) Clinical Trials Unit (CTU).
TRIAL DESIGN AND METHODS
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Review of relevant medical
history
✗ ✗
Collect demographic data ✗ ✗
Review of concomitant
medications
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Weight ✗
Heart rate ✗ ✗ (✗)






Trial intervention ✗ ✗
Wound check ✗ (✗) (✗) (✗)












































































































































































































































































































































































Additional CSF and blood
taken for substudy
(✗) (✗)






Health service diary ✗ ✗ ✗
Post-operative CT/MRI (✗) (✗) (✗) (✗)
Assessment of AEs ✗ ✗ ✗ ✗ ✗ ✗ ✗
AE, adverse event; CT, computerised tomography; MRI, magnetic resonance imaging.
a At baseline, all procedures were carried out before the trial intervention.
b The schedule of post-operative follow-up visits was dependent on the trust’s post-operative follow-up procedure, and the participant’s clinical condition.
c Informed consent should have always been sought prior to trial intervention. The exception to this rule is adults lacking capacity to consent. If an adult lacking capacity regained
capacity at any point during the trial, informed consent should have been sought.
d The CSF sample was taken during surgery.
e The CSF sample was taken using a CSF tap or lumbar puncture.
f The results were reviewed (and the microbiology form updated) within 72 hours of surgery, even if the patient had been discharged before the results were available. If the results
indicated a CSF infection, patients were only followed up for safety (until 48 hours after VPS removal).
g The health economics questionnaires were completed during the first 3-monthly follow-up telephone call only.
Note









































Participants were issued with diaries to record their health-care utilisation every 12 weeks and
administered questionnaires to measure quality of life. A planned analysis of data from NHS Digital
could not be achieved as the sponsor was unable to meet NHS Digital requirements for obtaining
Hospital Episode Statistics data within the project timeline. Electronic health-care data were therefore
obtained from Patient-Level Information and Costing Systems (PLICS).
Data were collected at baseline, randomisation, the peri-operative assessment, the early post-operative
assessment, the first routine post-operative assessment and the subsequent post-operative assessment,
and at the time points described in the remainder of this section.
The 12-weekly follow-up assessment
The 12-weekly follow-up was conducted face to face if there was a routine appointment scheduled at the
same time point; if not, the follow-up was conducted by telephone. The following data were recorded:
l related adverse events (AEs)
l concomitant medications
l pregnancy.
At the first 12-week assessment, the research nurse completed the relevant quality-of-life
questionnaire (Table 3) with the participant over the telephone.
Unscheduled visit/admission assessment
The ‘unscheduled visit/admission’ CRF was completed for any non-routine attendance at the treating
neurosurgical centre and the following data were recorded:
l source of unscheduled visit










l outcome of visit.
Shunt revision/removal
If a patient was admitted for a clean VPS revision (for mechanical shunt failure, functional shunt failure
or failure due to the patient) or removal (for suspected infection), the following data were recorded:
l surgery details (separate sections for revision/removal)
l surgeon details
l CSF sample details (including samples for substudies, if patient is taking part)
l related AEs
l concomitant medications.
In addition, the shunt surgery log was completed for all surgeries that took place after the initial
surgery when the randomised shunt was inserted.
For instances in which the shunt was removed for suspected infection, concomitant medications were
reported up until 14 days after removal and the patient was reviewed for 48 hours for AEs and serious
adverse events (SAEs).
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Quality of life and health service diaries
Questionnaires
The EuroQol-5 Dimensions, three-level version (EQ-5D-3L), the EQ-5D-3L Proxy, the EuroQol-5
Dimensions Youth (EQ-5D-Y) (youth version), the EuroQol Visual Analogue Scale (EQ-VAS) or the
Hydrocephalus Outcome Questionnaire (HOQ)25 were administered to participants, or their parent or
carer, according to age (see Table 3) to measure participants’ health outcome and quality of life.
Resource use questionnaires were given/posted out to participants every 12 weeks for participants to
complete and return to the centres 12 weeks later. Participants were reminded by the research nurse
to return diaries during the 12-weekly assessments if they had not done so.
Measures
Primary outcome
The primary outcome was time to VPS infection as assessed by the central review panel, which comprised
the chief investigator (or delegate for participants treated at the centre of the chief investigator) and
a microbiologist, who were masked to participant allocation. Each VPS revision was classified as infection
or no infection. Infections were further classified as definite (culture positive), probable (culture uncertain),
probable (culture negative), possible (culture uncertain) or VPS deep incisional infection according to the
microbiological samples sent and the criteria in the trial protocol.
Secondary outcomes
Secondary outcomes were as follows:
l time to removal of the first VPS due to suspected infection, as defined by the treating surgeon at
the time of revision
l time to VPS failure of any cause (infection, mechanical, patient or functional)
l reason for failure (infection, mechanical, patient, functional) as classified by the treating surgeon
l types of bacterial VPS infection (organism, antibiotic resistances)
l time to VPS infection following first clean (non-infected) revision, as classified by the central
review panel
l quality of life measured using the HOQ25
l health economics outcomes – incremental cost per VPS failure averted and quality-adjusted
life-year (QALY) gained, measured using the EQ-5D-3L, EQ-5D-3L Proxy and EQ-5D-Y questionnaires.




< 5 None administered None administered
5 to < 8 None administered HOQ (parent version)
EQ-5D-3L (proxy 1)a
8 to < 18 HOQ (child version) EQ-5D-3L (proxy 1)a (including EQ-VAS)
EQ-5D-Y (including EQ-VAS)
≥ 18 years EQ-5D-3L (including EQ-VAS) EQ-5D-3L (proxy 1)b (including EQ-VAS)
EQ-5D-3L, EuroQol-5 Dimensions, three-level version; EQ-5D-Y, EuroQol-5 Dimensions Youth; EQ-VAS, EuroQol
Visual Analogue Scale; HOQ, Hydrocephalus Outcome Questionnaire.
a If the EQ-5D-3L or HOQ is completed by proxy, every effort should be made to ensure that the same parent/
caregiver/consultee completes the questionnaire at subsequent time points.
b In the case of adults lacking capacity to consent for themselves, the EQ-5D-3L (proxy 1) will be completed by the
consultee with whom the study was discussed.
TRIAL DESIGN AND METHODS
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Data on complications and SAEs were also collected.
Sample size
The sample size for the primary outcome was calculated using the Pintilie26 method with the following
assumptions: (1) failure for infection was the event of interest, with all other reasons for failure a
competing risk, (2) the rate of infection was 8% in the standard silicone arm14 and 4% in the impregnated
shunt catheter arms, (3) the competing risk event rate was 30% and (4) there was a 5% loss to follow-up.
A total sample size of 1200 participants with 119 events demonstrated good statistical power (88%),
with leverage for a lower event rate if required (Table 4). A feasibility study conducted in trial centres for
1 month indicated an annual eligible participant figure of 1200; a conservative estimate of consent of
50% suggested that the sample size would be achievable within a 2-year recruitment period, with
participants followed up for a minimum of 6 months.
An interim analysis was planned after 50% of the total events had been observed, using the
Haybittle–Peto method.27
Monitoring of the infection rate during the trial demonstrated that the majority of events occur within
1 month of VPS insertion (i.e. they are not exponentially distributed), and that the rates of infection,
competing risk and loss to follow-up were lower than expected. In January 2016, the Independent Data
and Safety Monitoring Committee (IDSMC) reviewed the sample size calculations and recommended
increasing recruitment to a target of 1606 participants with 101 events, to provide 80% power; the
Trial Steering Committee (TSC) agreed and approved this change. The early occurrence of events and
assumption of exponential risk were managed in the Pintilie26 method assumptions by reducing the
accrual and follow-up rates to 1 month.
Statistical methods
The main features of the analysis plan were specified in the protocol; the final analyses were
undertaken according to a more detailed and prespecified statistical analysis plan (see Report
Supplementary Material 1), consistent with the protocol.
Efficacy outcomes were analysed according to the intention-to-treat principle as far as practically possible;
AEs and SAEs were reported according to the type of VPS in situ. A Bonferroni adjustment28 was made
to allow for multiple comparisons (antibiotic-impregnated vs. standard VPS, and silver-impregnated vs.
standard VPS) and a 2.5% level of statistical significance and 97.5% CIs were used throughout.
Outcomes with infection as the event of interest used Fine and Gray29 survival regression models with
cause-specific hazard ratios (csHRs) and subdistribution hazard ratios (sHRs) presented.30,31 Cox regression
models were used to analyse time to VPS failure due to any cause. Reason for VPS failure is presented




(across the three trial arms) (n)Control arm Treated arms
0.1 0.05 0.48 94 1140
0.08 0.04 0.49 80 942
0.08 0.04 0.49 88 1157
0.05 0.025 0.49 67 1144
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descriptively (see Chapter 3, Secondary outcome 3: reason for shunt failure) and with a chi-squared test. Types
of organisms and their resistances and sensitivities are presented descriptively in Chapter 3, Secondary
outcome 4: types of bacterial infection. Quality-of-life outcomes were analysed using mixed models.
All survival models were adjusted for the age category of the recruiting centre (paediatric or adult), with
adult centres further categorised by age > 65 years. A post hoc analysis was conducted that explored
revision rates, and reason for revision, by aetiology of the hydrocephalus, type of valve and operative
approach. Results of the post hoc analysis are presented descriptively in Chapter 3, Post hoc analyses.
Primary outcome and safety analyses were validated by independent programming from the point of
raw data extraction. All analyses were carried out with SAS® software version 9.4 with SAS/STAT
package 14.3 (SAS Institute Inc, Cary, NC, USA).
Patient and public involvement
The trial team collaborated with young people and parent contributors throughout the trial:
l Advice was sought from the Medicines for Children Research Network Young Person’s Group on
the content and presentation of patient information leaflets and consent forms. The Medicine
for Children’s Research Network is a division of the LCTC, part of the Liverpool Clinical
Trials Collaborative.
l Three lay members were invited at the trial outset to join the Trial Management Group (TMG) and
TSC; one was recruited to be a member of the TMG.
l Members of the TMG, including the lay member, met via teleconference with the patient and public
involvement co-ordinator for the LCTC early in the trial to establish the timings for return of the
patient-completed diaries and to identify ways to maximise the return rate of these diaries. They
decided that it would be appropriate for the centre team to contact the participant or representative
via telephone every 3 months as a reminder to complete and return the diaries.
l The charity Shine (Spina bifida Hydrocephalus Information Networking Equality) was continually
supportive of the trial. A Shine representative was a member of the TSC.
Trial oversight and role of funders
The TMG, comprising the chief investigator, other lead investigators (clinical and non-clinical) and
members of the LCTC CTU, was responsible for the day-to-day running and management of the trial.
The membership of the oversight committees was suggested by members of the TMG to the trial
funders and appointed by the funders with their constitution following funder requirements.
The TSC consisted of an independent chairperson, an independent microbiologist, a lay representative
from the Shine charity and an independent statistician. The chief investigator was a non-independent
member of the TSC. The role of the TSC was as the executive decision-making committee, considering
the recommendations of the IDSMC. Monitoring reports viewed by the TSC were not split by
treatment group.
The IDSMC consisted of an independent chairperson, plus two independent members: an expert in the
field of microbiology and an expert in medical statistics. The IDSMC was responsible for reviewing and
assessing recruitment, interim monitoring of safety and effectiveness, trial conduct and external data.
The IDSMC provided recommendations to the TSC concerning the continuation of the trial and viewed
accumulating data split by treatment group.
All protocol amendments were approved by the funder prior to ethics submission.
TRIAL DESIGN AND METHODS
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Chapter 3 Results
Parts of this chapter have been reproduced from Mallucci et al.2 This is an Open Access articledistributed under the terms of the Creative Commons Attribution License (https://creativecommons.
org/licenses/by-nd/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. The text below includes minor additions and formatting
changes to the original text.
Recruitment and screening
The trial opened to recruitment on 26 June 2013 and closed on 9 October 2017.
During this period, 3505 patients were screened for eligibility, of whom 1605 patients were randomised
from 21 centres. One patient was randomised twice and their data contributed from the first randomisation
only. See Appendix 2, Figure 8 and Tables 32 and 33, for screening and recruitment data.
Screened patients who were not randomised fell into four categories: the patient did not meet eligibility
criteria (n = 1020); the patient was eligible but consent was not sought (n = 435); consent was sought
but the patient declined (n = 369); and the patient was not randomised for another reason (n = 67).
The overall consent rate in patients who were approached for participation was 82%.
A Consolidated Standards of Reporting Trials (CONSORT) flow diagram illustrating the pathway of
patients from screening to consent and randomisation is provided in Figure 2.
Baseline comparability
The three groups were similar in their baseline characteristics (Table 5) and baseline risk assessment
(Table 6). Approximately 40% of all participants were paediatric patients, with one-quarter of all
participants being aged < 1 year at the time of randomisation. The factors recorded on the baseline
risk assessment were those regarded within the literature as being associated with a high risk of infection.
Retention and adherence
Table 7 summarises compliance with the randomly allocated shunt. Of the 1605 participants randomised,
four (0.2%) had no VPS inserted and 16 (1%) received a different VPS to the one that was randomly
allocated. Reasons for participants having an alternative trial VPS inserted or no VPS are provided
in Appendix 2, Tables 35 and 36, respectively. Participants receiving no VPS were excluded from the
intention-to-treat population; for the safety analysis, participants were analysed according to the VPS
received. The analysis sets are summarised in Table 8.
In total, 53 (3.3%) randomised participants withdrew from the trial. No participants withdrew consent
to use collected data. Table 9 summarises the level of and reasons for withdrawal.
Unblinding
A total of 32 participants from 10 centres were unblinded during the course of the trial.
Unblinding could be accidental or intentional. Accidental unblinding was defined as an unplanned occurrence;
for example, the allocation was incorrectly recorded in the participant notes. Intentional unblinding occurred
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• Not eligible, n = 1020
• Consent not sought, n = 435
• Consent not provided, n = 369
• Consent provided although not
    randomised, n = 67
• Unknown, n = 9
ITT population
(n = 536)
• Infection at insertion,











• Allocated VPS inserted,
    n = 530
• Allocated VPS not














• Allocated VPS inserted,
     n = 534
• Allocated VPS not








• Allocated VPS inserted,
    n = 521
• Allocated VPS not











• Infection at insertion,





• Infection at insertion,
     n = 3
Primary outcome set
(n = 526)
FIGURE 2 The CONSORT flow chart. ITT, intention to treat.








Number randomised 536 538 531 1605
Age (years)
n (n missing) 536 (0) 538 (0) 531 (0) 1605 (0)
Median (IQR) 42.5 (0.8–69.7) 43.9 (1.1–70.8) 41.1 (0.5–68.8) 42.5 (0.8–69.6)
Minimum, maximum 0.0, 90.3 0.0, 88.9 0.0, 91.1 0.0, 91.1
Age category
n (n missing) 536 (0) 538 (0) 531 (0) 1605 (0)
Paediatric, n (%) 200 (37.3) 201 (37.4) 198 (37.3) 599 (37.3)
Adult (≤ 65 years), n (%) 174 (32.5) 156 (29.0) 172 (32.4) 502 (31.3)
Adult (> 65 years), n (%) 162 (30.2) 181 (33.6) 161 (30.3) 504 (31.4)
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n (n missing) 535 (1) 538 (0) 531 (0) 1605 (0)
Female, n (%) 246 (46.0) 260 (48.3) 282 (53.1) 788 (49.1)
Male, n (%) 289 (54.0) 278 (51.7) 249 (46.9) 816 (50.9)
Weight (kg)
n (n missing) 523 (13) 523 (15) 515 (16) 1561 (44)
Median (IQR) 64.0 (8.8–82.7) 63.0 (9.6–82.0) 63.0 (7.3–80.0) 63.1 (8.7–81.5)
Minimum, maximum 1.1, 161.0 0.8, 163.0 1.3, 145.0 0.8, 163.0
Heart rate (BPM)
n (n missing) 530 (6) 532 (6) 521 (10) 1583 (22)
Median (IQR) 84 (72–120) 85 (70–116.5) 84 (70–124) 84 (70–121)
Minimum, maximum 48, 190 44, 185 43, 185 43, 190
BPM, beats per minute; IQR, interquartile range.










Previous Staphylococcus aureus infection (requiring treatment in the previous 6 months)
n (n missing) 534 (2) 538 (0) 531 (0) 1603 (2)
Yes, n (%) 18 (3.4) 15 (2.8) 16 (3.0) 49 (3.1)
No, n (%) 516 (96.6) 523 (97.2) 515 (97.0) 1554 (96.9)
Active skin/wound infection
n (n missing) 534 (2) 538 (0) 530 (1) 1602 (3)
Yes, n (%) 7 (1.3) 8 (1.5) 5 (0.9) 20 (1.2)
No, n (%) 527 (98.7) 530 (98.5) 525 (99.1) 1582 (98.8)
MRSA infection in the previous 6 months
n (n missing) 535 (1) 537 (1) 529 (2) 1601 (4)
Yes, n (%) 6 (1.1) 4 (0.7) 5 (0.9) 15 (0.9)
No, n (%) 529 (98.9) 533 (99.3) 524 (99.1) 1586 (99.1)
Pre-term at birth
n (n missing) 513 (23) 522 (16) 505 (26) 1540 (65)
Yes, n (%) 78 (15.2) 82 (15.7) 76 (15.0) 236 (15.3)
No, n (%) 435 (84.8) 440 (84.3) 429 (85.0) 1304 (84.7)
continued
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Abdominal surgery in the previous month
n (n missing) 533 (3) 538 (0) 531 (0) 1602 (3)
Yes, n (%) 3 (0.6) 3 (0.6) 8 (1.5) 14 (0.9)
No, n (%) 530 (99.4) 535 (99.4) 523 (98.5) 1588 (99.1)
Tracheotomy
n (n missing) 534 (2) 538 (0) 531 (0) 1603 (2)
Yes, n (%) 32 (6.0) 13 (2.4) 21 (4.0) 66 (4.1)
No, n (%) 502 (94.0) 525 (97.6) 510 (96.0) 1537 (95.9)
Percutaneous endoscopic gastrostomy
n (n missing) 534 (2) 538 (0) 531 (0) 1603 (2)
Yes, n (%) 14 (2.6) 7 (1.3) 15 (2.8) 36 (2.2)
No, n (%) 520 (97.4) 531 (98.7) 516 (97.2) 1567 (97.8)
CSF leak in the previous month
n (n missing) 534 (2) 538 (0) 531 (0) 1603 (2)
Yes, n (%) 57 (10.7) 51 (9.5) 35 (6.6) 143 (8.9)
No, n (%) 477 (89.3) 487 (90.5) 496 (93.4) 1460 (91.1)
EVD in previous 3 months
n (n missing) 532 (4) 538 (0) 531 (0) 1601 (4)
Yes, n (%) 105 (19.7) 95 (17.7) 90 (16.9) 290 (18.1)
No, n (%) 427 (80.3) 443 (82.3) 441 (83.1) 1311 (81.9)
MRSA, methicillin-resistant Staphylococcus aureus.










Standard 536 530 (98.9) 6 (1.1) 0 (0.0)
Antibiotic impregnated 538 534 (99.3) 2 (0.4) 2 (0.4)
Silver impregnated 531 521 (98.1) 8 (1.5) 2 (0.4)
Total 1605 1585 (98.8) 16 (1.0) 4 (0.2)
TABLE 8 Data sets analysed
Population
Trial group, n (%)





Randomised 536 (33.4) 538 (33.5) 531 (33.1) 1605 (100)
Intention to treat 536 (33.5) 536 (33.5) 529 (33.0) 1601 (99.8)
Safety 531 (33.2) 545 (34.0) 525 (32.8) 1601 (99.8)
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when the unblinding envelope was opened; for example, if a patient was transferred to another hospital and
staff needed to be aware of their allocation. Twenty-five participants from eight centres were accidentally
unblinded and seven participants from four centres were intentionally unblinded. Table 10 summarises
unblinding events, both overall and by randomised VPS.
TABLE 9 Withdrawal summary
Withdrawal summary










Randomised 536 (33.4) 538 (33.5) 531 (33.1) 1605 (100)
Withdrawals 14 (2.6) 22 (4.1) 17 (3.2) 53 (3.3)
Level of withdrawal
Withdrawal of dataa 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Consent revoked to use data collected 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Withdrawal from follow-upb 14 (2.6) 22 (4.1) 17 (3.2) 53 (3.3)
Consent revoked for trial-specific data to be collected 6 (1.1) 9 (1.7) 9 (1.7) 24 (1.5)
Consent revoked for any trial data to be collected 8 (1.5) 13 (2.4) 8 (1.5) 29 (1.8)
Consent revoked for additional substudy samples
to be taken
3 (0.6) 1 (0.2) 1 (0.2) 5 (0.3)
Reasons for withdrawal
Unexpected related AE or SAE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Burden of additional trial data collection 4 (0.7) 9 (1.7) 5 (0.9) 18 (1.1)
Other 10 (1.9) 16 (3) 13 (2.4) 39 (2.4)
Decision for withdrawal made by
Participant (aged ≥ 16 years) 1 (0.2) 5 (0.9) 5 (0.9) 11 (0.7)
Parent/guardian/consultee 8 (1.5) 12 (2.2) 7 (1.3) 27 (1.7)
Clinical 4 (0.7) 5 (0.9) 5 (0.9) 14 (0.9)
None listed 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.1)
a Withdrawal of consent: revoke consent to use data collected.
b Withdrawal from follow-up: data up to the time of withdrawal will be included in the analysis.









Accidental Patient 10 5 10 25
Centre 6 3 7 8
Intentional Patient 1 1 5 7
Centre 1 1 4 4
Total Patient 11 6 15 32
Centre 7 4 4 10
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Protocol deviations
Prespecified protocol deviations are summarised in Appendix 2, Table 37. The most common major
protocol deviation was that shunt components were not taken for culture at shunt revision/removal
(n = 320, 19.9%). This was not routine practice in many units, and the impact of this deviation on the
identification of infections for the primary outcome was mitigated by the low numbers of missing
CSF at revision (n = 14), as CSF analysis and culture was the primary factor used for defining shunt
infection (not culture of the shunt tubing or components).
Antibiotic sensitivity data were not returned on many isolates.
Primary outcome: time to ventriculoperitoneal infection as assessed by the
central review panel
The primary outcome was time to VPS infection, as assessed by the central review panel.
Four participants received no shunt and seven participants had an infection at insertion; these
participants were excluded from the primary analysis set (see Figure 2).
A summary of the first VPS revisions and infections among participants in the primary intention-to-
treat analysis set is provided in Table 11. The overall revision rate of first VPS was 25% (398/1594),
and was approximately equal between each of the three VPS groups.
TABLE 11 Summary of first VPS revisions and infections as classified by the central committee
Primary VPS revisions











Eligible for primary outcomea 533 (99.4) 535 (99.8) 526 (99.4) 1594 (99.6)
No VPS removal/revision 403 (75.6) 403 (75.3) 390 (74.1) 1196 (75.0)
VPS removal/revision (for any cause) 130 (24.4) 132 (24.7) 136 (25.9) 398 (25.0)
Reason for revision as classified by central review
Reason for revision
Revision for infection 32 (6.0) 12 (2.2) 31 (5.9) 75 (4.7)
Revision for other reason (no infection) 98 (18.4) 120 (22.4) 105 (20.0) 323 (20.3)
Type of infection
VPS CSF or peritoneal infection
Definite: culture positive 22 (68.8) 6 (50.0) 25 (80.6) 53 (70.7)
Probable: culture uncertain 1 (3.1) 0 (0.0) 2 (6.5) 3 (4.0)
Probable: culture negative 3 (9.4) 3 (25.0) 1 (3.2) 7 (9.3)
Possible: culture uncertain 1 (3.1) 0 (0.0) 1 (3.2) 2 (2.7)
Clinically classified infectionb 1 (3.1) 0 (0.0) 0 (0.0) 1 (1.3)
VPS deep incisional infection 4 (12.5) 3 (25.0) 2 (6.5) 9 (12.0)
a Randomised participants who did not receive a VPS (n = 4) and had infection at time of insertion (n= 7) were
excluded from the primary outcome set (see Figure 2).
b If the central review panel was unable to classify, an infection was classified by the operating surgeon on the CRFs.
In one case, the committee could not classify and this was clinically classified as an infection.
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All first revisions were classified as to whether or not the revision was for suspected infection by the
central review panel. If there was insufficient information for the central review panel to classify an
infection (n = 1/398; see Table 11), the clinical classification, as recorded on the CRFs by the treating
surgeon, was used.
Of the total number of first revisions, 75 were classified infections (4.7%). The infection rate was
approximately equal in the standard and silver-impregnated VPS arms (6.0% and 5.9%, respectively)
and lowest in the antibiotic-impregnated VPS arm (2.2%). The time to infection was similar across
all treatment arms {standard VPS arm: median 1 month [lower quartile (LQ)–upper quartile (UQ)
0–1.5 months]; antibiotic-impregnated VPS arm: median 1 month [LQ–UQ 0–2 months]; silver-impregnated
VPS arm: median 1 months [LQ–UQ 0–1 months]}.
When compared with the standard VPS, antibiotic-impregnated VPSs decreased the risk of infection
(csHR 0.38, 97.5% CI 0.18 to 0.80; p < 0.01) (Table 12). Silver-impregnated VPSs were comparable
to standard VPSs (csHR 0.99, 97.5% CI 0.56 to 1.74; p = 0.96) (see Table 12). Figure 3 displays the
TABLE 12 Estimates of csHRs and sHRs for first VPS revision for infection, as classified by the central review panel




Antibiotic-impregnated 0.38a (0.18 to 0.80); < 0.01 1.22b (0.90 to 1.65); 0.15
Silver-impregnated 0.99a (0.56 to 1.74); 0.96 1.11b (0.81 to 1.51); 0.47
Age group
Paediatric – –
Adult (≤ 65 years) 0.55a (0.31 to 0.97); 0.02 0.58b (0.44 to 0.77); < 0.01




Antibiotic-impregnated 0.38c (0.18 to 0.80); < 0.01 1.26d (0.93 to 1.70); 0.08
Silver-impregnated 0.99c (0.56 to 1.72); 0.95 1.10d (0.81 to 1.50); 0.50
Age group
Paediatric – –
Adult (≤ 65 years) 0.56c (0.32 to 0.99); 0.02 0.60d (0.45 to 0.80); < 0.01
Adult (> 65 years) 0.12c (0.04 to 0.35); < 0.01 0.30d (0.21 to 0.43); < 0.01
a Cause-specific HRs from multivariate Cox model with infection as event of interest and both VPS and age group
as covariates.
b Cause-specific HRs from multivariate Cox model with competing risk (revision not for infection) as event of interest
and both VPS and age group as covariates.
c Subdistribution HRs from multivariate Fine–Gray model with infection as event of interest, revision not for infection
as a competing risk, and both VPS and age group as covariates.
d Subdistribution HRs from multivariate Fine–Gray model with competing risk (revision not for infection) as event of
interest, infection as a competing risk, and both VPS and age group as covariates.
Notes
Follow-up time from first VPS summary statistics: n = 1594; median 22 months; LQ–UQ 10–24 months; minimum
0 months, maximum 24 months.
Time to infection from first VPS summary statistics: n= 75; median 1 month; LQ–UQ 0–1 months; minimum 0 months,
maximum 21 months.
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1.0 Gray’s test p = 0.0044






































1.0 Gray’s test p = 0.2464



























1.0 Gray’s test p < 0.0001







FIGURE 3 Cumulative incidence plots of revisions for infection and competing risk by VPS group and age group. (a) Infection
by VPS group; (b) competing risk by VPS group; (c) infection by age group; and (d) competing risk by age group. (continued )
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cumulative incidences of infection and no infection by VPS and age group. Figure 4 displays the
cumulative incidence plots of infection or no infection by VPS group, stratified by age group.
All revisions for infection were further classified by type, with the majority being classified as ‘definite:
culture positive’ across all arms (standard VPS arm: 22/32, 68.8%; antibiotic-impregnated VPS arm:
6/12, 50%; silver-impregnated VPS arm: 25/31, 80.6%).
Secondary outcomes
Secondary outcome 1: time to removal of first ventriculoperitoneal shunt due to suspected
infection as assessed by treating surgeon
This secondary outcome, time to removal of first VPS due to suspected infection, complemented the
primary outcome of revision for infection classified by central review by defining revision for infection
according to the treating surgeon, as reported on the CRFs.
Of the total number of revisions, 78 (4.9%) were classified as infections by the treating surgeon.
As with the primary outcome, when revisions were centrally classified, the infection rate was
approximately equal in the standard and silver-impregnated VPS arms (6.2% and 5.7%, respectively),
and was lowest in the antibiotic-impregnated arm (2.8%) (Table 13).
When compared with the standard VPS, antibiotic-impregnated VPSs decreased the risk of infection
(csHR 0.45, 97.5% CI 0.23 to 0.91; p = 0.01) (Table 14). Silver-impregnated VPSs were comparable to
standard VPSs (csHR 0.93, 97.5% CI 0.53 to 1.64; p = 0.77) (see Table 14). Appendix 2, Figure 9, displays
the cumulative incidences of infection and no infection by VPS and age group.
Secondary outcome 2: time to ventriculoperitoneal shunt failure due to any cause
The overall revision rate was 25.0% (398/1594), which was approximately equal between each of the
three VPS groups (standard VPS arm: 130/533, 24.4%; antibiotic-impregnated VPS arm: 132/535,
24.7%; silver-impregnated VPS arm: 136/526, 25.9%) (see Table 11).
There was no significant difference for time to failure between the antibiotic-impregnated or
silver-impregnated VPS arms when compared with the standard VPS arm (Table 15). Figure 5 shows

























1.0 Gray’s test p < 0.0001







FIGURE 3 Cumulative incidence plots of revisions for infection and competing risk by VPS group and age group. (a) Infection
by VPS group; (b) competing risk by VPS group; (c) infection by age group; and (d) competing risk by age group.
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FIGURE 4 Cumulative incidence plots of revisions for infection and competing risk by VPS group, stratified by age group.
(a) Infection in the paediatric group; (b) infection in those aged ≤ 65 years; (c) infection in those aged > 65 years;
(d) competing risk in the paediatric group; (e) competing risk in those aged ≤ 65 years; and (f) competing risk in those
aged > 65 years. (continued )
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FIGURE 4 Cumulative incidence plots of revisions for infection and competing risk by VPS group, stratified by age group.
(a) Infection in the paediatric group; (b) infection in those aged ≤ 65 years; (c) infection in those aged > 65 years;
(d) competing risk in the paediatric group; (e) competing risk in those aged ≤ 65 years; and (f) competing risk in those
aged > 65 years.
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TABLE 13 Summary of VPS revisions for infection, as classified by the treating surgeon
Reason for revision
Trial group, n (%)







130 (100) 132 (100) 136 (100) 398 (100)
Suspected infection 33 (6.2) 15 (2.8) 30 (5.7) 78 (4.9)
Revision for other
reason (no infection)
97 (18.2) 117 (21.9) 106 (20.2) 320 (20.1)
TABLE 14 Estimates for csHRs and sHRs for VPS revisions for infection, as classified by the treating surgeon




Antibiotic impregnated 0.45a (0.23 to 0.91); 0.01 1.20b (0.88 to 1.63); 0.19
Silver impregnated 0.93a (0.53 to 1.64); 0.77 1.13b (0.82 to 1.54); 0.39
Age group
Paediatric – –
Adult (≤ 65 years) 0.51a (0.29 to 0.91); < 0.01 0.59b (0.44 to 0.79); < 0.01




Antibiotic-impregnated 0.45c (0.23 to 0.91); 0.01 1.24d (0.92 to 1.68); 0.11
Silver-impregnated 0.92c (0.53 to 1.61); 0.74 1.13d (0.83 to 1.54); 0.38
Age group
Paediatric – –
Adult (≤ 65 years) 0.53c (0.30 to 0.93); 0.01 0.61d (0.46 to 0.81); < 0.01
Adult (> 65 years) 0.12c (0.04 to 0.33); < 0.01 0.31d (0.21 to 0.44); < 0.01
a Cause-specific HRs from multivariate Cox model with infection as event of interest and both VPS and age group
as covariates.
b Cause-specific HRs from multivariate Cox model with competing risk (revision not for infection) as event of interest
and both VPS and age group as covariates.
c Subdistribution HRs from multivariate Fine–Gray model with infection as event of interest, revision not for infection
as a competing risk, and both VPS and age group as covariates.
d Subdistribution HRs from multivariate Fine–Gray model with competing risk (revision not for infection) as event of
interest, infection as a competing risk, and both VPS and age group as covariates.
Note
Follow-up time from first VPS summary statistics: median 22 months; LQ–UQ 10–24 months; minimum 0 months,
maximum 24 months.
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TABLE 15 Estimates for Cox proportional HRs
Covariate Revision, HR (97.5% CI); p-value
VPS
Standard –
Antibiotic impregnated 1.01 (0.77 to 1.33); 0.94
Silver impregnated 1.08 (0.82 to 1.42); 0.54
Age group
Paediatric –
Adult (≤ 65 years) 0.57 (0.44 to 0.74); < 0.01
Adult (> 65 years) 0.25 (0.18 to 0.35); < 0.01
Follow-up time from first VPS summary statistics: median 22 months; LQ–UQ 10–24 months;








































































































FIGURE 5 Kaplan–Meier curves for time to VPS failure for any cause, split by (a) VPS group and (b) age group.
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Secondary outcome 3: reason for shunt failure
At the time of revision, the treating surgeon recorded the reason for shunt failure on the CRFs. The
reason for shunt failure could fall into one of four categories: suspected shunt infection, mechanical
shunt failure, functional shunt failure and failure due to the patient. The outcome explored the reasons
for shunt failure in the antibiotic-impregnated and silver-impregnated VPS arms, compared with the
standard VPS arm.
The reasons for shunt failure, according to VPS type, are summarised in Table 16. Although the number
of revisions across the VPS groups is similar, comparing the reasons within group indicates:
l Failures due to suspected shunt infections are lower in the antibiotic-impregnated group (n = 15/132,
11.4%) than in the standard (n = 33/130, 25.4%) or the silver-impregnated VPS groups (n = 30/136,
22.1%).
l Mechanical shunt failures are higher in the antibiotic-impregnated VPS group (n = 69/132, 52.3%)
than in the standard (n = 52/130, 43.0%) or the silver-impregnated VPS groups (n = 64/136, 47.1%).
These results indicate that, although the number of VPS failures is similar between the three groups,
the underlying reason for failure differs when comparing standard with antibiotic-impregnated VPSs
(p = 0.02), with fewer infections with antibiotic-impregnated VPSs, but a higher frequency of failure for
other causes.
Secondary outcome 4: types of bacterial infection
The proportion of ‘definite – culture positive’ infections was 68.8% in the standard VPS group, 50.0%
in the antibiotic-impregnated VPS group and 80.6% in the silver-impregnated VPS group. The central
review panel classified all shunt infections that were ‘definite – culture positive’ and ‘probable – culture
uncertain’ (n = 56/75; see Table 11) by the organism that was cultured.
The organisms cultured are summarised by species in Tables 17 and 18. Coagulase-negative staphylococci
(37.5%) and Staphylococcus aureus (30%) accounted for the majority of cultured organisms in ‘all
VPS infection’ but not in the antibiotic-impregnated VPS group. Culture results show a reduction in
TABLE 16 Reasons for VPS failure
Comparator











to patient Test Result
Antibiotic-impregnated vs. standard VPS
Standard 33 (25.4, 68.8) 52 (40.0, 43.0) 40 (30.8, 47.6) 5 (3.8, 55.6) 130 Value 9.4
Antibiotic-
impregnated
15 (11.4, 31.3) 69 (52.3, 57.0) 44 (33.3, 52.4) 4 (3.1, 44.4) 132 Degrees of
freedom
3
Total (n) 48 121 84 9 262 p-value 0.02
Silver-impregnated vs. standard VPS
Standard 33 (25.4, 52.4) 52 (40.0, 44.8) 40 (30.8, 51.9) 5 (3.8, 50.0) 130 Value 1.4
Silver-
impregnated
30 (22.1, 47.6) 64 (47.1, 55.2) 37 (27.2, 48.1) 5 (3.7, 50.0) 136 Degrees of
freedom
3
Total (n) 63 116 77 10 266 p-value 0.71
a Row percentages are calculated using a denominator as the total for that row. The total n for the row used as a
denominator in computing the percentages is shown in the Total (n) column.
b Column percentages are calculated using a denominator as the total for that column. The total n for the column
used as a denominator in computing the percentages is shown in the Total (n) row.
The numerator for each calculation is the number of observed failures in that cell.
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TABLE 18 Summary of Gram-negative organisms cultured, split by VPS type
Summary of Gram-negative





Total number of infectionsa 23b 6 27c 56
Gram-negative organisms isolated (n) 6 4 5 15
Gram-negative organisms cultured, n (%)d
Enterobacteriaceae
Enterobacter cloacae 0 (0.0) 1 (16.7) 2 (7.4) 3 (5.4)
Escherichia coli 0 (0.0) 1 (16.7) 2 (7.4) 3 (5.4)
Klebsiella pneumoniae 3 (13.0) 0 (0.0) 0 (0.0) 3 (5.4)
Citrobacter species 0 (0.0) 0 (0.0) 1 (3.7) 1 (1.8)
Serratia marcescens 1 (4.3) 0 (0.0) 0 (0.0) 1 (1.8)
Serratia species 1 (4.3) 0 (0.0) 0 (0.0) 1 (1.8)
Proteus mirabilis 0 (0.0) 1 (16.7) 0 (0.0) 1 (1.8)
Pseudomonas aeruginosa 1 (4.3) 1 (16.7) 0 (0.0) 2 (3.6)
a Organisms cultured for infections centrally classified as ‘definite – culture positive’ and ‘probable – culture uncertain’
only; see Table 11.
b There were 22 ‘definite – culture positive’ and one ‘probable – culture uncertain’ infections.
c There were 25 ‘definite – culture positive’ and two ‘probable – culture uncertain’ infections.
d If more than one organism was grown from one infection episode, except for mixed coagulase-negative
staphylococci, each organism has been listed.
TABLE 17 Summary of Gram-positive organisms cultured, split by VPS type
Summary of Gram-positive





Total number of infectionsa 23b 6 27c 56
Gram-positive organisms isolated (n) 20 2 23 45
Gram-positive organism cultured, n (%)d




5 (21.7) 1 (16.7) 3 (11.1) 9 (16.1)
Staphylococcus epidermidis 4 (17.4) 0 (0.0) 3 (11.1) 7 (12.5)
Staphylococcus capitas 3 (13.0) 0 (0.0) 1 (3.7) 4 (7.1)
Staphylococcus hominis 1 (4.3) 0 (0.0) 0 (0.0) 1 (1.8)
Other Gram-positive organisms
Enterococcus faecalis 0 (0.0) 0 (0.0) 2 (7.4) 2 (3.6)
Propionibacterium acnes 0 (0.0) 0 (0.0) 2 (7.4) 2 (3.6)
Propionibacterium species 0 (0.0) 1 (16.7) 0 (0.0) 1 (1.8)
Streptococcus mitis 0 (0.0) 0 (0.0) 1 (3.7) 1 (1.8)
Streptococcus salivaris 1 (4.3) 0 (0.0) 0 (0.0) 1 (1.8)
a Organisms cultured for infections centrally classified as ‘definite – culture positive’ and ‘probable – culture uncertain’
only; see Table 11.
b There were 22 ‘definite – culture positive’ and one ‘probable – culture uncertain’ infections.
c There were 25 ‘definite – culture positive’ and two ‘probable – culture uncertain’ infections.
d If more than one organism was grown from one infection episode, except for mixed coagulase-negative
staphylococci, each organism has been listed.
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staphylococcal/Gram-positive infections for the antibiotic-impregnated VPS group, compared with
the standard and the silver-impregnated VPS groups. All three VPS types have a similar number of
Gram-negative infections.
Line listings of details of each infection against their organism cultured and antibiotic sensitivities are
provided in Appendix 2, Table 38. Antibiotic sensitivity data were not consistently returned, so
displayed data are limited.
Secondary outcome 5: time to removal of ventriculoperitoneal shunt because of
suspected infection
Following first clean revision
This outcome explored revisions for infections in patients who had their first VPS revised for a reason
other than infection (clean revision), that is those with a competing risk in the primary outcome set
(n = 323; see Table 11). Participants in this group, who subsequently had a second revision, had their
data centrally assessed by the panel and had the reason for revision classified as infection, or no
infection, based on the data available. As with the primary outcome, for which there was insufficient
information for the central panel to classify, the clinical classification was used (n = 4/128; Table 19).
There were 128 secondary revisions following a first clean revision, of which 20 were classified as an
infection (6.2%; see Table 19). The infection rate was approximately equal in the antibiotic-impregnated
and silver-impregnated VPS groups (5.0% and 4.8%, respectively), and was higher in the standard VPS
group (9.2%). However, these differences were not statistically significant when survival models were
applied to the data (Table 20).













Eligible for primary outcomea 98 (100) 120 (100) 105 (100) 323 (100)
No VPS removal/revision 61 (62.2) 69 (57.5) 65 (61.9) 195 (60.4)
VPS removal/revision (for any cause) 37 (37.8) 51 (42.5) 40 (38.1) 128 (39.6)
Reason for revisions as classified by central review
Revision for infection 9 (9.2) 6 (5.0) 5 (4.8) 20 (6.2)
Revision for other reason (no infection) 28 (28.6) 45 (37.5) 35 (33.3) 108 (33.4)
VPS CSF or peritoneal infection
Definite – culture positive 7 (18.9) 3 (5.9) 5 (12.5) 15 (11.7)
Probable – culture uncertain 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Probable – culture negative 1 (2.7) 0 (0.0) 0 (0.0) 1 (0.8)
Possible – culture uncertain 1 (2.7) 2 (3.9) 0 (0.0) 3 (2.3)
Clinically classified infectionb 0 (0.0) 1 (2.0) 0 (0.0) 1 (0.8)
VPS deep incisional infection
VPS deep incisional infection 0 (0.0) 0 (0.0) 1 (2.5) 1 (0.8)
a Randomised participants who had their de novo VPSs removed for reasons other than infection, as assessed by
central review, were eligible for the outcome set (n= 323); see Table 11.
b When the central review panel was unable to classify, an infection was classified by the operating surgeon on the CRFs.
There was four cases for which the committee was unable to classify; one of these was clinically classified as an infection.
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Seventy-five per cent of the secondary revisions for infection were classified by the committee as
‘definite – culture positive’ (n = 15/20).
Additional analysis
Comparing the identification of infections between assessors
The reason for revision (infection or no infection), as classified by the central panel, was the primary
outcome (see Primary outcome: time to ventriculoperitoneal infection as assessed by the central review panel),
and the reason for revision, as classified by the treating surgeon, was a complementary secondary
outcome (see Secondary outcome 1: time to removal of first ventriculoperitoneal shunt due to suspected
infection, as assessed by the treating surgeon). The classification made by these two independent assessors
was the same in 95.7% (381/398) of revisions. Appendix 2, Table 39, provides further detail.
TABLE 20 Estimates of csHRs and sHRs for second VPS revision for infection, as classified by the central review panel




Antibiotic-impregnated 0.55a (0.17 to 1.81); 0.26 1.38b (0.80 to 2.36); 0.19
Silver-impregnated 0.47a (0.13 to 1.63); 0.17 1.11b (0.63 to 1.97); 0.67
Age group
Paediatric – –
Adult (≤ 65 years) 1.64a (0.58 to 4.61); 0.28 0.80b (0.49 to 1.30); 0.30




Antibiotic-impregnated 0.55c (0.17 to 1.75); 0.25 1.40d (0.83 to 2.37); 0.16
Silver-impregnated 0.48c (0.14 to 1.67); 0.19 1.14d (0.65 to 1.99); 0.61
Age group
Paediatric – –
Adult (≤ 65 years) 1.72c (0.62 to 4.81); 0.24 0.80d (0.50 to 1.28); 0.29
Adult (> 65 years) 0.38c (0.04 to 3.91); 0.14 0.44d (0.20 to 0.97); 0.11
a Cause-specific HRs from multivariate Cox model with infection as event of interest and both VPS and age group
as covariates.
b Cause-specific HRs from multivariate Cox model with competing risk (revision not for infection) as event of interest
and both VPS and age group as covariates.
c Subdistribution HRs from multivariate Fine–Gray model with infection as event of interest, revision not for infection
as a competing risk, and both VPS and age group as covariates.
d Subdistribution HRs from multivariate Fine–Gray model with competing risk (revision not for infection) as event of
interest, infection as a competing risk, and both VPS and age group as covariates.
Note
Follow-up time (months) from second VPS summary statistics: median 9 months; LQ–UQ 2–19 months; minimum
0 months, maximum 24 months.
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Revision and infection rates by age group
The proportion of revisions of first VPS for any cause ranged from 38.0% (n = 225/592) for paediatrics to
10.9% (n = 55/503) for those aged > 65 years. The proportion of infections, as classified by the central
review panel, was also higher for paediatrics than for older participants. Table 21 provides more detail.
All survival models were adjusted for age category of the recruiting centre (paediatric or adult), with
adult centre being further categorised by age > 65 years. The risk of infection was significantly lower
for participants aged 16–65 years (csHR 0.56, 97.5% CI 0.32 to 0.99; p = 0.02) and for those aged
> 65 years (csHR 0.12, 97.5% CI 0.04 to 0.35; p < 0.01) than for paediatric participants (see Table 12).
See Figure 3 for the cumulative incidence of infection by age category; see Figure 4 for the cumulative
incidence of infection by VPS type, stratified by age group.
Revision and infection rates by centre
Heterogeneity between centres in revision rates and infection rates was explored by summary statistics.
Revision rates varied from a minimum of 4.8% (97.5% CI 0.0% to 15.2%, adult-only centre) to a maximum
of 75.0% (97.5% CI 40.7% to 100.0%, paediatric-only centre), as presented in Appendix 2, Table 41.
Infection rates, presented in Appendix 2, Table 41, varied from 0.0% (97.5% CI 0.0% to 0.0%, adult-only
centre) to 25.0% (97.5% CI 0.0% to 59.3%, paediatric-only centre). Paediatric-only centres generally
had higher rates of revisions and infections than adult-only centres and centres that treated both adults
and paediatrics.
Post hoc analyses
A post hoc analysis explored revision rates, and reason for revision, by aetiology of the hydrocephalus,
type of valve, operative approach and component replaced at first revision.
Revision and infection rates by aetiology
Table 22 and Appendix 2, Table 42, summarise aetiologies of the hydrocephalus, overall and split by
treatment group, respectively. The rates of revision for infection and mechanical failure varied within
certain aetiologies. For example, the revision and infection rates for participants with congenital
malformations was 38.4% and 9.2%, respectively, both higher than the equivalent overall rates of
25.0% and 4.7% (see Table 11). Similarly, participants with idiopathic normal pressure hydrocephalus
had much lower revision and infection rates of 10.0% and 1.1%, respectively, than the rates for
patients with other aetiologies of hydrocephalus.
Rates between VPS groups also differed according to aetiology. For example, the infection rate
in participants with spina bifida in the antibiotic-impregnated VPS group was 2.9%, compared with
14.3% each for the standard and silver-impregnated VPS groups. The infection rate in participants
with idiopathic normal pressure hydrocephalus was 13.6% in the standard VPS group and 2.9% in the
antibiotic-impregnated VPS group.
TABLE 21 Summary of revisions, and reason for revisions, of first VPS according to age group
Summary of revisions
Age group
TotalPaediatric ≤ 65 years > 65 years
Eligible for primary outcome 592 (100) 499 (100) 503 (100) 1594 (100)
No VPS removal/revision 367 (62.0) 381 (76.4) 448 (89.1) 1196 (74.5)
Revision for other reason (no infection) 178 (30.1) 95 (19.0) 50 (9.9) 323 (20.3)
Revision for infection 47 (7.9) 23 (4.6) 5 (1.0) 75 (4.7)
RESULTS
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Total number of patients 1594 1196 398 14 121 185 78 320
Congenital malformations
Patients with congenital malformations 294 (18.4) 181 (61.6) 113 (38.4) 2 (0.7) 36 (12.2) 48 (16.3) 27 (9.2) 86 (29.3)
Type of congenital malformation
Aqueduct stenosis 68 (23.1) 46 (67.6) 22 (32.4) 0 (0.0) 8 (11.8) 7 (10.3) 7 (10.3) 15 (22.1)
Dandy–Walker 7 (2.4) 6 (85.7) 1 (14.3) 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0) 1 (14.3)
Chiari 62 (21.1) 43 (69.4) 19 (30.6) 0 (0.0) 7 (11.3) 7 (11.3) 5 (8.1) 14 (22.6)
Spina bifida 111 (37.8) 62 (55.9) 49 (44.1) 1 (0.9) 11 (9.9) 25 (22.5) 12 (10.8) 37 (33.3)
Other 72 (24.5) 38 (52.8) 34 (47.2) 1 (1.4) 12 (16.7) 13 (18.1) 8 (11.1) 26 (36.1)
Not known 1 (0.3) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Acquired hydrocephalus
Patients with acquired hydrocephalus 819 (51.4) 615 (75.1) 204 (24.9) 9 (1.1) 54 (6.6) 102 (12.5) 39 (4.8) 165 (20.1)
Type(s) of acquired hydrocephalus
Cysts (colloid or arachoid) 32 (3.9) 24 (75.0) 8 (25.0) 0 (0.0) 4 (12.5) 3 (9.4) 1 (3.1) 7 (21.9)
Trauma 30 (3.7) 25 (83.3) 5 (16.7) 1 (3.3) 1 (3.3) 3 (10.0) 0 (0.0) 5 (16.7)
Tumour: benign 124 (15.1) 96 (77.4) 28 (22.6) 2 (1.6) 9 (7.3) 14 (11.3) 3 (2.4) 25 (20.2)
Tumour: malignant 133 (16.2) 105 (78.9) 28 (21.1) 2 (1.5) 6 (4.5) 14 (10.5) 6 (4.5) 22 (16.5)
Post haemorrhagic/intracranial
haemorrhage
337 (41.1) 244 (72.4) 93 (27.6) 2 (0.6) 21 (6.2) 45 (13.4) 25 (7.4) 68 (20.2)








































































































































































































































































































































































Infection: cerebral abscess 8 (1.0) 7 (87.5) 1 (12.5) 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0) 1 (12.5)
Infection: other 21 (2.6) 17 (81.0) 4 (19.0) 0 (0.0) 0 (0.0) 4 (19.0) 0 (0.0) 4 (19.0)
Other factors 140 (17.1) 99 (70.7) 41 (29.3) 3 (2.1) 16 (11.4) 17 (12.1) 5 (3.6) 36 (25.7)
Idiopathic condition
Patients with idiopathic condition 496 (31.1) 408 (82.3) 88 (17.7) 4 (0.8) 32 (6.5) 38 (7.7) 14 (2.8) 74 (14.9)
Type(s) of idiopathic condition
Idiopathic normal pressure hydrocephalus
of the elderly
361 (72.8) 325 (90.0) 36 (10.0) 1 (0.3) 15 (4.2) 16 (4.4) 4 (1.1) 32 (8.9)
IIH 98 (19.8) 63 (64.3) 35 (35.7) 2 (2.0) 10 (10.2) 16 (16.3) 7 (7.1) 28 (28.6)
Other 38 (7.7) 20 (52.6) 18 (47.4) 1 (2.6) 7 (18.4) 7 (18.4) 3 (7.9) 15 (39.5)
a Clean insertion = no revision + revision.
b Revision = failure due to patient + functional shunt failure +mechanical shunt failure+ failure due to infection.




























Revision and infection rates by operative approach
Table 23 and Appendix 2, Table 43, summarise valve type and operative approach at insertion, both
overall and split by treatment group.
The rate of revisions when there was no evidence of infection (the competing risk in the primary
outcome analysis) was > 10% lower among participants with a programmable valve (n = 82/627, 13.1%)
than among those with a fixed valve (n = 227/935, 24.3%). On the other hand, revision rates for no
infection were equivalent when comparing frontal placement of proximal shunt catheter with parietal
and/or occipital placement: 20.9% and 19.8%, respectively.
Revision and infection rates by component replaced at first revision
Table 24 and Appendix 2, Table 44, summarise the component replaced in participants who had their
VPS revised for reason other than infection, as classified by the treating surgeon.
Most commonly, when a shunt is revised for a reason other than infection, the component replaced is
the ventricular shunt catheter (n = 72/268, 26.9%) or the valve (n = 76/268, 28.4%). The component
replaced was similar between VPS groups, although valve changes were more common in the
antibiotic-impregnated VPS group than in the standard or silver-impregnated VPS groups.
Safety analysis
Efficacy outcomes were analysed by the intention-to-treat analysis population as much as possible.
For AEs and SAEs, participants are reported according to the type of VPS in situ at the time of the event.
The shunt in situ was known for all patients up to the first revision. However, events occurring
following a revision whereby the shunt was not replaced like for like are reported in under ‘other VPS’
group.
The total number of AEs experienced and the number of participants experiencing at least one AE are
provided, both overall and split according to the VPS in situ at the time of the event. Of the 1601
participants who received a trial shunt, 413 (25.8%) experienced 654 events. Summarising these
events, split by VPS in situ at the time of event, indicates the following:
l Standard VPS – 135 out of 531 participants (25.4%) experienced 201 events.
l Antibiotic-impregnated VPS – 136 out of 545 participants (25.0%) experienced 210 events.
l Silver-impregnated VPS – 140 out of 525 participants (26.7%) experienced 191 events.
l Other VPS – when the initial trial shunt was removed and not replaced like for like, 35 out of
136 participants (25.7%) experienced 52 events.
Common events were ventricular shunt catheter obstruction (96 events in 79 participants), shunt valve
obstruction (65 events in 52 participants) and valve change for symptomatic overdrainage (54 events
in 50 participants).
Appendix 2, Table 45, provides the summary of related AEs.
No participant experienced a SAE.
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TABLE 23 Summary of valve type and operative approach
























Total number of patients 1594 1196 398 14 121 185 78 320
Use of guidance system
Patients for whom guidance system was
used for VPS placement
653 (41.0) 489 (74.9) 164 (25.1) 7 (1.1) 45 (6.9) 78 (11.9) 34 (5.2) 130 (19.9)
Type of guidance system
Electromagnetic 413 (63.2) 309 (74.8) 104 (25.2) 4 (1.0) 26 (6.3) 50 (12.1) 24 (5.8) 80 (19.4)
Ultrasonography 128 (19.6) 88 (68.8) 40 (31.3) 3 (2.3) 16 (12.5) 14 (10.9) 7 (5.5) 33 (25.8)
Optical 46 (7.0) 37 (80.4) 9 (19.6) 0 (0.0) 2 (4.3) 6 (13.0) 1 (2.2) 8 (17.4)
Stereotactic frame 63 (9.6) 52 (82.5) 11 (17.5) 0 (0.0) 1 (1.6) 8 (12.7) 2 (3.2) 9 (14.3)
Not known 3 (0.5) 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Placement of proximal shunt catheter
Frontal 134 (8.4) 93 (69.4) 41 (30.6) 0 (0.0) 13 (9.7) 15 (11.2) 13 (9.7) 28 (20.9)
Parietal, occipital or parietal/occipital 1453 (91.2) 1100 (75.7) 353 (24.3) 14 (1.0) 107 (7.4) 167 (11.5) 65 (4.5) 288 (19.8)
Combination 3 (0.2) 2 (66.7) 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 1 (33.3)
Not known 4 (0.3) 1 (25.0) 3 (75.0) 0 (0.0) 0 (0.0) 3 (75.0) 0 (0.0) 3 (75.0)
Type of valve
Fixed 935 (58.7) 652 (69.7) 283 (30.3) 10 (1.1) 91 (9.7) 126 (13.5) 56 (6.0) 227 (24.3)
Programmable 627 (39.3) 525 (83.7) 102 (16.3) 4 (0.6) 26 (4.1) 52 (8.3) 20 (3.2) 82 (13.1)
Not known 32 (2.0) 19 (59.4) 13 (40.6) 0 (0.0) 4 (12.5) 7 (21.9) 2 (6.3) 11 (34.4)
a Clean insertion = no revision + revision.
b Revision = failure due to patient + functional shunt failure +mechanical shunt failure+ failure due to infection.




























TABLE 24 Summary of components replaced at revision











Total number of patients 320 14 121 185
Was a complete new shunt inserted?
No 268 (83.8) 12 (4.5) 99 (36.9) 157 (58.6)
If no, which component was replaced?
Ventricular shunt catheter only 72 (26.9) 0 (0.0) 22 (30.6) 50 (69.4)
Peritoneal shunt catheter only 31 (11.6) 3 (9.7) 5 (16.1) 23 (74.2)
Valve only 76 (28.4) 3 (3.9) 35 (46.1) 38 (50.0)
Combination 38 (14.2) 1 (2.6) 19 (50.0) 18 (47.4)
Not known 51 (19.0) 5 (9.8) 18 (35.3) 28 (54.9)
a Failure – no infection = failure due to patient + functional shunt failure +mechanical shunt failure.
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Chapter 4 Economic evaluation
Parts of this chapter have been reproduced from Mallucci et al.2 This is an Open Access articledistributed under the terms of the Creative Commons Attribution License (https://creativecommons.
org/licenses/by-nd/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. The text below includes minor additions and formatting
changes to the original text.
Introduction
A number of studies32–36 (although none from the UK) have estimated the costs of managing patients
with VPS infections. These often combine cost estimates with observed differences in infection rates,
between antibiotic-impregnated and standard VPS catheters, in rudimentary cost-effectiveness analyses,
to calculate the incremental cost (saving) per VPS infection avoided. This is relevant to inform the best
use of health-care resources, given that impregnated VPS catheters are about twice as expensive as
standard shunt catheters, but are limited in not assessing all-cause VPS failure or impacts on patients’
health-related quality of life.
Adopting the perspective of the German health-care setting, Eymann et al.32 estimated the costs of
VPS infections by considering the lengths, and per diem costs, of adult and paediatric intensive care
and ward stays. Based on 48 cases of VPS infections among a cohort of 197 hydrocephalus patients
with antibiotic-impregnated VPS catheters and 98 patients with standard VPS catheters, the estimated
mean cost per infection was US$16,933 in children and US$14,886 in adults. Considering the benefits
and additional costs of antibiotic-impregnated shunt catheters, the authors estimated a net saving of
US$51,651 for the 197 patients.
Farber et al.33 conducted a retrospective cohort study of 500 shunt surgeries performed in adult
patients with hydrocephalus in a US hospital: 250 received antibiotic-impregnated VPS catheters and
250 received standard VPS catheters. The hospital billing records of all patients who were treated
were analysed to estimate the costs associated with hospital stays for infections. The overall mean cost
per VPS infection was US$40,371 and, based on an absolute reduction in the risk of shunt infections of
2.8% with antibiotic-impregnated shunt catheters, savings of US$47,193 in infection-related direct
costs were estimated per 100 shunt surgeries performed.
Attenello et al.34 analysed the hospital billing records of 406 paediatric patients who underwent 608
shunt placement procedures (400 antibiotic-impregnated and 208 standard shunt catheters) in a single
US hospital. The majority of procedures (93%) were for VPSs. The hospital resources used to treat the
38 patients in whom a shunt infection developed were estimated to cost an average of US$48,454.
Based on an observed decreased incidence of shunt infection in the antibiotic-impregnated shunt
catheter cohort, the estimated infection-related cost savings per 100 patients was $442,133 per
100 patients with shunts.
Parker et al.35,36 analysed patient discharge and billing records from 287 US hospitals to estimate the
shunt infection rates and costs of antibiotic-impregnated shunt catheters compared with standard
shunt catheters. The unadjusted difference in the incidence of shunt infection was 1.4% and 4.5% in
adult and paediatric populations, respectively, and the costs of managing infections was US$45,714 and
US$56,104, respectively. The authors estimated that the use of antibiotic-impregnated shunt catheters
in adults was associated with infection-related cost savings of US$42,125 per 100 de novo shunts
placed (US$230,390 per 100 in paediatrics), which corresponds to US$30,854 and US$51,181 per
shunt infection avoided, respectively (calculated from data presented in the paper).
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Each of the above studies relied on retrospective cohorts of patients, mainly from single centres, but
result in estimates for the costs of managing VPS infections in the order of US$50,000 in the US health-
care setting. A key limitation, however, is that, in each of these analyses, infection rates were determined
from observational data, and were therefore potentially subject to bias, reducing the reliability of the
cost-effectiveness estimates. Analyses that considered the RR of VPS infection associated with antibiotic-
impregnated shunt catheters, determined from clinical trial data, are limited to three studies.37–39
Root et al.37 conducted a meta-analysis of clinical trials and observational studies, and estimated that
the number needed to treat with antibiotic-impregnated (compared with standard) EVDs to prevent
a shunt catheter-associated infection was 19 (95% CI 15 to 36). Based on assumed costs of US$100
per antibiotic-impregnated shunt catheter and US$30,000 per episode of infection, they estimated
that antibiotic-impregnated shunt catheters could result in overall savings, from the perspective of
a US neurosurgical unit, of US$28,100 (95% CI US$26,400 to US$28,500) for each shunt catheter-
associated infection prevented.
Klimo et al.38 similarly reviewed the literature for clinical trials and observational studies of antibiotic-
impregnated shunts, and conducted a meta-analysis and a simple cost calculation. Assuming a cost of
US$50,000 to treat a shunt infection, the cost savings per shunt infection prevented ranged from just
under US$90,000 to > US$1.3M per 200 shunts performed. No data were presented on the incremental
cost (saving) of avoiding a shunt infection.
Edwards et al.39 developed a decision-analytic model of the clinical and economic consequences of using
antibiotic-impregnated shunts from the perspective of a US hospital. Using trial and observational data,
they estimated that, for every 100 patients requiring shunts, antibiotic-impregnated shunt catheters
may be associated with 0.5 fewer deaths, 71 fewer hospital days, 11 fewer surgeries and a net saving
of US$128,228 owing to decreased infection. The cost of a shunt infection was US$46,394, derived
from earlier estimates of Attenello et al.34 and Farber et al.33
All analyses have many limitations, not least the assumption that potential avoidance of the cost
of managing VPS infections can be equated to a cost saving. Moreover, the analyses lacked any
consideration of health outcomes associated with shunt catheter-associated infections or other
potential causes of VPS failure.
Aim
The aim of the economic evaluation was to assess the cost-effectiveness of antibiotic-impregnated,
silver-impregnated and standard VPS catheters in children and adults with hydrocephalus who were
recruited in the BASICS trial.
Methods
The economic analysis adopted the perspective of the NHS and Personal Social Services providers
in the UK. The analytical approach for the primary analysis was a cost-effectiveness analysis, based
on the incremental cost per first shunt failure (due to any cause) averted for impregnated and standard
VPSs. A cost–utility analysis was conducted to estimate the incremental cost per QALY gained in a
restricted sample of trial participants.
Resource use and costs
Within-trial costs were estimated by measuring the health-care resource use associated with each
of the trial interventions during the trial period. These included (1) hospital inpatient procedures;
(2) hospital outpatient and accident and emergency (A&E) visits; (3) concomitant medications; and
(4) contact with other health-care professionals, including general practitioners (GPs) and school nurses.
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Estimation of resource use was based on complementary approaches using data collected as part of
the trial and as part of routine care. These were as follows:
l Patient-Level Information and Costing System (PLICS). PLICS data contain details of admission and
discharges, Healthcare Resource Group (HRG) codes relating to the type of care patients received,
and the point of delivery (A&E, inpatient, outpatient). PLICS data were requested for all participants
from 3 months prior to randomisation to the final follow-up of the last participant (April 2018).
l Resource use questionnaires completed by trial participants, their guardian or their parents. These
were designed to collect information on participants’ use of primary care services, Personal Social
Services and non-scheduled clinic attendances.40,41 Resource use questionnaires were administered
early post operatively, and then posted to participants by research nurses every 12 weeks until the
end of the trial. Participants completed these and returned them to the trial centre.
l Dedicated sections in the CRF. These were used to record trial participants’ use of concomitant
medications at each clinic visit and for the duration of their participation in the trial, or up until
14 days following shunt removal in cases of confirmed infection.
l Interventions. The type of initial VPS catheter was according to a participant’s treatment allocation.
Costs associated with any subsequent revisions were included in participants’ PLICS data.
Unit costs
All resource use was valued in monetary terms using appropriate UK unit costs for the 2016–17 cost
year. When necessary, for any costs from an earlier period, adjustments were made for inflation using
the pay cost index and the health service cost index.42
The unit costs of shunt catheters were sourced from the manufacturers. A silver antimicrobial shunt
catheter set (Silverline), consisting of ventricular and peritoneal shunt catheters, costs £361.62.
A Bactiseal shunt catheter kit (ventricular and peritoneal) costs £384.00; and standard, plain Codman®
Hakim® (Integra LifeSciences Holdings Corporation) ventricular or peritoneal shunt catheters each
cost £172.00.
Health resource groups were used as the main currency of the economic analysis43 for inpatient stays
(see Appendix 3, Table 46) and outpatient contacts (see Appendix 3, Table 47), with cost codes allocated
based on the latest available national schedule of reference costs44 or, when not available, based on
the national tariff.45 Reference costs are the average unit costs of providing services to NHS patients
in England, and are collected each financial year. National tariff costs relate to bundled care packages
reimbursed at a national level, based on the NHS payment-by-results scheme. National average unit
costs were based on the hospital spell, and incorporated excess ward days and whether the case
was elective or emergency. National tariff codes were obtained primarily from PLICS data, but, if
unavailable, appropriate HRG codes were assigned based on the reason for admission and a patient’s
condition, extracted from the patient resource use questionnaires, which asked about participants’
contacts with health-care professionals during their time in the trial.
The compendium of Unit Costs of Health and Social Care42 was the source of unit costs of all items of
primary health-care resource use and outpatient contacts (see Appendix 3, Table 48). The number of
health-care professional contacts recorded in the resource use questionnaires and baseline forms were
multiplied by their respective unit costs.
The unit costs of medicines were based on drug tariff prices, as referenced in the British National
Formulary46 and the Prescription Costs Analysis Data47 for NHS England. The cost of each medicine was
calculated by multiplying the unit price by the daily quantity of prescribed medication (e.g. number of
vials, ampoules, prefilled syringes, capsules or tablets) and by the number of days of treatment. If the
dispensed medication was an oral suspension, the total quantity for the prescribed period was
calculated and rounded up to the nearest whole bottle.
DOI: 10.3310/hta24170 Health Technology Assessment 2020 Vol. 24 No. 17
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Mallucci et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
41
Health outcomes
The primary health outcome for the economic analysis was the first VPS failure (due to any cause)
averted. A sensitivity analysis considered the first VPS failure (due to confirmed infection) averted,
consistent with the primary clinical outcome.
The secondary economic health outcome measure was the QALY, calculated from responses to
EuroQol-5 Dimensions (EQ-5D) questionnaires. The EQ-5D-3L-Proxy (parent or guardian) questionnaire
was used for participants aged from 5 years to just under 18 years, and for participants aged > 18 years
who lacked capacity to consent for themselves. The EQ-5D-Y was administered to participants aged
from 8 years to just under 18 years. Adults were asked to complete the EQ-5D-3L questionnaire, and all
participants aged ≥ 8 years were administered the EQ-VAS.
The EQ-5D-3L descriptive system includes five dimensions (mobility, self-care, usual activities, pain and
anxiety); each dimension has three levels of morbidity (no problems, some problems and extreme problems),
which are scored 1, 2 and 3, respectively. UK tariff48 scores for the EQ-5D-3L questionnaire were
applied to responses to the EQ-5D-3L, EQ-5D-Y and EQ-5D-3L-Proxy questionnaires, as no separate
scoring systems are yet available for the youth and proxy versions.
Utility scores from each version of the EQ-5D questionnaires were combined to achieve the most
complete data set by taking scores from trial participants, when available, and incorporating
proxy responses.
In addition, the child version of the HOQ was administered to participants aged 8–18 years, and the
parent proxy version was administered for participants aged from 5 years to just under 8 years. The HOQ
is a Canadian 51-item outcome questionnaire designed specifically for use in paediatric hydrocephalus.25,49
Responses to each item are given a score from 0 (worse health status) to 4 (better health status). A set
combination of items make up three health dimensions: physical, socioemotional and cognitive. A final
score is obtained by summing each item score and then dividing it by the highest possible summed score,
which gives a utility value anchored at 0 (worse health state) or 1 (best health state).
Health outcome questionnaires were completed during clinic visits, or over the telephone at baseline
(pre-operative assessment visit), at the early post-operative assessment, 12 weeks after randomisation
and at the end of the trial.
Economic analyses
Analytic approach
Analyses included all randomised participants, consistent with the ‘intention to treat’ principle.
All statistical tests were two-sided; the statistical significance level was set at 2.5% and CIs were
calculated at 97.5% to adjust for multiplicity.
Data were examined for missingness. The appropriate method for dealing with missing cost data was
dependent on the number of missing data and the likely mechanism of missingness.50 Costs relating to
hospitalisations were primarily sourced from PLICS data. If PLICS data were not available or missing,
the use of hospital services was based on entries in CRFs, or otherwise from participants’ resource
use questionnaires.51 In the base-case analysis, any remaining missing data were multiply imputed
using the method of chained equations.52 The number of imputed data sets was based on the fraction
of missing information (FMI) value to limit the loss in power to no more than 1%, and to maximise
model convergence. Imputed data sets were generated using predictive mean matching, from a set of
imputation models that were constructed from all potential prognostic factors: sex, age (paediatrics
aged from 0 to just under 16 years, adults aged 16–65 years and adults aged > 65 years), site, time
spent in the trial, whether or not a first treatment failure had occurred and intervention group.
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In the base-case analysis, costs and outcomes incurred in the second year were discounted at a rate of
3.5%, in accordance with the NICE Guide to the Methods of Technology Appraisal 2013.53
Cost analysis
Hospitalisations were costed from baseline to 24 months. Hospital admissions were included if the
hospital episode start date commenced within the 0- to 24-month time horizon. Adjustments were
made to apportion the costs of hospital stays that crossed baseline or that continued after the
24-month time horizon. Similarly, adjustments were made to courses of drug treatment that spanned
the period preceding baseline or beyond the 24-month time horizon, to apportion costs to those
administered during the 0- to 24-month time horizon only.
Participants’ use of health care and Personal Social Services between randomised groups was
described and tabulated, reporting mean resource use items for each intervention and differences
between the intervention groups. The 97.5% CIs for differences in mean costs were calculated using
bias-corrected and accelerated non-parametric bootstrap with 10,000 replications.
Total costs were analysed using a regression model to account for any imbalance in participants’
characteristics between intervention groups, and to estimate the mean cost of VPS failure. Owing to the
large sample, the near-normality of sample means was assumed and ordinary least squares regression
was applied in the base case.54 The regression was specified with total (discounted) per-patient costs
as the dependent variable, and the stratifying variables [randomisation group, site (discrete), age
(three categories), time in the trial (continuous, in days) and treatment failure] as predictors:
Cost = β0 + β1rand group + β2treat fail + β3age + β4time in trial + β5site + e. (1)
Similarly, the mean outcome by intervention group was also calculated by ordinary least squares
regression, specified with treatment failure (discounted) as the dependent variable, and total cost
(discounted), site (discrete), age (three categories), time in the trial (continuous) and intervention group
as predictors:
Effect = β0 + β1rand group + β2total costs + β3age + β4time in trial + β5site + e. (2)
Cost-effectiveness analysis
In the base-case cost-effectiveness analysis, the outcome of interest was the incremental cost
per (first) VPS failure (due to any cause) averted. Interventions were ranked according to their
effectiveness (reverse order for interventions in the south-west quadrant of the cost-effectiveness
plane). Dominated and extendedly dominated interventions were removed, and the incremental
cost-effectiveness ratios (ICERs) were calculated for the remaining shunt catheters.
Sensitivity and scenario analyses
A number of sensitivity analyses were performed to assess the robustness of the base-case ICER to
key assumptions and analytic approaches. These were (1) bivariate sensitivity analyses to vary the unit
costs of antibiotic-impregnated and silver-impregnated VPSs, (2) applying different discount rates (0%,
1.5% and 6% per annum for both costs and outcomes), (3) using observed data for costs (no multiple
imputation) and (4) using a different analytic approach for analysing costs [generalised linear models
(GLMs), acknowledging the skewness in the underlying data]. The GLM regression was specified using
a combination of families (gamma, Gaussian and Poisson) and links (log and square root). Appropriate
link function was determined using the Akaike information criterion (AIC) and Bayesian information
criterion (BIC) and the modified Park test to determine the distribution family.55
In addition, a stratified cost-effectiveness analysis was undertaken for the three age categories of
paediatrics, adults aged 16–65 years and adults aged ≥ 65 years.
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Alternative cost-effectiveness and utility analysis
Additional cost-effectiveness analyses were conducted based on the incremental cost per averted case
of first shunt failure due to (1) confirmed infection, (2) a mechanical cause, (3) a functional reason and
(4) patient factors. A cost–utility analysis was performed to estimate the incremental cost per QALY
gained; this analysis was restricted to participants aged ≥ 5 years, as no utility data were collected for
children aged < 5 years. Uncertainty in the incremental cost–utility ratio was considered using non-
parametric bootstrap analysis, using 1000 replicates, and depicted in cost-effectiveness acceptability
curves, which present the probability of each VPS catheter being cost-effective for given ceiling
thresholds of costs per QALY.56 The cost–utility analysis considered the reference threshold range of
between £20,000 and £30,000 per QALY.53
All analyses were conducted using Stata® version 13 (StataCorp LP, College Station, TX, USA) and
reported according to the Consolidated Health Economic Evaluation Reporting Standards.57
Results
Data completeness
The PLICS data were provided by 10 out of the 21 neurosurgical units. These related to 199 out of
536 participants allocated to the standard VPS, 207 out of 538 participants allocated to the antibiotic-
impregnated VPS and 210 out of 531 participants allocated to the silver-impregnated VPS (Table 25).
The reasons given by the 11 centres for not providing PLICS data included:
l They were short staffed and were unable to assign resources to pull the data together.
l One centre was procuring a new PLICS system and were unable to supply any patient-level information.
l Finance officers were unwilling to provide data; others agreed to provide data but they did not
deliver by the deadline.
l Some trusts did not want to share the data or asked for data-sharing agreements, but these could
not be arranged within the project timelines.
Resource use questionnaires were completed by 423 (27%) participants: 145 participants allocated to
standard VPSs, 146 allocated to antibiotic-impregnated VPSs and 132 allocated to silver-impregnated
VPSs. The costs of concomitant medications were available for 88% of trial participants: 466, 463 and
467 participants allocated to standard, antibiotic-impregnated and silver-impregnated VPSs, respectively.
In relation to self-reported hospital stays, respondents rarely provided information that was amenable
to being costed. For example, most respondents who answered ‘yes’ to the question ‘Have you attended
any hospital as an outpatient because of your hydrocephalus since your last BASICS study visit?
(Please include reason and details of health-care professional seen)’ provided no information on the
reason for attending or the health-care professional seen, which limited our ability to cost episodes of
hospital care.
Overall, however, the numbers of missing hospital cost data, resource use diaries and concomitant
medication were balanced across the three intervention groups, and by age and sex (Table 26).
For the multiple imputation, and based on the variable with the highest FMI value (FMI 0.580), 50 data
sets were imputed.58
Resource use and cost analysis
Table 27 presents observed, mean disaggregated health-care resource use from randomisation up to
24 months, by intervention group. There were no discernible differences between intervention groups
with respect to participants’ use of primary or secondary health care.
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TABLE 25 Summary of data completenessa by type and intervention group
Trial group Variable
Participants (n)








Utility at baseline 240 129 369 N/A N/A N/A
Utility early post operatively 233 136 369 N/A N/A N/A
Utility at 12 weeks 190 179 369 N/A N/A N/A
Utility at the end of the trial 189 180 369 N/A N/A N/A
PLICS (total) 140 229 369 199 334 533
Diaries (total) 91 278 369 145 388 533
Concomitant medicines
(total)




Utility at baseline 244 125 369 N/A N/A N/A
Utility early post operatively 231 138 369 N/A N/A N/A
Utility at 12 weeks 174 195 369 N/A N/A N/A
Utility at the end of the trial 179 190 369 N/A N/A N/A
PLICS (total) 129 240 369 208 327 535
Diaries (total) 98 271 369 146 389 535
Concomitant medicines
(total)




Utility at baseline 224 136 360 N/A N/A N/A
Utility early post operatively 220 140 360 N/A N/A N/A
Utility at 12 weeks 177 183 360 N/A N/A N/A
Utility at the end of the trial 191 169 360 N/A N/A N/A
PLICS (total) 130 230 360 210 316 526
Diaries (total) 87 273 360 132 394 526
Concomitant medicines
(total)
310 50 360 467 59 526
Overall Utility at baseline 708 390 1098 N/A N/A N/A
Utility early post operatively 684 414 1098 N/A N/A N/A
Utility at 12 weeks 541 557 1098 N/A N/A N/A
Utility at the end of the trial 559 539 1098 N/A N/A N/A
PLICS (total) 399 699 1098 617 977 1594
Diaries (total) 276 822 1098 423 1171 1594
Concomitant medicines
(total)
933 165 1098 1396 198 1594
N/A, not applicable.
a The PLICS data were considered complete when at least one cost was reported as inpatient, outpatient or both.
Diaries within CRFs were considered complete when at least one episode of health-care resource use was reported.
Concomitant medications were considered complete when at least one prescription was reported. Responses to the
EQ-5D-3L were considered complete (for each administration) if respondents had assigned a level to each of the
five domains.
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TABLE 26 Number of trial participants with complete data for PLICS, concomitant medications and diary responses,





n (%) Diaries, n (%)
Standard 199 (37.3) 466 (87.4) 145 (27.2)
Antibiotic impregnated 208 (38.9) 463 (86.5) 146 (27.3)
Silver impregnated 210 (39.9) 467 (88.8) 132 (25.1)
Paediatric 261 (42.3) 550 (39.4) 167 (39.5)
Adult aged 16–65 years 200 (32.5) 461 (33.0) 116 (27.4)
Adult aged ≥ 65 years 156 (25.3) 385 (27.6) 140 (33.1)
Male 303 (49.1) 698 (50.0) 205 (48.5)
Female 314 (51.0) 698 (50.0) 218 (51.5)
TABLE 27 Disaggregated health-care resource use from randomisation up to 24 months, by intervention group
Item of resource use
Trial group, mean count (range), n participants
Standard VPS Antibiotic-impregnated VPS Silver-impregnated VPS
GP visits 2.7 (0–25), 140 1.9 (0–10), 112 2.0 (0–9), 110
Nurse visits 2.8 (0–18), 37 2.5 (0–18), 44 1.4 (0–5), 29
Health visitor 3.0 (0–10), 27 5.3 (0–25), 20 3.4 (0–15), 26
Physiotherapy 4.0 (0–30), 32 4.5 (0–21), 34 3.9 (0–12), 38
Occupational therapist 3.7 (0–35), 20 3.4 (0–15), 21 2.0 (0–6), 25
Inpatient HRG
AA13A 1.0 (0–1), 27 1.0 (0–1), 36 1.0 (0–2), 439
AA19A 1.4 (0–3), 7 1.5 (0–4), 8 1.5 (0–3), 10
AA25A 0.6 (0–3), 12 0.72 (0–3), 11 0.85 (0–2), 7
AA52C 1 (0–1), 12 1 (0–1), 9 0.83 (0–2), 12
PA44Z 2.3 (0–4), 3 3.0 (0–5), 4 4.0 (0–7), 3
PA42Z 6.7 (0–19), 4 6.7 (0–15), 4 3.0 (0–6), 4
AA52G 1.5 (0–3), 6 1.0 (0–1), 8 1.2 (0–3), 10
PM44Z 0.4 (0–4), 10 1 (0–1), 5 0.46 (0–6), 13
Outpatient HRG
WF01A 5.7 (0–36), 63 5.7 (0–72), 67 5.5 (0–28), 60
WF01B 2.4 (0–16), 38 2.0 (0–9), 38 1.7 (0–5), 38
VB05Z 0.44 (0–5), 18 0.28 (0–11), 25 0.25 (0–22), 35
VB02Z 1.3 (0–3), 7 1.8 (0–4), 4 2.0 (0–3), 3
VB03Z 1.0 (0–1), 2 1.5 (0–4), 6 1.7 (0–2), 3
VB09Z 6.0 (0–6), 1 1.0 (0–1), 3 1.0 (0–1), 3
WF01C 1 (0–1), 5 0.77 (0–2), 9 0.62 (0–4), 8
BZ 1 (0–1), 8 0.5 (0–4), 6 1 (0–1), 1
Note
Listed are the most frequent items of resource use, including the top 16 HRGs (out of 463).
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Based on the observed data, the majority of costs related to hospital inpatient procedures, followed
by outpatient clinic visits and contacts with health-care professionals in primary care (Table 28). With
the exception of GP costs, there were no significant differences in costs between the antibiotic- or
silver-impregnated VPSs and the standard VPS catheter groups.
The adjusted base-case analysis yielded a total cost of £18,707 (97.5% CI £13,888 to £26,966) in the
standard VPS group, £14,192 (97.5% CI £12,450 to £17,786) in the antibiotic-impregnated VPS group,
and £17,385 (97.5% CI £14,649 to £22,355) in the silver-impregnated VPS group. Based on incremental
analysis, the difference in 2-year costs between the silver-impregnated and the standard VPS groups
was –£1322 (97.5% CI –£9295 to £5592), and was –£3192 (97.5% CI –£8382 to £1227) between the
antibiotic-impregnated and the silver-impregnated VPSs (see Appendix 3, Table 49).
Overall, the cost of VPS failures was £8604 (97.5% CI £4696 to £12,511) due to any cause; £10,844
(97.5% CI £4267 to £17,436) due to confirmed infection; £5479 (97.5% CI £882 to £10,076) due to
mechanical failure; £5149 (97.5% CI –£542 to £10,840) due to functional failure; and £7028 (97.5% CI
–£5803 to £19,859) due to patient factors.
Economic health outcomes
The proportions of participants who experienced a first VPS failure (due to any cause) within 2 years
were 130 out of 533, 132 out of 535 and 136 out of 526 in the standard, antibiotic-impregnated and
silver-impregnated VPS groups, respectively. In the base-case analysis, with a 3.5% annual discount
rate, the VPS failure rate was 23.3% (97.5% CI 19.1% to 27.3%) in the standard VPS group, 25.9%
(97.5% CI 21.8% to 30.3%) in the antibiotic-impregnated VPS group and 25.4% (97.5% CI 20.9% to
29.6%) in the silver-impregnated VPS group.
The distribution of participants (or their parents’ or guardians’) responses to the EQ-5D questionnaires
are presented in Figure 6. There was a low return rate of the EQ-5D questionnaire, with combined
(EQ-5D-Y, EQ-5D-3L-Proxy and EQ-5D-3L) data available for only about half of the participants. Their
responses suggested that there was a general improvement across all dimensions from baseline to the
end of the trial, with no clear differences between intervention groups for any given dimension. Similarly,
the response rates of participants, their parents or their guardians to the EQ-VAS, which are presented in
Appendix 3, Table 50, were also low, but indicate a general trend for improvement from baseline to the
end of the trial.
Quality of life, assessed using the Hydrocephalus Outcome Questionnaire
The return rate for the HOQ was low, and is summarised in Appendix 3, Table 51. Because of the low
return rate, there were insufficient data to formally analyse the HOQ by mixed models, with the
patient model not converging and the parent model output containing warnings that the final Hessian
matrix not positive definite. For this reason, the patient questionnaire and the parent questionnaire are
presented descriptively in Appendix 3, Tables 52 and 53.
Incremental analysis: base case
In the base-case analysis, both antibiotic-impregnated and silver-impregnated VPSs were located in the
south-west quadrant of the cost-effectiveness plane; in relation to the standard VPS, they were less
effective (associated with higher rates of first VPS failure due to any reason), but also less expensive,
overall. The interpretation in the south-west quadrant is that interventions are more cost-effective with
increasingly negative ICERs (larger savings associated with small health losses result in increasingly
negative ICERs). Incrementally, silver-impregnated VPSs save £62,358 for each additional failure,
compared with standard VPSs, and antibiotic-impregnated VPS catheters save £638,600 per additional
failure, compared with silver-impregnated VPSs.
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TABLE 28 Disaggregated 2-year costs from randomisation, by intervention group
Costs relating to
Trial group, mean (97.5% CI) (£) Difference between
antibiotic-impregnated
and standard VPS,




mean (97.5% CI) (£)Standard VPS Antibiotic-impregnated VPS Silver-impregnated VPS
Inpatient visits 14,181 (10,618 to 20,557) 11,738 (9730 to 14,401) 14,481 (11,868 to 17,744) –2442 (–8954 to 1933) 300 (–6242 to 4965)
Outpatient visits 2336 (1542 to 3651) 2117 (1499 to 2989) 2220 (1562 to 3442) –219 (–1649 to 940) –116 (–1559 to 1295)
GP visits 188 (108 to 373) 91 (71 to 121) 91 (66 to 129) –97 (–280 to –11) –97 (–277 to –7)
Nurse visits 133 (57 to 314) 97 (49 to 169) 60 (28 to 119) –36 (–224 to 67) –73 (–254 to 22)
Health visitor 303 (77 to 784) 131 (76 to 205) 287 (157 to 378) –171 (–663 to 64) –15 (–490 to 245)
Physiotherapy 500 (242 to 1110) 190 (121 to 279) 655 (356 to 1084) –310 (–921 to –35) 155 (–472 to 666)
Occupational therapist 81 (18 to 184) 139 (60 to 243) 73 (15 to 175) 58 (–69 to 173) –8 (–123 to 119)
Other health-care professionals 392 (211 to 817) 367 (189 to 682) 246 (190 to 328) 24 (–465 to 329) –145 (–592 to 57)
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FIGURE 6 Distribution of participants’ responses to each EQ-5D attribute, by treatment allocated and time. Levels range
from 1 to 3, with 3 representing the most severe problem. The numbers of completed responses (n) are reported by
intervention group. (a) Mobility; (b) self-care; (c) usual activities; (d) pain or discomfort; (e) anxiety or depression.
(continued )
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Baseline Early post operation
Treatment time and VPS allocation
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FIGURE 6 Distribution of participants’ responses to each EQ-5D attribute, by treatment allocated and time. Levels range
from 1 to 3, with 3 representing the most severe problem. The numbers of completed responses (n) are reported by
intervention group. (a) Mobility; (b) self-care; (c) usual activities; (d) pain or discomfort; (e) anxiety or depression.
(continued )
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Sensitivity analyses
The ICERs were sensitive to changes in the unit costs of antibiotic-impregnated VPSs (Table 29).
Compared with silver-impregnated VPSs, the incremental cost per first VPS failure became positive
(north-east quadrant of the cost-effectiveness plane) when the cost of an antibiotic-impregnated VPS
exceeded 10 times its current list price. The ICER (of antibiotic- vs. silver-impregnated VPSs) was
insensitive to a change in the cost of silver-impregnated VPSs, even at 10% of the list price. However,
a 35% reduction in cost, combined with a ninefold increase in the cost of antibiotic-impregnated VPSs,
resulted in a positive ICER. In the comparison of silver-impregnated with standard VPSs, a fivefold
increase in the cost of a silver-impregnated VPS resulted in a positive ICER (north-east quadrant of
the cost-effectiveness plane), whereas no degree of reduction in the price of standard VPSs had a
meaningful influence on the ICER.
The ICERs were stable to changes in discount rate (ranging from undiscounted to a discount rate of
6% per annum) and choice of regression modelling (Table 30). However, there were differences in
cost-effectiveness when limiting the analysis to observed data, without multiple imputation. In this
analysis, antibiotic-impregnated VPS dominated silver-impregnated VPS catheters, and saved £56,771
for each additional failure, compared with standard VPS catheters.
Based on the GLM, whereby the gamma family and log-link performed best (lowest AIC and BIC values
and a coefficient close to 2 in the modified Park test), the ICERs were consistent with the base case,
with a saving of £336,000 per additional VPS failure (due to any cause) with antibiotic-impregnated
shunt catheters (compared with silver-impregnated VPSs), and a saving of £85,802 per additional VPS
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FIGURE 6 Distribution of participants’ responses to each EQ-5D attribute, by treatment allocated and time. Levels range
from 1 to 3, with 3 representing the most severe problem. The numbers of completed responses (n) are reported by
intervention group. (a) Mobility; (b) self-care; (c) usual activities; (d) pain or discomfort; (e) anxiety or depression.
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TABLE 29 Results of the bivariate sensitivity analyses: the impact on the ICERs of changing the price of antibiotic-impregnated, silver-impregnated and standard VPSs
ICER vs. silver-impregnated VPS x-fold decrease in the price of a silver-impregnated VPS
x-fold increase in the price of an
antibiotic-impregnated VPS
1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
1 –638,600 –631,368 –624,135 –616,903 –609,670 –602,438 –595,206 –587,973 –580,741 –573,508
2 –561,800 –554,568 –547,335 –540,103 –532,870 –525,638 –518,406 –511,173 –503,941 –496,708
3 –485,000 –477,768 –470,535 –463,303 –456,070 –448,838 –441,606 –434,373 –427,141 –419,908
4 –408,200 –400,968 –393,735 –386,503 –379,270 –372,038 –364,806 –357,573 –350,341 –343,108
5 –331,400 –324,168 –316,935 –309,703 –302,470 –295,238 –288,006 –280,773 –273,541 –266,308
6 –254,600 –247,368 –240,135 –232,903 –225,670 –218,438 –211,206 –203,973 –196,741 –189,508
7 –177,800 –170,568 –163,335 –156,103 –148,870 –141,638 –134,406 –127,173 –119,941 –112,708
8 –101,000 –93,768 –86,535 –79,303 –72,070 –64,838 –57,606 –50,373 –43,141 –35,908
9 –24,200 –16,968 –9735 –2503 4730 11,962 19,194 26,427 33,659 40,892
10 52,600 59,832 67,065 74,297 81,530 88,762 95,994 103,227 110,459 117,692
ICER vs. standard VPS x–fold decrease in the price of a standard VPS
x-fold increase in the price of a
silver-impregnated VPS
1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
1 –62,358 –61,547 –60,736 –59,925 –59,113 –58,302 –57,491 –56,679 –55,868 –55,057
2 –45,301 –44,490 –43,678 –42,867 –42,056 –41,244 –40,433 –39,622 –38,810 –37,999
3 –28,243 –27,432 –26,621 –25,809 –24,998 –24,187 –23,375 –22,564 –21,753 –20,942
4 –11,186 –10,375 –9563 –8752 –7941 –7129 –6318 –5507 –4695 –3884
5 5872 6683 7494 8306 9117 9928 10,740 11,551 12,362 13,174
6 22,929 23,741 24,552 25,363 26,175 26,986 27,797 28,608 29,420 30,231
7 39,987 40,798 41,609 42,421 43,232 44,043 44,855 45,666 46,477 47,289
8 57,044 57,856 58,667 59,478 60,290 61,101 61,912 62,724 63,535 64,346
9 74,102 74,913 75,725 76,536 77,347 78,158 78,970 79,781 80,592 81,404
10 91,159 91,971 92,782 93,593 94,405 95,216 96,027 96,839 97,650 98,461
Note




























































































































































































Negative ICERs relate to incremental cost and outcome co-ordinates in the south-west quadrant of the
cost-effectiveness plane.
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Subgroup analyses
A stratified cost-effectiveness analysis indicated that cost-effectiveness was dependent on age
(Table 31). In paediatrics, antibiotic-impregnated VPS catheters were dominant (south-east quadrant
of the cost-effectiveness plane), with mean savings of £5312 and additional benefits of 0.004 VPS
failures (due to any reason) averted. Put another way, for every 250 patients first receiving an
antibiotic-impregnated instead of a standard VPS catheter, there would be one fewer case of VPS
failure (due to any reason), and a cost-saving of £1,328,000.
For adults aged 16–65 years, silver-impregnated VPSs were the most cost-effective, with antibiotic-
impregnated VPS catheters being extendedly dominated. In adults aged > 65 years, silver-impregnated
VPSs save £29,375 for each additional failure, compared with standard VPSs, and antibiotic-impregnated
VPSs save £786,375 per additional failure, compared with silver-impregnated VPSs.









































































































Negative ICERs relate to incremental cost and outcome co-ordinates in the south-west quadrant of the
cost-effectiveness plane.
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Alternative cost-effectiveness and cost–utility analyses
A cost-effectiveness analysis based on the incremental cost per confirmed infection averted indicated that
silver-impregnated VPS catheters were dominated by standard VPSs, whereas antibiotic-impregnated VPS
catheters were dominant, saving £4059 per 0.030 fewer infection-related VPS failures. Compared with
standard VPSs, antibiotic-impregnated VPS catheters save £135,753 per VPS infection avoided (Table 32).


















































































































Negative ICERs relate to incremental cost and outcome co-ordinates in the south-west quadrant of the
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For the cost-effectiveness measure of incremental cost per mechanical failure averted, both silver-
impregnated and antibiotic-impregnated VPS catheters were dominated by standard VPSs, as they
were associated with higher rates of mechanical failures and higher costs than standard VPSs. With
regards to functional VPS failures, antibiotic-impregnated VPS catheters are both less effective and
less expensive than standard VPSs, whereas silver-impregnated shunt catheters cost an additional
£387,667 per additional functional failure averted. The opposite was observed when considering the
incremental cost per VPS failure due to patient-related factors, although failure rates due to patient
influences are much lower, and the reporting of this outcome was less reliable. Antibiotic-impregnated
VPS catheters cost an additional £7.4M per failure averted, whereas silver-impregnated VPS catheters
save £3.9M per additional failure, each in comparison with standard shunt catheters.
In the cost–utility analysis of trial participants aged ≥ 5 years, and based on multiple imputation to
account for missing data, antibiotic-impregnated VPS catheters were dominated by silver-impregnated
VPS. Compared with standard VPSs, silver-impregnated VPSs are £183 more costly, and yield 0.096
additional QALYs overall, resulting in an incremental cost of £1904 per QALY gained. The cost-effectiveness
acceptability curve showing the probability of each VPS catheter being cost-effective, by a range of
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FIGURE 7 Cost-effectiveness acceptability curves indicating the probability of each VPS catheter being cost-effective
(based on the incremental cost per QALY gained) for a range of threshold (willingness-to-pay) values. Vertical lines
indicate the usual NICE threshold range53 of £20,000–30,000 per QALY.
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Chapter 5 Discussion
Parts of this chapter have been reproduced from Mallucci et al.2 This is an Open Access articledistributed under the terms of the Creative Commons Attribution License (https://creativecommons.
org/licenses/by-nd/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. The text below includes minor additions and formatting
changes to the original text.
Summary of findings
In this trial of patients with hydrocephalus who were undergoing insertion of their first permanent VPS,
the infection rates were 6.0% in the standard VPS group, 2.2% in the antibiotic-impregnated VPS group
and 5.9% in the silver-impregnated VPS group. Compared with standard VPSs, antibiotic-impregnated
VPSs were associated with a significantly lower rate of infection, whereas silver-impregnated VPSs were
not. This effect was present across all age categories. There is significant economic benefit for every
shunt infection averted. There were notable differences in infection rates for differing aetiologies of
hydrocephalus and between different age groups.
Clinical effectiveness
The BASICS trial provides definitive evidence favouring the use of antibiotic-impregnated VPSs to
reduce infection. A previously reported underpowered randomised trial15 demonstrated a trend favouring
antibiotic-impregnated over standard VPSs, but did not show a statistically significant difference between
the two groups in the risk of infection (RR 0.38, 95% CI 0.11 to 1.30). Silver-impregnated shunt catheters
have been evaluated only in a randomised trial of EVDs,22 which found a reduction in infection from
21.4% (30/140) with standard shunt catheters to 12.3% (17/138) (p = 0.043) with silver-impregnated
shunt catheters, although this is much higher than the UK national reported infection rate (9.3%) for
EVDs.59 The BASICS trial was conceived to evaluate both antibiotic-impregnated and silver-impregnated
VPSs before the widespread introduction of these products into routine practice, despite a lack of
evidence. The results of this trial will inform neurosurgery practice and choice of VPS for insertion,
to the benefit of patients.
In this trial, the classification of VPS infection was determined by the central review committee.
The proportion of culture-positive infections was 68.8% in the standard VPS group, 50.0% in antibiotic-
impregnated VPS group and 80.6% in silver-impregnated VPS group; there was a lower rate of culture-
positive infection with antibiotic-impregnated VPSs than with either the standard-impregnated or
the silver-impregnated VPS. The analysis allowed for culture-negative infections to be included when
there was sufficient supporting clinical evidence of VPS infection. We postulate that the presence
of antibiotic-impregnated shunt catheters reduced the ability to culture organisms in infected VPSs.
This trial would have shown an even greater effect in favour of antibiotic-impregnated VPSs if we
had included culture-positive infections only.
The reduction of types of infections seen is consistent with the expected microbiological spectrum of
the antibiotic-impregnated VPSs, which are especially active against Gram-positive organisms, and
were incorporated to prevent staphylococcus species infections. The culture results show a large
reduction in staphylococcal infection with antibiotic-impregnated VPSs, compared with the standard
and silver-impregnated VPSs, which accounts for the majority of the infections prevented and supports
the biological plausibility as clindamycin and rifampicin are preferentially active against Gram-positive
organisms. All three VPS types have a similar number of Gram-negative infections, which the
antibiotics were not expected to reduce.
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It should be noted that the overall VPS failure rate was the same for all groups, although infection was
reduced in the antibiotic-impregnated VPS arm. When infection is removed as a cause, the clean non-
infected revision rates were slightly higher in the antibiotic-impregnated VPS group. In the post hoc
analysis, the only pattern that could be found was a higher rate of valve change in the antibiotic-
impregnated VPS group than in the standard and silver-impregnated VPS groups when analysing the
components of the shunt that were changed and/or blocked at surgery, as reported by the operating
surgeon on the CRF. Interestingly, the valve itself is not impregnated and is common to all shunt types.
Unfortunately, in most cases, the valves were not sent for culture as it was not part of most units’
protocol at clean shunt revision. Of note, there were no increased revisions for any group for
peritoneal shunt catheters. One of the concerns voiced by some of the surgeons was that silver-
impregnated peritoneal shunt catheters were more rigid than the other types, and that this might lead
to more peritoneal catheter revisions. This was not borne out in the results.
The reasons for the higher non-infective blockages in the antibiotic-impregnated VPS group are not
known. One hypothesis is that the antibiotic-impregnated shunt catheters convert an ‘infected’ shunt
revision to an apparently ‘clean’ shunt revision in the following ways:
l Low virulent pathogens are restricted to a biofilm in the valve, not causing a CSF change as there is
no ventriculitis and not isolated from the revision CSF as the planktonic bacteria are low in number
or not able to grow in the presence of the eluted antibiotics.
l A sufficient change in CSF composition and flow (such as debris or high protein) to promote a blockage
in the system such as the valve, which is probably the most vulnerable to content of CSF in terms of
blockage in view of the intricate mechanical valve mechanisms. This study has not been powered or
designed to answer this question directly, but, in future research, this question will be important.
Of note, from a patient well-being and health economic standpoint, a mechanical clean shunt revision,
such as a valve change, will have a minor effect on the patient and a minor cost to the NHS. A clean
revision for valve change typically involves an overnight stay only, no brain operation (as the ventricular
shunt catheter is not changed) and none of the health implications of suffering from clinical meningitis.
In contrast, a shunt infection will involve two brain operations: a first operation to remove the whole
shunt system and to insert a temporary ventricular shunt catheter (an average of 2 weeks in a hospital
bed for both intravenous and intrathecal antibiotics, and the health implications of clinical meningitis)
and a second operation to re-insert a whole new shunt system including a ventricular shunt catheter.
In addition to the above, if a patient has ventricular shunt catheter change at shunt revision [as
opposed to valve change or peritoneal shunt catheter change, (not a brain operation)], they will lose
their driving licence for 6 months because of the increased risk of epilepsy after ventricular shunt
catheter revision (as it is a brain operation).
Cost effectiveness
Complications associated with VPS failures are expensive to manage.32–38 Consequently, the use of VPS
catheters, which result in fewer complications, even if more expensive to purchase, could be cost-
effective or yield cost savings to the NHS. The economic analysis within the BASICS trial estimated
that, although antibiotic-impregnated shunt catheters are about twice the price of standard silicone
shunt catheters, this upfront cost could be justified by the reduced infection rate and associated cost
savings of further surgery and prolonged hospital care. Based on the primary economic outcome of
incremental cost per VPS failure (due to any cause) averted, there appeared to be large potential
savings for additional cases of VPS failures with silver- and antibiotic-impregnated VPSs compared with
standard VPSs. This conservative estimate does not assume equivalence, despite no difference between
groups in VPS failure rate. Had a cost-minimisation analysis been considered appropriate, the saving
per patient having an antibiotic-impregnated rather than a standard VPS would be £4515 (97.5% CI
£140 to £9170).
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In this context, the secondary outcome based on the incremental cost per confirmed infection averted
is more relevant, as well as for comparison with previous such analyses, which use the same outcome
measure. Notably, antibiotic-impregnated VPS catheters were dominant, saving £4059 per 0.030 fewer
infection-related VPS failures. Compared with standard VPSs, antibiotic-impregnated VPS catheters
save £135,753 per VPS infection avoided. In terms of determining technical efficiency, no cost-
effectiveness threshold is necessary, given the dominance of antibiotic-impregnated VPS catheters.
For the purposes of informing decisions on allocative efficiency, the cost–utility analysis of participants
aged ≥ 5 years indicated that antibiotic-impregnated VPSs were dominant, whereas the incremental
cost per QALY gained with silver-impregnated VPSs was £1904, which is within the threshold applied
by NICE for the determination of cost-effectiveness. However, the cost–utility analysis was limited, with
respect to missing data and the exclusion of participants who were at the highest risk of VPS infections.
The analyses are robust to a range of assumptions and analytic approaches. Important subgroup
analyses indicate differences in cost-effectiveness by age. The risk of infection in the BASICS trial was
highest in paediatrics; it was lower for adults and was particularly low for the elderly. Some patterns
also emerged with the aetiology of hydrocephalus; for example, congenital causes and post-haemorrhagic
hydrocephalus (both prevalent in the paediatric age group) resulted in much higher infection rates than
those observed for other aetiologies seen in older patients. Although the primary economic analysis was
based on all-cause VPS failures, subgroup analyses demonstrated higher cost-effectiveness in paediatrics
than in adult populations.
Generalisability and cost impact
In the context of the NHS, there should be a major health benefit and cost-saving impact by routinely
adopting antibiotic-impregnated VPSs for all first-time VPS insertions for hydrocephalus.
Clearly, in paediatrics, for whom the effect of reduction in shunt infections is greatest, the economic
benefit will also be the most significant. For example, for every 100 paediatric new VPS insertions,
using antibiotic-impregnated rather than standard shunt catheters should avert up to six or seven
shunt infections, which translates to a potential cost saving of between £814,000 and £950,000.
Even in those aged > 65 years, averting one infection per 100 shunts could potentially save £135,753.
Such savings may well translate to equivalent health economies, such as the in the USA, but clearly the
potential value and savings will vary in different health models internationally.
Strengths and limitations
The strengths of this trial are that (1) infections were centrally classified by a panel blinded to
treatment allocation, thereby removing the risk of treating-surgeon bias; (2) participant retention was
very high owing to the nature of the intervention and the primary outcome (patients with infected
VPSs are always re-admitted to hospital); (3) patient withdrawal was low (n = 53, 3.3%) so it is unlikely
that events were missed; (4) participants were recruited across the whole of the UK and the Republic
of Ireland to encompass all ages and socioeconomic classes; and (5) the trial sample size was large.
Some limitations of the trial should be noted. First, it was not possible to blind the treating
neurosurgeon to the VPS type, because the physical appearance of each shunt catheter is distinctive.
Participants were blinded to the shunt catheter type, and shunt catheter type was not recorded in
patient records. The majority of VPS revisions and removals for infection happen as emergencies
and are managed by the emergency neurosurgery team. Therefore, the likelihood of the same
neurosurgeon who inserted the VPS being involved in the decision to remove the VPS was low,
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given the work rotas of neurosurgical staff. Furthermore, there was high agreement (95.7%) in the
classification of VPS infection between treating surgeons and the central review panel, suggesting
that any bias that the treating surgeon may have had did not affect the study conclusion. Second,
ventriculoatrial and ventriculopleural shunts were excluded, although we postulate that the results
are translatable to patients undergoing these procedures. Finally, the return rate for patient-reported
outcomes was low, thereby limiting the analysis of the impact of VPS infection.
Limitations to the economic evaluation include a lack of detailed costing for revisions, and failure to obtain
Hospital Episode Statistics data from NHS Digital, as per protocol. Reliance on PLICS data mitigated these
limitations, but, as with other data on costs, there was a high degree of missingness due to some centres
not being able to share electronic data and patient questionnaires not being returned. This was addressed
using robust methods (multiple imputation), but still may have introduced bias to the analysis.
Safety
The data suggest that there is no increased health risk in using impregnated shunt catheters. There
were no serious AEs. All of the AEs that were seen were expected events predominantly related to
expected shunt revisions and/or due to re-admission for expected known complications associated
with VPS surgery; no differences were seen between catheter types.
Implications for practice and health care
From a patient perspective and that of the treating clinician, the hospital and the health service, every
effort to reduce shunt infection should be made, and health technologies such as antibiotic-impregnated
shunt catheters, with their potential to reduce VPS infections, deserve proper evaluation through
appropriately planned and powered trials.
Having demonstrated a marked reduction in such infections, with all of the potentially catastrophic and
life-changing health sequalae that result from each infection, the BASICS trial has provided evidence to
support that the adoption of antibiotic-impregnated shunt catheters is justified in all patients receiving
their first VPS in the UK. The increased upfront cost of the impregnated shunt catheters is offset by
the added health economic benefit demonstrated in the health economic analysis and in a previous
publication.39 The benefits and implications, both from an efficacy and health economic point of view,
are most pronounced in younger patients.
A wider discussion and analysis, particularly from a health economics point of view, is required when
considering recommendations and implications globally.
Conclusions
In conclusion, antibiotic-impregnated shunt catheters significantly reduce the VPS infection rate and
the probability of infection, compared with standard silicone shunt catheters in all age groups, whereas
silver-impregnated shunt catheters do not. The routine use of these shunt catheters would result in a
significant cost saving to the NHS.
These results support the use of antibiotic-impregnated shunt catheters in the treatment of patients
undergoing insertion of a first VPS for hydrocephalus.
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Implications for future research
To our knowledge, the BASICS trial is the largest-ever prospective randomised trial for VPSs in
hydrocephalus worldwide.
A critical value-added aspect of the BASICS trial was the development of systematic clinical sample
collection (of CSF and blood) from participants undergoing VPS insertion. We have established a unique
neurosurgical patient sample collection, which will enable us to identify surrogate markers of VPS
infection in CSF or blood using molecular techniques (transcriptomics/proteomics); to assess whether
or not infection may be associated with shunt failure cases (by detection of pathogen nucleic acid via
next-generation sequencing); and to begin to explore whether or not host differences contribute to the
different rates of infection in children, compared with adults. Proteomic analysis of CSF has already
been undertaken to identify a series of candidate surrogate markers of neurosurgical infection. These
candidate markers are now being re-tested among the BASICS trial samples to assess their accuracy in
identifying confirmed infection. The BASICS trial sample collection, stored at the University of Liverpool,
is a valuable resource to help answer the ongoing questions around VPS infection identified in the
BASICS trial (as outlined in this paragraph) and to support future additional studies.
A large number of data was collected regarding aetiology, surgical techniques, types of valves and the
technology used, which can guide future management and trials. We plan to undertake further analysis
exploring patterns related to mechanical shunt failure. This is led by the results and will, therefore,
be post hoc. We also plan to create a detailed shunt failure model and predictive score. Failure and
infection rates across different aetiologies of hydrocephalus will be analysed further.
Surgical techniques and factors that potentially affect failure rates will be further analysed, such as
the use of neuronavigation and the placement of the ventricular shunt catheter, surgical site infection
information collected at the time of surgery and seniority of the surgeon. This may feed further
questions and prospective randomised studies.
From a methodological perspective, the economic evaluation was significantly affected by missing data.
However, organisational familiarity with the procedures and requirements for accessing routine data,
post General Data Protection Regulation,60 should facilitate Hospital Episode Statistics data access
from NHS Digital in future trials. Acute trusts are now mandated to produce PLICS data, and early
engagement with hospital finance offices should resolve many of the difficulties that were faced in the
BASICS trial. Poor response rates to questionnaires is a common problem in self-reported resource
use. Further research into methods to mitigate this ought to focus not just on technical solutions,
but also on operational solutions, including a broader appreciation that achieving complete data on
economic outcomes should be regarded as having equal importance to achieving complete data on
primary clinical end points. This may be especially relevant for time-to-event analyses, in which costs
and disutilities are most likely to accrue after such events.
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Appendix 2 Clinical effectiveness study:
additional data
Parts of this appendix have been reproduced from Mallucci et al.2 This is an Open Access articledistributed under the terms of the Creative Commons Attribution License (https://creativecommons.
org/licenses/by-nd/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. The text below includes minor additions and formatting
changes to the original text.


















0243 26 June 2013 9 October 2017 70 26 June 2013 12 September 2017 119
0114 3 July 2013 30 September 2017 115 5 July 2013 15 September 2017 175
0578 24 July 2013 9 October 2017 100 25 July 2013 9 October 2017 155
0232 1 October 2013 28 August 2015 50 29 December 2013 12 August 2015 22
0249 7 October 2013 31 August 2017 100 16 October 2013 4 August 2017 71
0400 8 October 2013 30 September 2017 80 23 October 2013 4 July 2017 82
0213 1 November 2013 30 September 2017 90 27 November 2013 13 September 2017 141
0248 21 November 2013 30 September 2017 50 16 December 2013 10 May 2017 41
0133 10 December 2013 31 August 2016 40 28 January 2014 24 June 2016 30
0007 21 January 2014 30 September 2017 60 7 February 2014 13 September 2017 85
0246 12 March 2014 30 September 2017 65 29 April 2014 22 September 2017 48
0352 1 April 2014 30 September 2017 65 7 April 2014 20 September 2017 129
0030 29 April 2014 30 September 2017 115 17 June 2014 22 September 2017 92
0185 17 June 2014 30 September 2017 65 26 June 2014 10 July 2017 188
0161 25 September 2014 30 September 2017 60 25 September 2014 15 December 2016 36
0361 1 October 2014 31 August 2016 20 31 October 2014 3 September 2015 5
0393 1 October 2014 31 August 2016 20 4 March 2015 14 January 2016 8
0006 7 January 2015 30 September 2017 0 30 January 2015 19 May 2017 22
9999 23 February 2015 30 September 2017 35 23 February 2015 5 June 2017 69
0672 1 April 2015 30 September 2017 0 16 April 2015 4 September 2017 73
0004 20 October 2015 30 September 2017 0 6 November 2015 9 September 2016 14
All centres 26 June 2013 9 October 2017 1200 26 June 2013 9 October 2017 1605
a Table ordered by date of centre opening.
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a + b + c
0243 194 47 (24.2) 5 (2.6) 18 (9.3) 5 (2.6) 119 (61.3) 87.3
0114 508 197 (38.8) 68 (13.4) 55 (10.8) 13 (2.6) 175 (34.4) 77.4
0578 223 33 (14.8) 14 (6.3) 14 (6.3) 7 (3.1) 155 (69.5) 92.0
0232 70 32 (45.7) 9 (12.9) 4 (5.7) 3 (4.3) 22 (31.4) 86.2
0249 164 26 (15.9) 28 (17.1) 35 (21.3) 3 (1.8) 71 (43.3) 67.9
0400 266 87 (32.7) 62 (23.3) 26 (9.8) 8 (3.0) 82 (30.8) 77.6
0213 327 105 (32.1) 52 (15.9) 26 (8.0) 3 (0.9) 141 (43.1) 84.7
0248 130 54 (41.5) 11 (8.5) 21 (16.2) 2 (1.5) 41 (31.5) 67.2
0133 105 26 (24.8) 28 (26.7) 21 (20.0) 0 (0.0) 30 (28.6) 58.8
0007 184 12 (6.5) 59 (32.1) 22 (12.0) 6 (3.3) 85 (46.2) 80.5
0246 200 129 (64.5) 12 (6.0) 9 (4.5) 2 (1.0) 48 (24.0) 84.7
0352 238 65 (27.3) 18 (7.6) 20 (8.4) 1 (0.4) 129 (54.2) 86.7
0030 199 71 (35.7) 11 (5.5) 21 (10.6) 3 (1.5) 92 (46.2) 81.9
0185 225 3 (1.3) 17 (7.6) 10 (4.4) 7 (3.1) 188 (83.6) 95.1
0161 53 1 (1.9) 1 (1.9) 15 (28.3) 0 (0.0) 36 (67.9) 70.6
0361 8 1 (12.5) 2 (25.0) 0 (0.0) 0 (0.0) 5 (62.5) 100.0
0393 11 0 (0.0) 0 (0.0) 2 (18.2) 1 (9.1) 8 (72.7) 81.8
0006 36 10 (27.8) 3 (8.3) 1 (2.8) 0 (0.0) 22 (61.1) 95.7
9999 144 34 (23.6) 13 (9.0) 26 (18.1) 2 (1.4) 69 (47.9) 73.2
0672 176 62 (35.2) 19 (10.8) 21 (11.9) 1 (0.6) 73 (41.5) 77.9
0004 44 25 (56.8) 3 (6.8) 2 (4.5) 0 (0.0) 14 (31.8) 87.5
a Table ordered by date of centre opening.
b Patients could be screened multiple times. This table presents the most recent screening per patient.
c Eligible: yes/no; not known for two patients.
d Consent sought: yes/no; not known for seven patients.
APPENDIX 2



























































































































































































































































































































































5 19 43 72 105 183 229 279 332 389142








636 698 761 824
399
396
886 949 1012 1074 1137 1200


































































































































































































































































































































































































TABLE 35 Reasons participants received other (not allocated) VPS
Reason











Allocated VPS not available 1 (16.7) 1 (14.3) 0 (0.0) 2 (12.5)
Allocated catheter not available 3 (50.0) 1 (14.3) 0 (0.0) 4 (25.0)
Allocated shunt not available 0 (0.0) 1 (14.3) 0 (0.0) 1 (6.3)
Allocated shunt too short 0 (0.0) 1 (14.3) 1 (33.3) 2 (12.5)
Allocated tubing not available 0 (0.0) 1 (14.3) 0 (0.0) 1 (6.3)
Catheter too firm; difficult to remove if required 0 (0.0) 0 (0.0) 1 (33.3) 1 (6.3)
Consultant felt that allocated shunt would
affect quality of future scans
0 (0.0) 1 (14.3) 0 (0.0) 1 (6.3)
Miscommunication within the trial team 0 (0.0) 1 (14.3) 1 (33.3) 2 (12.5)
No long catheter available for allocated VPS 1 (16.7) 0 (0.0) 0 (0.0) 1 (6.3)
Technical difficulties 1 (16.7) 0 (0.0) 0 (0.0) 1 (6.3)
The terms catheter, shunt and tube signify shunt catheter.
TABLE 36 Reasons participants did not receive a VPS
Reason











MRI brain reviewed (done pre surgery); decision
made to cancel surgery as ventricle size had
reduced
0 (0.0) 0 (0.0) 1 (50.0) 1 (25.0)
Unsuccessful ventricular shunt catheter
insertion
0 (0.0) 1 (50.0) 0 (0.0) 1 (25.0)
Abnormal ECG; surgery abandoned 0 (0.0) 0 (0.0) 1 (50.0) 1 (25.0)
Pus found intraoperatively; EVD inserted 0 (0.0) 1 (50.0) 0 (0.0) 1 (25.0)
ECG, electrocardiogram; MRI, magnetic resonance imaging.
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TABLE 37 Protocol deviations
Deviation












Any protocol deviation 134 (25.0) 146 (27.1) 159 (29.9) 439 (27.4)
Major deviations
PD1: consent not obtained 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
PD2: patient has had at least one previous
indwelling VPS
2 (0.4) 2 (0.4) 1 (0.2) 5 (0.3)
PD3: patient had an active CSF infection at the
time of VPS insertion
3 (0.6) 1 (0.2) 3 (0.6) 7 (0.4)
PD4: patient had an allergy to the antibiotics with
which one of the randomised shunts is impregnated
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
PD5: patient could have an allergy to the silver
with which one of the randomised shunts
is impregnated
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
PD6: patient did not receive allocated intervention 0 (0.0) 2 (0.4) 2 (0.4) 4 (0.2)
PD7A: CSF samples not taken or sent for culture at
time of VPS insertion
16 (3.0) 12 (2.2) 19 (3.6) 47 (2.9)
PD7B: CSF samples not taken or sent for culture at
time shunt revision/removal
6 (1.1) 3 (0.6) 5 (0.9) 14 (0.9)
PD7C: shunt components not taken for culture at
shunt revision/removal
99 (18.5) 108 (20.1) 113 (21.3) 320 (19.9)
At least one major deviation 112 (20.9) 120 (22.3) 131 (24.7) 363 (22.6)
Minor deviations
PD8: patient had multiloculated hydrocephalus,
necessitating multiple VPSs or neuroendoscopy
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
PD9: patient had ventriculoatrial or
ventriculopleural shunt planned
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
PD10: patient prematurely withdrew
from follow-up
14 (2.6) 22 (4.1) 17 (3.2) 53 (3.3)
PD11: patient missed scheduled assessments
(early post-operative assessment)
1 (0.2) 2 (0.4) 6 (1.1) 9 (0.6)
PD12: randomisation envelope opened out
of sequence
12 (2.2) 9 (1.7) 10 (1.9) 31 (1.9)
PD13: unblinding occurred 11 (2.1) 6 (1.1) 15 (2.8) 32 (2.0)
At least one minor deviation 38 (7.1) 37 (6.9) 45 (8.5) 120 (7.5)
PD, protocol deviation.
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1.0 Gray’s test p = 0.0214


































1.0 Gray’s test p = 0.3139







FIGURE 9 Cumulative incidence plots of revisions for infection and competing risk as classified by treating surgeon,
by VPS group and age group. (a) Infection by VPS group; (b) competing risk by VPS group; (c) infection by age group;
(d) competing risk by age group. (continued )
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1.0 Gray’s test p < 0.0001





































Gray’s test p < 0.0001
16–65 years
> 65 years
FIGURE 9 Cumulative incidence plots of revisions for infection and competing risk as classified by treating surgeon,
by VPS group and age group. (a) Infection by VPS group; (b) competing risk by VPS group; (c) infection by age group;
(d) competing risk by age group.
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TABLE 38 Line listings of infection type, organism cultured and level of sensitivities











(A) Line listings of infections associated with the standard VPS (n = 23)
1 A ‘definite – culture
positive’ infection
Staphylococcus capitas 1 Vancomycin





Serratia species a Yes
Staphylococcus capitas 1 Clarithromycin, doxycycline,
erythromycin, flucloxacillin,
Fucidin® (Leo Pharma A/S,
Ballerup, Denmark)
3 A ‘probable – culture
uncertain’ infection
Staphylococcus epidermidis 1 Yes
4 A ‘definite – culture
positive’ infection
Pseudomonas aeruginosa 1 Meropenem
2 Meropenem
3 Meropenem
5 A ‘definite – culture
positive’ infection
Staphylococcus epidermidis 1 Vancomycin Ciprofloxacin, clindamycin,
flucloxacillin, gentamicin,
rifampicin, trimethoprim
2 Fusidic acid; vancomycin Erythromycin,
flucloxacillin, penicillin
6 A ‘definite – culture
positive’ infection




7 A ‘definite – culture
positive’ infection
Staphylococcus aureus 1 Cefuroxime, flucloxacillin














































9 A ‘definite – culture
positive’ infection
Staphylococcus aureus 1 Flucloxacillin, vancomycin
2 Flucloxacillin
3 Flucloxacillin, vancomycin





11 A ‘definite – culture
positive’ infection
Klebsiella pneumoniae 1 Cefotaxime, gentamicin







13 A ‘definite – culture
positive’ infection















14 A ‘definite – culture
positive’ infection
Staphylococcus epidermidis 1 Amikacin, vancomycin Flucloxacillin


























































































































































































































































































































































TABLE 38 Line listings of infection type, organism cultured and level of sensitivities (continued )











17 A ‘definite – culture
positive’ infection
Staphylococcus aureus 1 Flucloxacillin
2 Flucloxacillin
18 A ‘definite – culture
positive’ infection
Klebsiella pneumoniae 1 Meropenem
2 Meropenem
19 A ‘definite – culture
positive’ infection
Staphylococcus epidermidis 1 Vancomycin
2 Vancomycin
3 Vancomycin
20 A ‘definite – culture
positive’ infection
Serratia marcescens 1 Gentamicin, meropenem
21 A ‘definite – culture
positive’ infection












22 A ‘definite – culture
positive’ infection
Staphylococcus aureus 1 Vancomycin
3 Vancomycin
Staphylococcus capitas 2 Vancomycin
23 A ‘definite – culture
positive’ infection










































(B) Line listings of infections associated with the antibiotic-impregnated VPSs (n = 6)
1 A ‘definite – culture
positive’ infection




2 A ‘definite – culture
positive’ infection
Propionibacterium species 1 Penicillin





4 A ‘definite – culture
positive’ infection
Escherichia coli 1 Cefotaxime
5 A ‘definite – culture
positive’ infection
Enterobacter cloacae 1 Cefotaxime, ciprofloxacin
6 A ‘definite – culture
positive’ infection
Proteus mirabilis 1 Cefuroxime
(C) Line listings of infections associated with silver-impregnated VPSs (n = 27)
1 A ‘definite – culture
positive’ infection
Staphylococcus epidermidis 1
2 A ‘definite – culture
positive’ infection
Staphylococcus capitas 1
3 A ‘definite – culture
positive’ infection
Streptococcus mitis 1 Penicillin, vancomycin
2 Penicillin, vancomycin
4 A ‘definite – culture
positive’ infection
Staphylococcus aureus 1 Erythromycin, flucloxacillin,
vancomycin
5 A ‘probable – culture
uncertain’ infection
















































































































































































































































































































































TABLE 38 Line listings of infection type, organism cultured and level of sensitivities (continued )











6 A ‘definite – culture
positive’ infection






3 Rifampicin, vancomycin Flucloxacillin
7 A ‘definite – culture
positive’ infection
Escherichia coli 1 Colomycin® (Teva
Pharmaceutical Industries






8 A ‘definite – culture
positive’ infection














10 A ‘definite – culture
positive’ infection
Enterobacter cloacae 1
11 A ‘definite – culture
positive’ infection










































12 A ‘definite – culture
positive’ infection
Staphylococcus aureus 1 Flucloxacillin,
vancomycin
2 Flucloxacillin, vancomycin
13 A ‘definite – culture
positive’ infection
Staphylococcus aureus 1 Vancomycin Flucloxacillin
14 A ‘definite – culture
positive’ infection
Staphylococcus aureus 1 Vancomycin
15 A ‘definite – culture
positive’ infection




16 A ‘probable – culture
uncertain’ infection
Enterococcus faecalis 1 Amoxicillin, teicoplanin,
vancomycin






18 A ‘definite – culture
positive’ infection
Staphylococcus aureus 1 Flucloxacillin
19 A ‘definite – culture
positive’ infection
Enterococcus faecalis 1 Ampicillin, gentamicin,
vancomycin












22 A ‘definite – culture
positive’ infection
Staphylococcus aureus 1 Flucloxacillin, rifampicin,
teicoplanin, vancomycin
23 A ‘definite – culture
positive’ infection

















































































































































































































































































































































TABLE 38 Line listings of infection type, organism cultured and level of sensitivities (continued )











24 A ‘definite – culture
positive’ infection
Propionibacterium acnes 1 Ciprofloxacin, penicillin,
vancomycin
25 A ‘definite – culture
positive’ infection
Citrobacter species 1 Flucloxacillin
Staphylococcus aureus 1 Flucloxacillin
2 Vancomycin
26 A ‘definite – culture
positive’ infection




27 A ‘definite – culture
positive’ infection













A, standard VPS; B, antibiotic-impregnated VPS; C, silver-impregnated VPS.































TABLE 39 Classifications of infection and no infection by assessor type
Reason for revision (central panel)
Reason for revision (treating surgeon), n (%)
Infection No infection
Infection 68 (17.1) 7 (1.8)
No infection 10 (2.5) 313 (78.6)
TABLE 40 Summary of revision rates by centre
Centre code Centre demographic Primary outcome set (N)
Revisions
n % (97.5% CI)
0393 Paediatric only 8 6 75.0 (40.7 to 100.0)
9999 Paediatric only 68 34 50.0 (36.4 to 63.6)
0243 Paediatric only 118 56 47.5 (37.2 to 57.8)
0248 Paediatric only 40 19 47.5 (29.8 to 65.2)
0246 Paediatric only 47 20 42.6 (26.4 to 58.7)
0006 Adults only 22 9 40.9 (17.4 to 64.4)
0361 Adults only 5 2 40.0 (0.0 to 89.1)
0249 Paediatric only 71 23 32.4 (20.0 to 44.8)
0400 Adults only 81 25 30.9 (19.4 to 42.4)
0133 Paediatric only 30 8 26.7 (8.6 to 44.8)
0578 Adults only 154 40 26.0 (18.1 to 33.9)
0352 Both adults and paediatrics 128 30 23.4 (15.1 to 31.8)
0030 Both adults and paediatrics 91 21 23.1 (13.2 to 33.3)
0114 Both adults and paediatrics 175 35 20.0 (13.2 to 26.8)
0161 Both adults and paediatrics 36 6 16.7 (2.8 to 30.6)
0213 Both adults and paediatrics 140 23 16.4 (9.4 to 23.4)
0004 Adults only 14 2 14.3 (0.0 to 35.2)
0007 Both adults and paediatrics 84 12 14.3 (5.7 to 22.8)
0672 Adults only 73 8 11.0 (2.8 to 19.1)
0185 Both adults and paediatrics 188 18 9.6 (4.8 to 14.4)
0232 Adults only 21 1 4.8 (0.0 to 15.2)
Note
Table sorted by revision rate (highest rate to lowest rate).
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TABLE 41 Summary of infection rates by centre
Centre code Centre demographic Primary outcome set (N)
Infection
n % (97.5% CI)
0393 Paediatric only 8 2 25.0 (0.0 to 59.3)
0361 Adults only 5 1 20.0 (0.0 to 60.1)
0243 Paediatric only 118 13 11.0 (4.6 to 17.5)
0248 Paediatric only 40 4 10.0 (0.0 to 20.6)
0006 Adults only 22 2 9.1 (0.0 to 22.8)
0249 Paediatric only 71 6 8.5 (1.1 to 15.8)
9999 Paediatric only 68 5 7.4 (0.3 to 14.4)
0161 Both adults and paediatrics 36 2 5.6 (0.0 to 14.1)
0578 Adults only 154 8 5.2 (1.2 to 9.2)
0400 Adults only 81 4 4.9 (0.0 to 10.3)
0030 Both adults and paediatrics 91 4 4.4 (0.0 to 9.2)
0246 Paediatric only 47 2 4.3 (0.0 to 10.9)
0672 Adults only 73 3 4.1 (0.0 to 9.3)
0007 Both adults and paediatrics 84 3 3.6 (0.0 to 8.1)
0213 Both adults and paediatrics 140 5 3.6 (0.1 to 7.1)
0133 Paediatric only 30 1 3.3 (0.0 to 10.7)
0352 Both adults and paediatrics 128 4 3.1 (0.0 to 6.6)
0114 Both adults and paediatrics 175 3 1.7 (0.0 to 3.9)
0185 Both adults and paediatrics 188 3 1.6 (0.0 to 3.6)
0004 Adults only 14 0 0.0 (0.0 to 0.0)
0232 Adults only 21 0 0.0 (0.0 to 0.0)
Note
Table sorted by infection rate (highest rate to lowest rate).
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TABLE 42 Summary of aetiologies, and type of aetiologies, of the hydrocephalus by VPS group
























Total number of patients 1594 1196 398 14 121 185 78 320
Congenital malformations
Patients with congenital malformations
Overall 294 (18.4) 181 (61.6) 113 (38.4) 2 (0.7) 36 (12.2) 48 (16.3) 27 (9.2) 86 (29.3)
Standard VPS 95 (17.8) 62 (65.3) 33 (34.7) 1 (1.1) 13 (13.7) 11 (11.6) 8 (8.4) 25 (26.3)
Antibiotic-impregnated VPS 93 (17.4) 57 (61.3) 36 (38.7) 0 (0.0) 13 (14.0) 17 (18.3) 6 (6.5) 30 (32.3)
Silver-impregnated VPS 106 (20.2) 62 (58.5) 44 (41.5) 1 (0.9) 10 (9.4) 20 (18.9) 13 (12.3) 31 (29.2)
Type(s) of congenital malformation
Aqueduct stenosis
Overall 68 (23.1) 46 (67.6) 22 (32.4) 0 (0.0) 8 (11.8) 7 (10.3) 7 (10.3) 15 (22.1)
Standard VPS 21 (22.1) 15 (71.4) 6 (28.6) 0 (0.0) 4 (19.0) 1 (4.8) 1 (4.8) 5 (23.8)
Antibiotic-impregnated VPS 15 (16.1) 9 (60.0) 6 (40.0) 0 (0.0) 2 (13.3) 3 (20.0) 1 (6.7) 5 (33.3)
Silver-impregnated VPS 32 (30.2) 22 (68.8) 10 (31.3) 0 (0.0) 2 (6.3) 3 (9.4) 5 (15.6) 5 (15.6)
Dandy–Walker
Overall 7 (2.4) 6 (85.7) 1 (14.3) 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0) 1 (14.3)
Standard VPS 2 (2.1) 1 (50.0) 1 (50.0) 0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0) 1 (50.0)
Antibiotic-impregnated VPS 3 (3.2) 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
















































































































































































































































































































































TABLE 42 Summary of aetiologies, and type of aetiologies, of the hydrocephalus by VPS group (continued )

























Overall 62 (21.1) 43 (69.4) 19 (30.6) 0 (0.0) 7 (11.3) 7 (11.3) 5 (8.1) 14 (22.6)
Standard VPS 23 (24.2) 17 (73.9) 6 (26.1) 0 (0.0) 4 (17.4) 0 (0.0) 2 (8.7) 4 (17.4)
Antibiotic-impregnated VPS 22 (23.7) 15 (68.2) 7 (31.8) 0 (0.0) 3 (13.6) 4 (18.2) 0 (0.0) 7 (31.8)
Silver-impregnated VPS 17 (16.0) 11 (64.7) 6 (35.3) 0 (0.0) 0 (0.0) 3 (17.6) 3 (17.6) 3 (17.6)
Spina bifida
Overall 111 (37.8) 62 (55.9) 49 (44.1) 1 (0.9) 11 (9.9) 25 (22.5) 12 (10.8) 37 (33.3)
Standard VPS 35 (36.8) 19 (54.3) 16 (45.7) 1 (2.9) 3 (8.6) 7 (20.0) 5 (14.3) 11 (31.4)
Antibiotic-impregnated VPS 34 (36.6) 22 (64.7) 12 (35.3) 0 (0.0) 4 (11.8) 7 (20.6) 1 (2.9) 11 (32.4)
Silver-impregnated VPS 42 (39.6) 21 (50.0) 21 (50.0) 0 (0.0) 4 (9.5) 11 (26.2) 6 (14.3) 15 (35.7)
Other
Overall 72 (24.5) 38 (52.8) 34 (47.2) 1 (1.4) 12 (16.7) 13 (18.1) 8 (11.1) 26 (36.1)
Standard VPS 27 (28.4) 18 (66.7) 9 (33.3) 0 (0.0) 4 (14.8) 4 (14.8) 1 (3.7) 8 (29.6)
Antibiotic-impregnated VPS 23 (24.7) 11 (47.8) 12 (52.2) 0 (0.0) 4 (17.4) 4 (17.4) 4 (17.4) 8 (34.8)
Silver-impregnated VPS 22 (20.8) 9 (40.9) 13 (59.1) 1 (4.5) 4 (18.2) 5 (22.7) 3 (13.6) 10 (45.5)
Not known
Overall 1 (0.3) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Standard VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Antibiotic-impregnated VPS 1 (1.1) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)























































Number of types per patient with congenital malformations
0
Overall 1 (0.3) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Standard VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Antibiotic-impregnated VPS 1 (1.1) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Silver-impregnated VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1
Overall 268 (91.2) 166 (61.9) 102 (38.1) 2 (0.7) 33 (12.3) 44 (16.4) 23 (8.6) 79 (29.5)
Standard VPS 83 (87.4) 55 (66.3) 28 (33.7) 1 (1.2) 10 (12.0) 10 (12.0) 7 (8.4) 21 (25.3)
Antibiotic-impregnated VPS 87 (93.5) 52 (59.8) 35 (40.2) 0 (0.0) 13 (14.9) 16 (18.4) 6 (6.9) 29 (33.3)
Silver-impregnated VPS 98 (92.5) 59 (60.2) 39 (39.8) 1 (1.0) 10 (10.2) 18 (18.4) 10 (10.2) 29 (29.6)
2
Overall 23 (7.8) 13 (56.5) 10 (43.5) 0 (0.0) 3 (13.0) 4 (17.4) 3 (13.0) 7 (30.4)
Standard VPS 11 (11.6) 6 (54.5) 5 (45.5) 0 (0.0) 3 (27.3) 1 (9.1) 1 (9.1) 4 (36.4)
Antibiotic-impregnated VPS 5 (5.4) 4 (80.0) 1 (20.0) 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0) 1 (20.0)
Silver-impregnated VPS 7 (6.6) 3 (42.9) 4 (57.1) 0 (0.0) 0 (0.0) 2 (28.6) 2 (28.6) 2 (28.6)
3
Overall 2 (0.7) 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0)
Standard VPS 1 (1.1) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Antibiotic-impregnated VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
















































































































































































































































































































































TABLE 42 Summary of aetiologies, and type of aetiologies, of the hydrocephalus by VPS group (continued )

























Patients with acquired hydrocephalus
Overall 819 (51.4) 615 (75.1) 204 (24.9) 9 (1.1) 54 (6.6) 102 (12.5) 39 (4.8) 165 (20.1)
Standard VPS 274 (51.4) 201 (73.4) 73 (26.6) 3 (1.1) 22 (8.0) 27 (9.9) 21 (7.7) 52 (19.0)
Antibiotic-impregnated VPS 266 (49.7) 207 (77.8) 59 (22.2) 2 (0.8) 15 (5.6) 37 (13.9) 5 (1.9) 54 (20.3)
Silver-impregnated VPS 279 (53.0) 207 (74.2) 72 (25.8) 4 (1.4) 17 (6.1) 38 (13.6) 13 (4.7) 59 (21.1)
Type(s) of acquired hydrocephalus
Cysts (colloid or arachoid)
Overall 32 (3.9) 24 (75.0) 8 (25.0) 0 (0.0) 4 (12.5) 3 (9.4) 1 (3.1) 7 (21.9)
Standard VPS 11 (4.0) 8 (72.7) 3 (27.3) 0 (0.0) 2 (18.2) 0 (0.0) 1 (9.1) 2 (18.2)
Antibiotic-impregnated VPS 13 (4.9) 10 (76.9) 3 (23.1) 0 (0.0) 2 (15.4) 1 (7.7) 0 (0.0) 3 (23.1)
Silver-impregnated VPS 8 (2.9) 6 (75.0) 2 (25.0) 0 (0.0) 0 (0.0) 2 (25.0) 0 (0.0) 2 (25.0)
Trauma
Overall 30 (3.7) 25 (83.3) 5 (16.7) 1 (3.3) 1 (3.3) 3 (10.0) 0 (0.0) 5 (16.7)
Standard VPS 12 (4.4) 10 (83.3) 2 (16.7) 1 (8.3) 1 (8.3) 0 (0.0) 0 (0.0) 2 (16.7)
Antibiotic-impregnated VPS 7 (2.6) 6 (85.7) 1 (14.3) 0 (0.0) 0 (0.0) 1 (14.3) 0 (0.0) 1 (14.3)
























































Overall 124 (15.1) 96 (77.4) 28 (22.6) 2 (1.6) 9 (7.3) 14 (11.3) 3 (2.4) 25 (20.2)
Standard VPS 40 (14.6) 33 (82.5) 7 (17.5) 0 (0.0) 3 (7.5) 4 (10.0) 0 (0.0) 7 (17.5)
Antibiotic-impregnated VPS 35 (13.2) 26 (74.3) 9 (25.7) 1 (2.9) 3 (8.6) 5 (14.3) 0 (0.0) 9 (25.7)
Silver-impregnated VPS 49 (17.6) 37 (75.5) 12 (24.5) 1 (2.0) 3 (6.1) 5 (10.2) 3 (6.1) 9 (18.4)
Tumour: malignant
Overall 133 (16.2) 105 (78.9) 28 (21.1) 2 (1.5) 6 (4.5) 14 (10.5) 6 (4.5) 22 (16.5)
Standard VPS 38 (13.9) 29 (76.3) 9 (23.7) 1 (2.6) 1 (2.6) 5 (13.2) 2 (5.3) 7 (18.4)
Antibiotic-impregnated VPS 54 (20.3) 45 (83.3) 9 (16.7) 1 (1.9) 2 (3.7) 4 (7.4) 2 (3.7) 7 (13.0)
Silver-impregnated VPS 41 (14.7) 31 (75.6) 10 (24.4) 0 (0.0) 3 (7.3) 5 (12.2) 2 (4.9) 8 (19.5)
Post haemorrhagic/intracranial haemorrhage
Overall 337 (41.1) 244 (72.4) 93 (27.6) 2 (0.6) 21 (6.2) 45 (13.4) 25 (7.4) 68 (20.2)
Standard VPS 118 (43.1) 81 (68.6) 37 (31.4) 0 (0.0) 9 (7.6) 12 (10.2) 16 (13.6) 21 (17.8)
Antibiotic-impregnated VPS 102 (38.3) 76 (74.5) 26 (25.5) 0 (0.0) 5 (4.9) 18 (17.6) 3 (2.9) 23 (22.5)
Silver-impregnated VPS 117 (41.9) 87 (74.4) 30 (25.6) 2 (1.7) 7 (6.0) 15 (12.8) 6 (5.1) 24 (20.5)
Infection: meningitis
Overall 32 (3.9) 23 (71.9) 9 (28.1) 0 (0.0) 2 (6.3) 5 (15.6) 2 (6.3) 7 (21.9)
Standard VPS 13 (4.7) 9 (69.2) 4 (30.8) 0 (0.0) 1 (7.7) 2 (15.4) 1 (7.7) 3 (23.1)
Antibiotic-impregnated VPS 9 (3.4) 7 (77.8) 2 (22.2) 0 (0.0) 1 (11.1) 1 (11.1) 0 (0.0) 2 (22.2)
















































































































































































































































































































































TABLE 42 Summary of aetiologies, and type of aetiologies, of the hydrocephalus by VPS group (continued )

























Overall 8 (1.0) 7 (87.5) 1 (12.5) 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0) 1 (12.5)
Standard VPS 6 (2.2) 5 (83.3) 1 (16.7) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 1 (16.7)
Antibiotic-impregnated VPS 1 (0.4) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Silver-impregnated VPS 1 (0.4) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Infection: other
Overall 21 (2.6) 17 (81.0) 4 (19.0) 0 (0.0) 0 (0.0) 4 (19.0) 0 (0.0) 4 (19.0)
Standard VPS 8 (2.9) 5 (62.5) 3 (37.5) 0 (0.0) 0 (0.0) 3 (37.5) 0 (0.0) 3 (37.5)
Antibiotic-impregnated VPS 6 (2.3) 5 (83.3) 1 (16.7) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 1 (16.7)
Silver-impregnated VPS 7 (2.5) 7 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other factors
Overall 140 (17.1) 99 (70.7) 41 (29.3) 3 (2.1) 16 (11.4) 17 (12.1) 5 (3.6) 36 (25.7)
Standard VPS 47 (17.2) 34 (72.3) 13 (27.7) 1 (2.1) 8 (17.0) 1 (2.1) 3 (6.4) 10 (21.3)
Antibiotic-impregnated VPS 49 (18.4) 37 (75.5) 12 (24.5) 1 (2.0) 3 (6.1) 8 (16.3) 0 (0.0) 12 (24.5)























































Number of types per patient with acquired hydrocephalus
0
Overall 1 (0.1) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Standard VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Antibiotic-impregnated VPS 1 (0.4) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Silver-impregnated VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1
Overall 782 (95.5) 590 (75.4) 192 (24.6) 8 (1.0) 50 (6.4) 98 (12.5) 36 (4.6) 156 (19.9)
Standard VPS 257 (93.8) 189 (73.5) 68 (26.5) 3 (1.2) 20 (7.8) 26 (10.1) 19 (7.4) 49 (19.1)
Antibiotic-impregnated VPS 254 (95.5) 199 (78.3) 55 (21.7) 1 (0.4) 14 (5.5) 35 (13.8) 5 (2.0) 50 (19.7)
Silver-impregnated VPS 271 (97.1) 202 (74.5) 69 (25.5) 4 (1.5) 16 (5.9) 37 (13.7) 12 (4.4) 57 (21.0)
2
Overall 33 (4.0) 22 (66.7) 11 (33.3) 1 (3.0) 3 (9.1) 4 (12.1) 3 (9.1) 8 (24.2)
Standard VPS 15 (5.5) 11 (73.3) 4 (26.7) 0 (0.0) 1 (6.7) 1 (6.7) 2 (13.3) 2 (13.3)
Antibiotic-impregnated VPS 11 (4.1) 7 (63.6) 4 (36.4) 1 (9.1) 1 (9.1) 2 (18.2) 0 (0.0) 4 (36.4)
Silver-impregnated VPS 7 (2.5) 4 (57.1) 3 (42.9) 0 (0.0) 1 (14.3) 1 (14.3) 1 (14.3) 2 (28.6)
3
Overall 3 (0.4) 2 (66.7) 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 1 (33.3)
Standard VPS 2 (0.7) 1 (50.0) 1 (50.0) 0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0) 1 (50.0)
Antibiotic-impregnated VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
















































































































































































































































































































































TABLE 42 Summary of aetiologies, and type of aetiologies, of the hydrocephalus by VPS group (continued )

























Patients with idiopathic condition
Overall 496 (31.1) 408 (82.3) 88 (17.7) 4 (0.8) 32 (6.5) 38 (7.7) 14 (2.8) 74 (14.9)
Standard VPS 169 (31.7) 145 (85.8) 24 (14.2) 3 (1.8) 5 (3.0) 11 (6.5) 5 (3.0) 19 (11.2)
Antibiotic-impregnated VPS 177 (33.1) 142 (80.2) 35 (19.8) 0 (0.0) 15 (8.5) 17 (9.6) 3 (1.7) 32 (18.1)
Silver-impregnated VPS 150 (28.5) 121 (80.7) 29 (19.3) 1 (0.7) 12 (8.0) 10 (6.7) 6 (4.0) 23 (15.3)
Type(s) of idiopathic condition
Idiopathic ‘normal pressure’ hydrocephalus of the elderly
Overall 361 (72.8) 325 (90.0) 36 (10.0) 1 (0.3) 15 (4.2) 16 (4.4) 4 (1.1) 32 (8.9)
Standard VPS 119 (70.4) 110 (92.4) 9 (7.6) 1 (0.8) 3 (2.5) 4 (3.4) 1 (0.8) 8 (6.7)
Antibiotic-impregnated VPS 135 (76.3) 118 (87.4) 17 (12.6) 0 (0.0) 8 (5.9) 8 (5.9) 1 (0.7) 16 (11.9)
Silver-impregnated VPS 107 (71.3) 97 (90.7) 10 (9.3) 0 (0.0) 4 (3.7) 4 (3.7) 2 (1.9) 8 (7.5)
IIH
Overall 98 (19.8) 63 (64.3) 35 (35.7) 2 (2.0) 10 (10.2) 16 (16.3) 7 (7.1) 28 (28.6)
Standard VPS 38 (22.5) 27 (71.1) 11 (28.9) 1 (2.6) 1 (2.6) 5 (13.2) 4 (10.5) 7 (18.4)
Antibiotic-impregnated VPS 32 (18.1) 19 (59.4) 13 (40.6) 0 (0.0) 5 (15.6) 7 (21.9) 1 (3.1) 12 (37.5)
Silver-impregnated VPS 28 (18.7) 17 (60.7) 11 (39.3) 1 (3.6) 4 (14.3) 4 (14.3) 2 (7.1) 9 (32.1)
Other
Overall 38 (7.7) 20 (52.6) 18 (47.4) 1 (2.6) 7 (18.4) 7 (18.4) 3 (7.9) 15 (39.5)
Standard VPS 13 (7.7) 8 (61.5) 5 (38.5) 1 (7.7) 1 (7.7) 3 (23.1) 0 (0.0) 5 (38.5)
Antibiotic-impregnated VPS 10 (5.6) 5 (50.0) 5 (50.0) 0 (0.0) 2 (20.0) 2 (20.0) 1 (10.0) 4 (40.0)























































Number of types per patient with idiopathic condition
0
Overall 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Standard VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Antibiotic-impregnated VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Silver-impregnated VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1
Overall 495 (99.8) 408 (82.4) 87 (17.6) 4 (0.8) 32 (6.5) 37 (7.5) 14 (2.8) 73 (14.7)
Standard VPS 168 (99.4) 145 (86.3) 23 (13.7) 3 (1.8) 5 (3.0) 10 (6.0) 5 (3.0) 18 (10.7)
Antibiotic-impregnated VPS 177 (100.0) 142 (80.2) 35 (19.8) 0 (0.0) 15 (8.5) 17 (9.6) 3 (1.7) 32 (18.1)
Silver-impregnated VPS 150 (100.0) 121 (80.7) 29 (19.3) 1 (0.7) 12 (8.0) 10 (6.7) 6 (4.0) 23 (15.3)
2
Overall 1 (0.2) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
Standard VPS 1 (0.6) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
Antibiotic-impregnated VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Silver-impregnated VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
a Clean insertion = no revision + revision.
b Revision = failure due to patient + functional shunt failure +mechanical shunt failure+ failure due to infection.








































































































































































































































































































































































Total number of patients 1594 1196 398 14 121 185 78 320
Use of guidance system
Patients for whom guidance system used for ventricular shunt catheter placement
Overall 653 (41.0) 489 (74.9) 164 (25.1) 7 (1.1) 45 (6.9) 78 (11.9) 34 (5.2) 130 (19.9)
Standard VPS 225 (42.2) 174 (77.3) 51 (22.7) 2 (0.9) 9 (4.0) 24 (10.7) 16 (7.1) 35 (15.6)
Antibiotic-impregnated VPS 218 (40.7) 164 (75.2) 54 (24.8) 3 (1.4) 17 (7.8) 29 (13.3) 5 (2.3) 49 (22.5)
Silver-impregnated VPS 210 (39.9) 151 (71.9) 59 (28.1) 2 (1.0) 19 (9.0) 25 (11.9) 13 (6.2) 46 (21.9)
Type of guidance system
Electromagnetic
Overall 413 (63.2) 309 (74.8) 104 (25.2) 4 (1.0) 26 (6.3) 50 (12.1) 24 (5.8) 80 (19.4)
Standard VPS 147 (65.3) 120 (81.6) 27 (18.4) 1 (0.7) 5 (3.4) 12 (8.2) 9 (6.1) 18 (12.2)
Antibiotic-impregnated VPS 138 (63.3) 99 (71.7) 39 (28.3) 1 (0.7) 12 (8.7) 22 (15.9) 4 (2.9) 35 (25.4)
Silver-impregnated VPS 128 (61.0) 90 (70.3) 38 (29.7) 2 (1.6) 9 (7.0) 16 (12.5) 11 (8.6) 27 (21.1)
Ultrasonography
Overall 128 (19.6) 88 (68.8) 40 (31.3) 3 (2.3) 16 (12.5) 14 (10.9) 7 (5.5) 33 (25.8)
Standard VPS 38 (16.9) 22 (57.9) 16 (42.1) 1 (2.6) 4 (10.5) 5 (13.2) 6 (15.8) 10 (26.3)
Antibiotic-impregnated VPS 40 (18.3) 33 (82.5) 7 (17.5) 2 (5.0) 2 (5.0) 3 (7.5) 0 (0.0) 7 (17.5)
Silver-impregnated VPS 50 (23.8) 33 (66.0) 17 (34.0) 0 (0.0) 10 (20.0) 6 (12.0) 1 (2.0) 16 (32.0)
Optical
Overall 46 (7.0) 37 (80.4) 9 (19.6) 0 (0.0) 2 (4.3) 6 (13.0) 1 (2.2) 8 (17.4)
Standard VPS 16 (7.1) 13 (81.3) 3 (18.8) 0 (0.0) 0 (0.0) 2 (12.5) 1 (6.3) 2 (12.5)
Antibiotic-impregnated VPS 19 (8.7) 15 (78.9) 4 (21.1) 0 (0.0) 2 (10.5) 2 (10.5) 0 (0.0) 4 (21.1)
























































Overall 63 (9.6) 52 (82.5) 11 (17.5) 0 (0.0) 1 (1.6) 8 (12.7) 2 (3.2) 9 (14.3)
Standard VPS 22 (9.8) 17 (77.3) 5 (22.7) 0 (0.0) 0 (0.0) 5 (22.7) 0 (0.0) 5 (22.7)
Antibiotic-impregnated VPS 20 (9.2) 16 (80.0) 4 (20.0) 0 (0.0) 1 (5.0) 2 (10.0) 1 (5.0) 3 (15.0)
Silver-impregnated VPS 21 (10.0) 19 (90.5) 2 (9.5) 0 (0.0) 0 (0.0) 1 (4.8) 1 (4.8) 1 (4.8)
Not known
Overall 3 (0.5) 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Standard VPS 2 (0.9) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Antibiotic-impregnated VPS 1 (0.5) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Silver-impregnated VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Placement of proximal shunt catheter
Frontal
Overall 134 (8.4) 93 (69.4) 41 (30.6) 0 (0.0) 13 (9.7) 15 (11.2) 13 (9.7) 28 (20.9)
Standard VPS 49 (9.2) 33 (67.3) 16 (32.7) 0 (0.0) 5 (10.2) 4 (8.2) 7 (14.3) 9 (18.4)
Antibiotic-impregnated VPS 48 (9.0) 35 (72.9) 13 (27.1) 0 (0.0) 4 (8.3) 7 (14.6) 2 (4.2) 11 (22.9)
Silver-impregnated VPS 37 (7.0) 25 (67.6) 12 (32.4) 0 (0.0) 4 (10.8) 4 (10.8) 4 (10.8) 8 (21.6)
Parietal, occipital or parietal/occipital
Overall 1453 (91.2) 1100 (75.7) 353 (24.3) 14 (1.0) 107 (7.4) 167 (11.5) 65 (4.5) 288 (19.8)
Standard VPS 481 (90.2) 369 (76.7) 112 (23.3) 5 (1.0) 35 (7.3) 46 (9.6) 26 (5.4) 86 (17.9)
Antibiotic-impregnated VPS 486 (90.8) 368 (75.7) 118 (24.3) 4 (0.8) 39 (8.0) 62 (12.8) 13 (2.7) 105 (21.6)










































































































































































































































































































































































Overall 3 (0.2) 2 (66.7) 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 1 (33.3)
Standard VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Antibiotic-impregnated VPS 1 (0.2) 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
Silver-impregnated VPS 2 (0.4) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Not known
Overall 4 (0.3) 1 (25.0) 3 (75.0) 0 (0.0) 0 (0.0) 3 (75.0) 0 (0.0) 3 (75.0)
Standard VPS 3 (0.6) 1 (33.3) 2 (66.7) 0 (0.0) 0 (0.0) 2 (66.7) 0 (0.0) 2 (66.7)
Antibiotic-impregnated VPS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Silver-impregnated VPS 1 (0.2) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
Type of valve
Fixed
Overall 935 (58.7) 652 (69.7) 283 (30.3) 10 (1.1) 91 (9.7) 126 (13.5) 56 (6.0) 227 (24.3)
Standard VPS 320 (60.0) 228 (71.3) 92 (28.8) 3 (0.9) 28 (8.8) 37 (11.6) 24 (7.5) 68 (21.3)
Antibiotic-impregnated VPS 304 (56.8) 212 (69.7) 92 (30.3) 3 (1.0) 32 (10.5) 47 (15.5) 10 (3.3) 82 (27.0)
Silver-impregnated VPS 311 (59.1) 212 (68.2) 99 (31.8) 4 (1.3) 31 (10.0) 42 (13.5) 22 (7.1) 77 (24.8)
Programmable
Overall 627 (39.3) 525 (83.7) 102 (16.3) 4 (0.6) 26 (4.1) 52 (8.3) 20 (3.2) 82 (13.1)
Standard VPS 202 (37.9) 172 (85.1) 30 (14.9) 2 (1.0) 8 (4.0) 13 (6.4) 7 (3.5) 23 (11.4)
Antibiotic-impregnated VPS 219 (40.9) 182 (83.1) 37 (16.9) 1 (0.5) 12 (5.5) 19 (8.7) 5 (2.3) 32 (14.6)

























































Overall 32 (2.0) 19 (59.4) 13 (40.6) 0 (0.0) 4 (12.5) 7 (21.9) 2 (6.3) 11 (34.4)
Standard VPS 11 (2.1) 3 (27.3) 8 (72.7) 0 (0.0) 4 (36.4) 2 (18.2) 2 (18.2) 6 (54.5)
Antibiotic-impregnated VPS 12 (2.2) 9 (75.0) 3 (25.0) 0 (0.0) 0 (0.0) 3 (25.0) 0 (0.0) 3 (25.0)
Silver-impregnated VPS 9 (1.7) 7 (77.8) 2 (22.2) 0 (0.0) 0 (0.0) 2 (22.2) 0 (0.0) 2 (22.2)
a Clean insertion = no revision + revision.
b Revision = failure due to patient + functional shunt failure +mechanical shunt failure+ failure due to infection.
















































































































































































































































































































































TABLE 44 Summary of components replaced at revision by VPS group














Total number of patients 320 14 121 185
Was a complete new shunt inserted?
No
Overall 268 (83.8) 12 (4.5) 99 (36.9) 157 (58.6)
Standard VPS 84 (86.6) 5 (6.0) 35 (41.7) 44 (52.4)
Antibiotic-impregnated VPS 97 (82.9) 3 (3.1) 33 (34.0) 61 (62.9)
Silver-impregnated VPS 87 (82.1) 4 (4.6) 31 (35.6) 52 (59.8)
If no, which component was replaced?
Ventricular shunt catheter only
Overall 72 (26.9) 0 (0.0) 22 (30.6) 50 (69.4)
Standard VPS 21 (25.0) 0 (0.0) 7 (33.3) 14 (66.7)
Antibiotic-impregnated VPS 27 (27.8) 0 (0.0) 11 (40.7) 16 (59.3)
Silver-impregnated VPS 24 (27.6) 0 (0.0) 4 (16.7) 20 (83.3)
Peritoneal shunt catheter only
Overall 31 (11.6) 3 (9.7) 5 (16.1) 23 (74.2)
Standard VPS 12 (14.3) 1 (8.3) 4 (33.3) 7 (58.3)
Antibiotic-impregnated VPS 12 (12.4) 0 (0.0) 1 (8.3) 11 (91.7)
Silver-impregnated VPS 7 (8.0) 2 (28.6) 0 (0.0) 5 (71.4)
Valve only
Overall 76 (28.4) 3 (3.9) 35 (46.1) 38 (50.0)
Standard VPS 20 (23.8) 0 (0.0) 10 (50.0) 10 (50.0)
Antibiotic-impregnated VPS 33 (34.0) 2 (6.1) 13 (39.4) 18 (54.5)
Silver-impregnated VPS 23 (26.4) 1 (4.3) 12 (52.2) 10 (43.5)
Combination
Overall 38 (14.2) 1 (2.6) 19 (50.0) 18 (47.4)
Standard VPS 15 (17.9) 1 (6.7) 8 (53.3) 6 (40.0)
Antibiotic-impregnated VPS 11 (11.3) 0 (0.0) 5 (45.5) 6 (54.5)
Silver-impregnated VPS 12 (13.8) 0 (0.0) 6 (50.0) 6 (50.0)
Not known
Overall 51 (19.0) 5 (9.8) 18 (35.3) 28 (54.9)
Standard VPS 16 (19.0) 3 (18.8) 6 (37.5) 7 (43.8)
Antibiotic-impregnated VPS 14 (14.4) 1 (7.1) 3 (21.4) 10 (71.4)
Silver-impregnated VPS 21 (24.1) 1 (4.8) 9 (42.9) 11 (52.4)
a Failure – no infection = failure due to patient + functional shunt failure +mechanical shunt failure.
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TABLE 45 Summary of AEs related to the VPS
Summary of AEs
VPS








an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%)
Total 201 135 (25.4) 210 136 (25.0) 191 134 (36.4) 52 35 (25.7) 654 413 (25.8)
Expected AEs related to the VPS
Ventricular shunt catheter
obstruction
21 20 (3.8) 39 31 (5.7) 29 26 (5.0) 7 7 (5.1) 96 79 (4.9)
Shunt infectionb 40 39 (7.3) 17 16 (2.9) 24 24 (4.6) 9 9 (6.6) 90 88 (5.5)
Shunt valve obstructionc 15 12 (2.3) 25 22 (4.0) 18 17 (3.2) 7 7 (5.1) 65 52 (3.2)
Valve change for symptomatic
over/underdrainage
13 12 (2.3) 19 19 (3.5) 16 15 (2.9) 6 5 (3.7) 54 50 (3.1)
CSF leak 16 16 (3.0) 17 14 (2.6) 16 12 (2.3) 4 3 (2.2) 53 45 (2.8)
Wound infectionb,c 13 10 (1.9) 11 11 (2.0) 16 14 (2.7) 3 2 (1.5) 43 37 (2.3)
Distal shunt catheter obstruction 16 15 (2.8) 10 9 (1.7) 12 10 (1.9) 3 3 (2.2) 41 36 (2.2)
Seizures (early, post operatively,
delayed)
13 12 (2.3) 7 7 (1.3) 9 9 (1.7) 1 1 (0.7) 30 29 (1.8)
Migration of shunt 10 7 (1.3) 6 5 (0.9) 7 6 (1.1) 1 1 (0.7) 24 18 (1.1)
Subdural haematoma from
excessive CSF drainage
4 4 (0.8) 10 10 (1.8) 6 6 (1.1) 0 0 (0.0) 20 20 (1.2)
Misplacement of distal shunt
catheter
4 3 (0.6) 7 6 (1.1) 5 5 (1.0) 0 0 (0.0) 16 14 (0.9)
Misplacement of ventricular shunt
catheter
3 3 (0.6) 5 5 (0.9) 4 4 (0.8) 1 1 (0.7) 13 13 (0.8)
Disconnection of shunt 1 1 (0.2) 3 3 (0.6) 3 3 (0.6) 2 2 (1.5) 9 9 (0.6)

















































































































































































































































































































































TABLE 45 Summary of AEs related to the VPS (continued )
Summary of AEs
VPS








an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%)
Independent abdominal infections 5 4 (0.8) 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 6 5 (0.3)
Intracranial haemorrhage 1 1 (0.2) 4 3 (0.6) 1 1 (0.2) 0 0 (0.0) 6 5 (0.3)
Brain injury related to procedure
with new neurologic deficit
0 0 (0.0) 0 0 (0.0) 5 4 (0.8) 0 0 (0.0) 5 4 (0.2)
Fracture of shunt 2 2 (0.4) 1 1 (0.2) 2 2 (0.4) 0 0 (0.0) 5 5 (0.3)
Bowel perforation as a result of
shunt surgery
0 0 (0.0) 2 2 (0.4) 2 2 (0.4) 0 0 (0.0) 4 4 (0.2)
Extra-axial fluid collections 3 3 (0.6) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 3 3 (0.2)
Tunnelling injury (organ, viscus,
lung, vascular)
1 1 (0.2) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 2 2 (0.1)
Abdominal hernia 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Loculation of ventricles 0 0 (0.0) 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 1 1 (0.1)
Malabsorption 0 0 (0.0) 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 1 1 (0.1)
Pseudocysts 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Sunken fontanelle 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Vascular injury to brain
pseudoaneurysm
0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Unexpected AEs related to the VPS
Vomiting 4 3 (0.6) 1 1 (0.2) 1 1 (0.2) 2 2 (1.5) 8 6 (0.4)
Headaches 1 1 (0.2) 3 3 (0.6) 0 0 (0.0) 1 1 (0.7) 5 4 (0.2)
Abdominal pain 0 0 (0.0) 2 2 (0.4) 2 2 (0.4) 0 0 (0.0) 4 4 (0.2)










































an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%)
Lethargy 1 1 (0.2) 0 0 (0.0) 1 1 (0.2) 1 1 (0.7) 3 3 (0.2)
Swelling at shunt site 0 0 (0.0) 2 1 (0.2) 1 1 (0.2) 0 0 (0.0) 3 2 (0.1)
Functional valve problems 1 1 (0.2) 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 2 2 (0.1)
Irritability 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.7) 2 2 (0.1)
Blank spells 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Blurred vision 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Difficult to cannulate, catheter too
short
0 0 (0.0) 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 1 1 (0.1)
Distal shunt catheter extra
peritoneal
1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Externalisation of VPS 0 0 (0.0) 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 1 1 (0.1)
Fluid leaking from ears 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Foreign body removed from shunt
surgery site
1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Intracranial pressure bolt insertion 0 0 (0.0) 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 1 1 (0.1)
Intra-abdonimal collection 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Itching at shunt site 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Losing balance 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Memory loss 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Nausea and vomiting 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)

















































































































































































































































































































































TABLE 45 Summary of AEs related to the VPS (continued )
Summary of AEs
VPS








an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%) Events (n)
Patients
experiencing
an AE, n (%)
Numbness 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Pneumocephalus 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Poor feeding 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.7) 1 1 (0.1)
Pseudomeningocoele 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Pyrexia 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.7) 1 1 (0.1)
Seizure 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Shutting-down episodes 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Skull fracture associated with VPS
migration
0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Tremor in hand 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.7) 1 1 (0.1)
Ventriculer shunt catheter coiled
and kinked
1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
Vision bubbles 0 0 (0.0) 1 1 (0.2) 0 0 (0.0) 0 0 (0.0) 1 1 (0.1)
a Table ordered by total number of events column (most common to least common) within expected and unexpected events.
b Shunt and wound infections include all revisions; infections as an outcome in the efficacy analyses are a subset of these.
c Wound infections as AEs include VPS superficial incisional infections (without CSF or tubing involvement) and VPS deep incisional infection; only VPS deep incisional infections are
































Appendix 3 Health economics study:
additional data
Parts of this chapter have been reproduced from Mallucci et al.2 This is an Open Access articledistributed under the terms of the Creative Commons Attribution License (https://creativecommons.
org/licenses/by-nd/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. The text below includes minor additions and formatting
changes to the original text.
TABLE 46 Unit costs of elective and day-case inpatient hospital attendances for the most frequent HRG codes
(top 15 out of 281)
HRG code HRG name Attendance Unit cost (£) Source
AA13A Intermediate intracranial procedures except
trauma with cerebral degenerations or
miscellaneous disorders of nervous system,
with CCs
Elective/day case 4888.00 NHS National Tariff
Payment System45
PA42Z Brain tumours with length of stay of ≥ 1 day Elective/day case 3052.00 NHS National Tariff
Payment System45
AA19A Minor intracranial procedures except trauma
with cerebral degenerations or miscellaneous
disorders of nervous system, with CCs
Elective/day case 2041.00 NHS National Tariff
Payment System45
AA52G Very major intracranial procedures, aged
≤ 18 years an, with a CC score of 0–3
Elective/day case 6210.00 NHS Reference Costs
2015 to 201644
PA44Z Neoplasm diagnoses with length of stay of
0 days
Elective/day case 533.00 NHS National Tariff
Payment System45
AA25A Cerebral Degenerations or miscellaneous
disorders of nervous system, with CCs
Elective/day case 1269.00 NHS National Tariff
Payment System45
AA52C Very major intracranial procedures, aged
≤ 18 years, with a CC score of 0–3
Elective/day case 6210.00 NHS Reference Costs
2015 to 201644
PM44Z Paediatric neoplasm diagnoses with length of
stay of 0 days
Elective/day case 1373.00 NHS Reference Costs
2015 to 201644
AA13B Intermediate intracranial procedures except
trauma with cerebral degenerations or
miscellaneous disorders of nervous system
without CCs
Elective/day case 4409.00 NHS National Tariff
Payment System45
PA01A Nervous system disorders with CCs Elective/day case 1056.00 NHS National Tariff
Payment System45
AA21A Minor intracranial procedures except trauma
with other diagnoses with CCs
Elective/day case 1489.00 NHS National Tariff
Payment System45
AA52D Very major intracranial procedures, aged
≥ 19 years, with a CC score of 0–3
Elective/day case 7907.00 NHS Reference Costs
2015 to 201644
PR01C Paediatric nervous system disorders with a
CC score of 2–4
Elective/day case 2417.00 NHS Reference Costs
2015 to 201644
PA28A Feeding difficulties and vomiting, without
CCs
Elective/day case 2190.00 NHS National Tariff
Payment System45
AA54A Intermediate intracranial procedures, aged
≥ 19 years, with a CC score of ≥ 4
Elective/day case 5787.00 NHS Reference Costs
2015 to 201644
CC, complication or comorbidity.
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TABLE 47 Unit costs of hospital outpatient attendances, ordered by the most frequent HRG codes (top 15 out of 122




code HRG name Unit cost (£) Source
WF01A 150 Neurosurgery 188.00 NHS Reference Costs 2015 to 201644
WF01A 218 Paediatric neurosurgery 179.00 NHS Reference Costs 2015 to 201644
WF01A 300 General medicine 164.00 NHS Reference Costs 2015 to 201644
WF01A 400 Neurology 161.00 NHS Reference Costs 2015 to 201644
WF01A 216 Paediatric ophthalmology 115.00 NHS Reference Costs 2015 to 201644
WF01A 420 Paediatrics 180.00 NHS Reference Costs 2015 to 201644
WF01A 252 Paediatric endocrinology 229.00 NHS Reference Costs 2015 to 201644
WF01A 260 Paediatric medical oncology 243.00 NHS Reference Costs 2015 to 201644
WF01A 218 Paediatric neurosurgery 179.00 NHS Reference Costs 2015 to 201644
WF01A 251 Paediatric gastroenterology 195.00 NHS Reference Costs 2015 to 201644
WF01A 100 General surgery 123.00 NHS Reference Costs 2015 to 201644
WF01A 258 Paediatric respiratory medicine 204.00 NHS Reference Costs 2015 to 201644
WF01A 290 Community paediatrics 265.00 NHS Reference Costs 2015 to 201644
WF01B 150 Neurosurgery 236.00 NHS Reference Costs 2015 to 201644
WF01B 400 Neurology 217.00 NHS Reference Costs 2015 to 201644
WF01B 290 Community paediatrics 376.00 NHS Reference Costs 2015 to 201644
WF01B 216 Paediatric ophthalmology 119.00 NHS Reference Costs 2015 to 201644
WF01B 320 Cardiology 156.00 NHS Reference Costs 2015 to 201644
WF01B 252 Paediatric endocrinology 330.00 NHS Reference Costs 2015 to 201644
WF01B 218 Paediatric neurosurgery 255.00 NHS Reference Costs 2015 to 201644
WF01B 303 Clinical haematology 223.00 NHS Reference Costs 2015 to 201644
WF01B 214 Paediatric trauma and orthopaedics 136.00 NHS Reference Costs 2015 to 201644
WF01B 314 Rehabilitation service 248.00 NHS Reference Costs 2015 to 201644
WF01B 130 Ophthalmology 110.00 NHS Reference Costs 2015 to 201644
WF01B 171 Paediatric surgery 185.00 NHS Reference Costs 2015 to 201644
WF01B 180 A&E 157.00 NHS Reference Costs 2015 to 201644
WF01B 713 Psychotherapy 158.00 NHS Reference Costs 2015 to 201644
WF01B 191 Pain management 177.00 NHS Reference Costs 2015 to 201644
WF02A 216 Paediatric ophthalmology 102.00 NHS Reference Costs 2015 to 201644
WF02A 214 Paediatric trauma and orthopaedics 142.00 NHS Reference Costs 2015 to 201644
WF02A 260 Paediatric medical oncology 258.00 NHS Reference Costs 2015 to 201644
WF02A 421 Paediatric neurology 375.00 NHS Reference Costs 2015 to 201644
WF02A 218 Paediatric neurosurgery 170.00 NHS Reference Costs 2015 to 201644
WF02A 258 Paediatric respiratory medicine 176.00 NHS Reference Costs 2015 to 201644
WF02A 251 Paediatric gastroenterology 251.00 NHS Reference Costs 2015 to 201644
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TABLE 47 Unit costs of hospital outpatient attendances, ordered by the most frequent HRG codes (top 15 out of 122




code HRG name Unit cost (£) Source
WF02A 256 Paediatric infectious diseases 269.00 NHS Reference Costs 2015 to 201644
WF02A 252 Paediatric endocrinology 230.00 NHS Reference Costs 2015 to 201644
WF02A 253 Paediatric clinical haematology 328.00 NHS Reference Costs 2015 to 201644
WF02A 219 Paediatric plastic surgery 145.00 NHS Reference Costs 2015 to 201644
TABLE 48 Unit costs of consultations with health-care professionals
Consultation Unit cost (£) Source
GP surgery visit (per 9.22-minute consultation) 38.00 PSSRU 201742
Nurse at surgery (per 9-minute consultation) 5.40 PSSRU 201742
Telephone triage: GP led (per call) 14.75 PSSRU 201742
Telephone triage: nurse led (per call) 7.90 PSSRU 201742
Prescription 29.20 PSSRU 201742
Paediatric consult (per consultation) 196.00 PSSRU 201742
Physiotherapy (per consultation) 86.00 PSSRU 201742
Continence nurse (per consultation) 80.00 NHS Reference Costs 2015 to 201644
Specialist nurse, adult, face to face (per consultation) 77.00 NHS Reference Costs 2015 to 201644
District nurse 38.00 NHS Reference Costs 2015 to 201644
Doctor: home visit (per visit) 87.46 PSSRU 201742
Consultant psychiatrist (per consultation) 108.00 PSSRU 201742
Health visitor (per consultation) 53.00 NHS Reference Costs 2015 to 201644
School nurse (per consultation) 54.00 NHS Reference Costs 2015 to 201644
Occupational therapist (per consultation) 79.00 NHS Reference Costs 2015 to 201644
Speech therapist, adult (per consultation) 88.00 NHS Reference Costs 2015 to 201644
Dietitian (per consultation) 81.00 NHS Reference Costs 2015 to 201644
Speech therapist, child (per consultation) 94.00 NHS Reference Costs 2015 to 201644
Clinical psychologist (per consultation) 144.70 NHS Reference Costs 2015 to 201644
Care work and social care (per intervention) 54.00 PSSRU 201742
Social worker (per intervention) 54.00 PSSRU 201742
Community nurse (per consultation) 89.00 NHS Reference Costs 2015 to 201644
Shunt nurse specialist (per consultation) 77.00 NHS Reference Costs 2015 to 201644
PSSRU, Personal Social Services Research Unit.
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TABLE 49 Adjusted total (24-month, discounted) costs: results of the ordinary least squares regression based on imputed
data
Variable Coefficient (£) p-value 97.5% CI (£)
Intercept 28,796.83 0.000 10,845.34 to 46,748.32
Antibiotic-impregnated VPS –4514.67 0.030 –9169.53 to 140.19
Silver-impregnated VPS –1322.34 0.557 –6456.95 to 3812.27
Treatment failure 8603.91 0.000 4696.00 to 12,511.82
Age: 16–65 years –3670.40 0.113 –8886.24 to 1545.44
Age: > 65 years –2872.09 0.227 –8233.51 to 2489.33
Time in trial (days) –7.09 0.129 –17.61 to 3.43
Centre
A 33.59 0.997 –23,137.15 to 23,204.33
B –901.01 0.906 –18,118.44 to 16,316.41
C 732.23 0.922 –16,116.42 to 17,580.88
D –8262.26 0.289 –25,868.11 to 9343.59
E –1615.54 0.856 –21,698.98 to 18,467.90
F –8657.07 0.282 –26,785.97 to 9471.82
G –11,152.65 0.147 –28,493.21 to 6187.91
H –5695.04 0.477 –23,805.53 to 12,415.46
I 638.42 0.943 –19,533.70 to 20,810.55
J –1701.73 0.825 –19,070.15 to 15,666.69
K –4921.65 0.543 –23,203.33 to 13,360.04
L –4898.48 0.561 –23,919.14 to 14,122.18
M –6878.41 0.374 –24,346.42 to 10,589.60
N –7992.50 0.295 –25,226.53 to 9241.53
O 1158.21 0.940 –33,654.62 to 35,971.04
P –2290.29 0.846 –28,875.46 to 24,294.88
Q –5408.04 0.485 –22,913.22 to 12,097.13
R –7347.52 0.336 –24,590.30 to 9895.26
S –1171.56 0.878 –18,447.40 to 16,104.27
T –5911.51 0.460 –23,978.95 to 12,155.93
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TABLE 50 Responses to the EQ-VAS questionnaire, by version and intervention group
EQ-VAS
Trial group
Standard VPS Antibiotic-impregnated VPS Silver-impregnated VPS
n Mean (97.5% CI) n Mean (97.5% CI) n Mean (97.5% CI)
Youth version (8–18 years)
Baseline 8 43.25 (13.73 to 72.75) 10 58.00 (40.18 to 75.81) 4 72.75 (46.59 to 98.90)
Early post operatively 12 65.33 (50.33 to 80.32) 10 68.90 (49.42 to 88.37) 8 65.75 (45.56 to 85.93)
12 weeks 9 80.77 (64.42 to 97.13) 8 79.25 (63.31 to 95.18) 8 81.37 (66.28 to 96.46)
End of trial 7 70.14 (45.79 to 94.48) 6 80.00 (55.49 to 104.50) 6 84.00 (50.87 to 117.12)
Adult version
Baseline 182 54.12 (50.70 to 57.54) 171 56.79 (53.34 to 60.24) 162 55.79 (51.94 to 59.64)
Early post operatively 173 61.15 (57.99 to 64.30) 168 61.49 (58.33 to 64.65) 157 60.29 (56.50 to 64.08)
12 weeks 145 67.34 (63.68 to 71.00) 137 67.09 (63.27 to 70.91) 133 69.20 (64.94 to 73.45)
End of trial 155 68.15 (64.71 to 71.59) 159 67.53 (63.84 to 71.22) 155 71.71 (68.20 to 75.23)
Proxy version
Baseline 57 36.75 (29.46 to 44.04) 63 38.55 (31.56 to 45.54) 55 43.43 (36.25 to 50.61)
Early post operatively 62 46.38 (39.35 to 53.41) 61 50.22 (43.32 to 57.13) 59 54.15 (47.53 to 60.76)
12 weeks 42 61.45 (52.86 to 70.03) 39 63.00 (54.47 to 71.52) 38 65.10 (56.11 to 74.09)
End of trial 34 64.61 (57.12 to 72.10) 22 57.27 (43.28 to 71.25) 39 58.87 (50.16 to 67.18)
Combined
Baseline 247 50.32 (47.11 to 53.53) 246 52.92 (49.76 to 56.08) 224 52.98 (49.66 to 56.30)
Early post operatively 246 57.22 (54.23 to 60.20) 240 58.90 (55.95 to 61.84) 225 58.00 (54.75 to 61.24)
12 weeks 194 65.94 (62.58 to 69.30) 187 65.95 (62.59 to 69.31) 183 67.86 (64.14 to 71.58)
End of trial 196 67.00 (63.85 to 70.14) 187 66.43 (62.94 to 69.93) 200 68.90 (65.53 to 72.27)
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TABLE 51 Summary of HOQ return by time point
Questionnaire
Trial group





























































HOQ patient 25 7 (28.0) 14 (56.0) 8 (32.0) 5 (20.0) 27 7 (25.9) 7 (25.9) 4 (14.8) 5 (18.5) 18 5 (27.8) 8 (44.4) 8 (44.4) 7 (38.9) 70 19 (27.1) 29 (41.4) 20 (28.6) 17 (24.3)
HOQ parent 11 4 (36.4) 5 (45.5) 6 (54.5) 2 (18.2) 12 8 (66.7) 8 (66.7) 7 (58.3) 2 (16.7) 11 6 (54.5) 8 (72.7) 6 (54.5) 3 (27.3) 34 18 (52.9) 21 (61.8) 19 (55.9) 7 (20.6)
TABLE 52 The HOQ – patient questionnaire
Scale
Trial group
TotalStandard VPS Antibiotic-impregnated VPS Silver-impregnated VPS
Baseline
Early post
operatively 12 weeks End of trial Baseline
Early post
operatively 12 weeks End of trial Baseline
Early post
operatively 12 weeks End of trial Baseline
Early post




7 (100.0) 14 (100.0) 8 (100.0) 5 (100.0) 7 (100.0) 7 (100.0) 4 (100.0) 5 (100.0) 5 (100.0) 8 (100.0) 8 (100.0) 7 (100.0) 19 (100.0) 29 (100.0) 20 (100.0) 17 (100.0)




6 (85.7) 14 (100.0) 8 (100.0) 5 (100.0) 7 (100.0) 6 (85.7) 3 (75.0) 5 (100.0) 5 (100.0) 8 (100.0) 8 (100.0) 7 (100.0) 18 (94.7) 28 (96.6) 19 (95.0) 17 (100.0)




5 (71.4) 14 (100.0) 8 (100.0) 5 (100.0) 7 (100.0) 6 (85.7) 3 (75.0) 5 (100.0) 5 (100.0) 8 (100.0) 8 (100.0) 6 (85.7) 17 (89.5) 28 (96.6) 19 (95.0) 16 (94.1)




6 (85.7) 14 (100.0) 8 (100.0) 5 (100.0) 7 (100.0) 6 (85.7) 4 (100.0) 5 (100.0) 5 (100.0) 8 (100.0) 8 (100.0) 7 (100.0) 18 (94.7) 28 (96.6) 20 (100.0) 17 (100.0)

































TABLE 53 The HOQ – parent questionnaire
Scale
Trial group
TotalStandard VPS Antibiotic-impregnated VPS Silver-impregnated VPS
Baseline
Early post
operatively 12 weeks End of trial Baseline
Early post
operatively 12 weeks End of trial Baseline
Early post
operatively 12 weeks End of trial Baseline
Early post




4 (100.0) 5 (100.0) 6 (100.0) 2 (100.0) 8 (100.0) 8 (100.0) 7 (100.0) 2 (100.0) 6 (100.0) 8 (100.0) 6 (100.0) 3 (100.0) 18 (100.0) 21 (100.0) 19 (100.0) 7 (100.0)




2 (50.0) 3 (60.0) 6 (100.0) 2 (100.0) 7 (87.5) 7 (87.5) 6 (85.7) 2 (100.0) 6 (100.0) 8 (100.0) 6 (100.0) 3 (100.0) 15 (83.3) 18 (85.7) 18 (94.7) 7 (100.0)




3 (75.0) 2 (40.0) 5 (83.3) 2 (100.0) 7 (87.5) 6 (75.0) 4 (57.1) 2 (100.0) 6 (100.0) 8 (100.0) 6 (100.0) 3 (100.0) 16 (88.9) 16 (76.2) 15 (78.9) 7 (100.0)




3 (75.0) 3 (60.0) 6 (100.0) 2 (100.0) 7 (87.5) 6 (75.0) 6 (85.7) 2 (100.0) 6 (100.0) 8 (100.0) 6 (100.0) 3 (100.0) 16 (88.9) 17 (81.0) 18 (94.7) 7 (100.0)
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